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Abstract 
Background and aims: In vitro studies with rodent beta cells suggest that individual 
free fatty acids (FFA) can exert differential effects such that long-chain saturated fatty 
acids (LC-SFA) promote toxicity while their monounsaturated counterparts (e.g. 
C18:1) are benign. This is potentially important, if also true in humans, because 
patients with type 2 diabetes often display elevated circulating FFA. Furthermore, 
elevated levels of odd chain SFA (C15:0, C17:0) have been associated with a reduced 
prevalence of diabetes, but their impact on beta cell viability has not been assessed. 
The investigations detailed within this thesis have characterised the effects of various 
FFA on beta cell viability. Further, the subcellular distribution of long-chain fatty acids 
(LC-FFA) has been characterised to elucidate the underlying mechanisms of 
lipotoxicity in the human EndoC-βH1 and the rat INS-1 beta cell lines. 
Methods: Cells were exposed to a range of LC-FFA for increasing periods and viability 
was subsequently assessed using either vital dye staining or flow cytometry. The 
distribution of LC-FFA within cells was studied using a fluorescent palmitate analogue, 
BODIPY FL C16, and Transmission Electron Microscopy (TEM). Golgi co-localisation 
was determined with the aid of Golgi-RFP. The oxygen consumption rate (OCR) of 
cells was measured using a Seahorse XF96e analyser.   
Results:  Exposure of INS-1 cells to C15:0, C16:0, C17:0 and C18:0 caused a dose-
dependent loss of viability over 24h, which was completely attenuated with the co-
incubation of C18:1. Conversely, exposure of EndoC-βH1 cells to C15:0, C16:0, C17:0 
and C18:0 did not cause a loss in viability, even at concentrations up to 1mM, and for 
exposure periods of 72hrs. Furthermore, EndoC-βH1 cells were resistant to the 
cytotoxic effects of C16:0 (0.5mM) and glucose (20mM) combined, a phenomenon 
previously observed in rodent beta cells. Interestingly, the stearoyl-CoA desaturase 
4 
 
(SCD-1) inhibitor 10,12-CLA, and the V-ATPase inhibitor, bafilomycin, both caused 
EndoC-βH1 cell death. The long-chain monounsaturated fatty acid (LC-MUFA) C18:1 
also caused a modest increase in EndoC-βH1 cell death relative to control, although 
cell death was not observed in those cells treated with C16:1.  
In the INS-1 cell line, exposing cells to both C16:0, C18:1 and the fluorescent tracer 
BODIPY FL C16, caused C16:0 to become distributed in a punctate manner throughout 
the cytosol, a feature not observed when INS-1 cells were solely treated with C16:0 
and BODIPY FL C16. Treating INS-1 cells with unlabelled C16:0 caused the ER to 
appear dilated. Moreover, C16:0 was found to accumulate at the Golgi apparatus. In 
contrast, C18:1 did not cause swelling of the Golgi apparatus; it did not cause 
alterations to ER morphology and C18:1 was routed to the mitochondria for oxidation. 
To what extent C18:1 is oxidised in INS-1 cells, however, remains unclear. Strikingly, 
C16:0-induced ER dilation and swelling of the Golgi apparatus was not observed in 
the presence of C18:1. 
In the EndoC-βH1 cell line, similarly to the INS-1 cell line when treated with C18:1, 
C16:0 did not localise to the Golgi, was distributed in a punctate manner throughout 
the cytosol, and did not cause the ER to become dilated. Furthermore, cytosolic puncta 
were observed in EndoC-βH1 cells treated with C16:0 and BODIPY FL C16 in 
combination with C17:0, C19:0, and C18:1.  
Conclusion: Differences observed in the viability profile of LC-FFA in human 
compared to rodent β-cells may be due to differential routing of lipids. Further research 
is required to determine whether lipotoxicity occurs in human pancreatic β-cells in the 
pathophysiology of T2D. 
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1.1 Diabetes mellitus  
Diabetes is the most prevalent endocrine disorder globally, with >422 million 
individuals living with the disease worldwide (WHO, 2016). It is a lifelong condition 
characterised by elevated blood glucose (hyperglycaemia). The two main forms of 
diabetes are type 1 (T1D) and type 2 diabetes (T2D); with less prevalent forms 
including gestational, neonatal and maturity-onset diabetes of the young (MODY). T1D 
was traditionally considered a disease of children and adolescents although, it is now 
recognised that the onset of T1D can occur in adulthood (Thomas et al. 2018) with 
equal frequency. T1D is an autoimmune disease where β-cells of the pancreas are 
destroyed leading to insulin deficiency. Subsequently, individuals with T1D are fully 
reliant on exogenous insulin. In T2D however, cells of the body become resistant to 
the effects of insulin, and pancreatic β-cells may become dysfunctional and die (as 
reviewed by Blair, 2016). The causes of T2D, however, remains unclear, although it is 
thought to be a polygenic disorder triggered by environmental factors including, most 
notably obesity and sedentary lifestyle (figure 1.1) (Ali et al. 2013). 
1.2 Type 2 diabetes mellitus  
Long considered a disease of adulthood (>40 years old), T2D is now being diagnosed 
in increasing numbers of children and younger people (<40 years old) (WHO, 2006; 
Dabelea et al. 2014). T2D (and other forms of diabetes) is diagnosed by measuring 
the concentration of glucose present in the blood, as individuals with T2D have 
elevated circulating glucose (hyperglycaemia) (WHO, 2006; Kumar et al. 2010). The 
development of hyperglycaemia is often preceded by insulin resistance which can 
occur with ageing or following an increase in bodyweight and fat mass (as reviewed 
by Barzilai et al. 2012). Insulin resistance is an increasing insensitivity to the actions 
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of insulin in target tissues (such as the liver, skeletal muscles, and adipose tissue; 
reviewed by Blair, 2016). Subsequently, blood glucose concentrations rise, with 
pancreatic β-cells adapting to hyperglycaemia by increasing their secretion of insulin. 
T2D develops when β-cells fail to secrete sufficient amounts of insulin to compensate 
for the rising insulin resistance, and ultimately, they may undergo cell death (as 
discussed by Prentki et al. 2002). However, recently it has been proposed that 
pancreatic β-cells do not undergo cell death in T2D but instead dedifferentiate, losing 
their function and identity as a β-cell due to a decrease in the expression of β-cell 
specific markers (Diedisheim et al. 2018). However, the concept of β-cell 
dedifferentiation in T2D is still a subject under investigation.  
Treatment of T2D aims to maintain blood glucose levels as close to the normal range 
(4-7mmol/L before eating) as possible to minimise the risk of developing microvascular 
(such as retinopathy and nephropathy) and macrovascular (cardiovascular disease 
and stroke) complications (as reviewed by Rask-Maden & King, 2013). At diagnosis, 
hyperglycaemia is often managed mainly with lifestyle interventions such as dietary 
modifications and increased physical activity. If hyperglycaemia cannot be managed 
by lifestyle interventions alone, medications such as metformin are prescribed. The 
biguanide metformin acts to target insulin resistance, whereas other drugs, such as 
sulphonylureas, act to stimulate insulin secretion from pancreatic β-cells (Arner et al. 
2018; Bailey et al. 2016). Later stages of treatment may, however, require the 
introduction of insulin therapy (Bastaki, 2005; NICE, 2015). 
T2D accounts for approximately 90% of all diabetes cases, with >380 million 
individuals worldwide living with the condition (WHO, 2016). Since 1985 there has 
been a 10-fold increase in the number of people living with T2D and this figure is set 
to continue to rise. By 2030 it is predicted that more than 552 million people worldwide 
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will have T2D (Murea et al. 2012). Out of the 380 million individuals currently living 
with T2D, 3.7 million reside in the UK, with an estimated 1 million additional UK 
residents having T2D that has not been diagnosed (DiabetesUK, 2017). T2D and its 
complications cost the NHS more than £6 billion each year in patient care (NHS 
England, 2018). Consequently, T2D poses a serious financial and clinical challenge 
to the NHS. The majority of therapies currently available for T2D aim to manage 
hyperglycaemia, thereby preventing or reducing the complications of T2D (as 
reviewed by Upadhyay et al. 2017). Few drugs promote β-cell viability directly, and it 
is of paramount importance that mechanisms involved in regulating β-cell death and 
viability are elucidated. This will then facilitate the development of new approaches to 
therapy which complement the existing agents and their targets.  
1.3 Type 2 diabetes and obesity 
The risk that a person may develop T2D depends on both their inherent genetic 
makeup and certain lifestyle factors, including sedentary behaviour and poor diet 
which can lead to obesity (figure 1.1). There is a strong association between obesity 
and T2D, with more than half of those individuals with T2D being obese in the UK 
(Holman et al. 2011). In the UK it has been observed that subjects with obesity are 
seven times more likely to be diagnosed with T2D compared to those who are not 
obese (Abdullah et al. 2010). Just as the incidence of obesity has risen so has that of 
T2D, suggesting a firm correlation between the two conditions. Since 1993 the rates 
of obesity have almost doubled, and it is predicted that by 2050 60% of men and 50% 
of women in the UK will be obese (Health Survey for England 1993-2012). 
Public Health England classifies obesity as having a body mass index (BMI) of 
30kg/m2 or over (NIHC, 2014). The primary cause of obesity is an energy imbalance, 
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where more energy is consumed than the body requires. The surplus energy is stored 
as fat which can lead to obesity if the energy imbalance remains unaddressed (Eckel 
et al. 2011). The precise mechanisms which link obesity and T2D, however, remain 
unclear, as does our understanding of inter-individual differences, since many obese 
subjects never develop T2D and conversely, many lean individuals do develop T2D.  
1.3.1 Genetics of T2D and obesity 
Epidemiological studies support the principle of inherited genetic susceptibility as a 
major risk factor for developing T2D. Population-based studies have observed that 
when one parent has T2D, there is a 40% risk of the offspring developing T2D, 
whereas if both parents have the disease, there is a 70% risk. Furthermore, first 
degree relatives of those subjects with T2D are three times more likely to develop the 
disease compared to those with no family history (Meigs et al. 2000).  
Recent advances in genome-wide association studies (GWAS) have facilitated the 
identification of >128 common genetic risk variants associated with T2D, supporting 
the theory that T2D is a polygenetic condition (Xue et al. 2018; Scott et al. 2017; 
Mahajan et al. 2018). Many of the T2D genes identified by GWAS are associated with 
β-cell dysfunction, such as KCNJ11 where a single nucleotide polymorphism (SNP) in 
this gene causes impaired insulin secretion (Laukkanen et al. 2004). Genetic 
polymorphisms are thought to contribute towards sustained β-cell dysfunction, 
contributing towards β-cell death and subsequently overt T2D (Ali, 2013). 
Advances in GWAS have also enabled a genetic link between obesity and T2D to be 
investigated. In 2007, Frayling et al. conducted a genome-wide search for T2D-
susceptibility genes, in UK individuals with T2D and their age-matched controls. The 
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Figure 1.1 Pathogenesis of T2D triggered by obesity. Excess consumption of fats and carbohydrates can lead to hyperinsulinemia 
and elevated circulatory fatty acid concentrations. In turn, this can lead to insulin resistance which, in genetically susceptible subjects, 
can contribute towards pancreatic β-cell death, ultimately leading to overt T2D (Prentki, 2002). 
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researchers identified a common variant in the FTO (fat mass and obesity associated 
gene) which was confirmed to predispose to T2D through an increase in body mass 
index (BMI). It was observed that those individuals who were homozygous for the risk 
allele weighed approximately 3kg more than those without the FTO risk allele, and had 
a 1.67-fold increase in the odds ratio for development of obesity (Frayling et al. 2007). 
The risk variants in the FTO gene are seemingly the only genetic variants which link 
obesity and T2D. The full genetic architecture of T2D and obesity is however not 
known, so GWAS may yet identify additional genes which link T2D and obesity in the 
future. 
1.3.2 Fat storage and T2D 
Ectopic fat storage is thought to be a contributing factor in the pathogenesis of T2D 
(as reviewed by Lewis et al. 2002). Adipose tissue is the main site of fat storage in the 
body. It is the largest endocrine tissue in humans, secreting a range of biologically 
active compounds including free fatty acids (FFA), numerous hormones (for example 
leptin and adiponectin) and inflammatory mediators (such as tumour necrosis factor-
α (TNF-α) and interleukin-6 (IL-6)). In obesity, however, the secretion of these 
compounds by adipose tissue becomes deranged (Eckel et al. 2011; Trayhurn & 
Wood, 2004). In subjects with obesity, excess adipose tissue releases elevated 
concentrations of pro-inflammatory cytokines (predominantly TNF-α and IL-6), 
whereas anti-inflammatory cytokine production (for example IL-10) is suppressed 
(Schmidt et al. 2015). Pro-inflammatory cytokines have the potential to cause 
pancreatic β-cell death, contributing to the development of T2D (as reviewed by 
Donath et al. 2003). Moreover, the increase in circulating FFA from adipose tissue 
(specifically the long-chain saturated fatty acid (LC-SFA) palmitate) can induce 
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chemokine and cytokine expression in human islets, which further contribute towards 
islet inflammation and subsequently β-cell death in T2D (Igoille-Esteve et al. 2010).  
Adiponectin, the most abundant secretory protein released from adipocytes, is 
decreased in obesity. When administered systemically to obese rodent models, 
adiponectin increases the rates of fatty acid oxidation and causes a decrease in fatty 
acid accumulation in the muscle (Shetty et al. 2004). Adiponectin is also associated 
with the profile of circulatory FFA. With a decrease in adiponectin concentrations, there 
is a significant increase in the LC-SFA palmitic acid (C16:0), observed in both rodents 
and humans, which can be toxic to pancreatic β-cells during chronic exposure (Welters 
et al. 2004). With elevated adiponectin, however, there is an elevation in the LC-MUFA 
oleic acid (C18:1), which may play a protective role against LC-SFA induced β-cell 
death (see section 1.8) (Heredia et al. 2009; Fernandez-Real et al. 2005; Welters et 
al. 2004). Elevated adiponectin is associated with a lower incidence of T2D. This may, 
in part be due to adiponectin’s role in regulating fatty acid metabolism, and its ability 
to partially rescue β-cells from fatty acid-induced toxicity (Rakatzi et al. 2004; Duncan 
et al. 2004).  
Excess ectopic fat in the pancreas is also thought to be a feature of T2D. Ectopic fat 
is the deposition of triglycerides in cells that are not adipose tissue and which normally 
contain only small amounts of fat (as reviewed by Lettner et al. 2008).  Lee et al. (1992) 
were first to identify fat accumulation in the pancreatic islets of T2D Zucker diabetic 
fatty (ZDF) rats. Subsequently, Lee and colleagues (1992) showed that triglycerides 
accumulate in the pancreatic islets of T2D rodent models, two weeks before β-cell 
apoptosis occurred, implying that pancreatic ectopic fat may contribute towards β-cell 
death in these models of T2D. Magnetic resonance spectroscopy (MRS) studies have 
shown pancreatic fat also to be elevated in human subjects with obesity, but 
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significantly more so in those individuals with obesity and T2D (Tushuizen et al. 2007). 
In a recent clinical study, pancreatic triglyceride content decreased with weight loss in 
subjects with T2D and obesity but not in BMI-matched controls, despite a comparable 
decrease in body weight (Steven et al. 2015). This implies that pancreatic ectopic fat 
is a feature of T2D and that the pancreatic extracellular milieu has a high concentration 
of fatty acids, possibly contributing to β-cell death.  
1.4 Insulin resistance in T2D 
It has long been recognised that insulin resistance is linked to the development of T2D 
(Weyer et al. 1999). Insulin resistance can be caused by elevated concentrations of 
circulating FFA, inactivity, overconsumption of energy-dense foods, and age (as 
reviewed in Peterson & Shulman, 2018). Insulin resistance is a condition whereby 
insulin-target cells no longer respond appropriately to circulating insulin. At a cellular 
level, insulin resistance occurs due to the insulin signal being disrupted (often by the 
degradation of insulin receptor substrate-1) which reduces the strength of the signal, 
causing attenuation of insulin’s final actions (Pederson et al. 2001). 
The main role of insulin in healthy target tissues, such as adipose, liver and muscle, 
is to coordinate the storage, mobilisation and utilisation of fatty acids and glucose. 
Insulin resistance prevents glucose uptake and its subsequent conversion to glycogen 
in muscle and triglycerides in adipose tissue. Glucose, therefore, remains in the blood 
leading to hyperglycaemia. Hyperglycaemia is further exacerbated by hepatic glucose 
production, as hepatocytes continue to produce glucose due to the gluconeogenic 
pathways not being appropriately inhibited by insulin (Cerf, 2013). Moreover, insulin 
resistance results in an increase in fatty acids in the blood. In healthy individuals, 
insulin increases the activity of lipoprotein lipase (LPL), which facilitates the clearance 
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of triglyceride-rich lipoproteins from the blood, and inhibits the activity of hormone-
sensitive lipase (HSL) in adipose tissue, which reduces the release of FFA into 
circulation (Liu et al. 2005; Meijssen et al. 2001). In insulin resistance, triglycerides are 
not cleared from the blood, which can manifest as dyslipidaemia (abnormal fat 
concentrations in the blood). Insulin resistance can, therefore, cause dyslipidaemia, 
but conversely, lipids can also cause insulin resistance. Studies using an intravenous 
lipid infusion (with heparin to activate LPL) to elevate circulating fatty acids in healthy 
individuals have demonstrated that fatty acids cause a dose-dependent inhibition of 
insulin-stimulated glucose uptake by cells and an increase in hepatic gluconeogenesis 
(Boden et al. 1994; Roden et al. 2000).  
In summary, insulin resistance causes an increase in circulating fatty acids which, in 
turn, exacerbates insulin resistance of peripheral tissue. Insulin resistance of the 
peripheral tissues subsequently causes glucose concentrations in the blood to rise. 
Elevated fatty acids and glucose are thought to contribute towards the death of 
pancreatic β-cells and T2D in genetically susceptible individuals (as reviewed by Ruan 
& Lodish, 2003). 
1.5 Fatty acids 
Fatty acids present in the body are either derived from the diet or from de novo 
lipogenesis (DNL) in the liver and adipose tissue, where surplus carbohydrates are 
converted to fats. Fatty acids are a diverse group of compounds which differ in their 
carbon chain length, configuration and metabolic effects (figure 1.2). They are used 
by cells for a range of processes including as a fuel source, a component of cellular 
membranes, and as precursors for a range of signalling molecules including hormones 
and inflammatory mediators (figure 1.3) (as reviewed by Carta et al. 2017). Fatty acids 
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are transported around the body either esterified, predominantly as triglycerides (three 
fatty acids esterified to glycerol) or in a non-esterified form (i.e. FFA). The majority of 
non-esterified FFA are transported in plasma bound to albumin, although a small 
fraction of FFA circulates unbound to albumin (Huber & Kleinfeld, 2017). Alterations in 
the ratio and concentrations of fatty acids in the circulation have been shown to play 
a significant role in the pathophysiology of T2D (Lee et al. 1994). Dyslipidaemia can 
be classified as elevated FFA, increased low-density lipoproteins (LDL) (which 
transport fats in circulation), high cholesterol, raised triglycerides and/or low levels of 
high-density lipoproteins (as discussed in Thompson, 2004). In the pathophysiology 
of insulin resistance and T2D however, an elevation in the plasma FFA pool seemingly 
assumes greater importance than disruption of lipoprotein levels or triglycerides 
(Acosta-Montano & Garcia-Gonzalez, 2018).  
1.5.1 The free fatty acid plasma pool 
Adipose tissue is the main source of FFA in plasma. Under normal physiological 
conditions, plasma FFA is tightly regulated according to the energy demands of the 
body (see section 1.5.2). The concentration of the plasma FFA pool is between 100μM 
to >1mM, although concentrations vary depending on factors such as the time of day, 
physiological state, and stress levels (Huber and Kleinfeld, 2017). In subjects with 
obesity and insulin resistance, there is an elevation in circulating FFA (Eckel et al. 
2011), although the source of surplus FFA remains to be fully elucidated. Elevated 
FFA can, however, in part, be attributed to a reduction in FFA clearance, enlarged 
adipocytes releasing more FFA, and/or an increase in the activity of LPL and inhibition 
of HPL in adipose tissue due to insulin resistance (as reviewed by Boden, 2008).  
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Figure 1.2 Fatty acid classification. Fatty acids are classified according to the 
number of carbons in their aliphatic chain or by the number of double carbon-carbon 
bonds. Fatty acids with <14 carbons are short to medium chain fatty acids whereas 
fatty acids with 14-20 carbons are LC-FFA. Those fatty acids with no double bonds in 
the hydrocarbon chain are the saturated fatty acids. The insertion of one double 
carbon bond, however, generates fatty acids referred to as monounsaturates, and 
those with more than one double carbon bond are polyunsaturated fatty acids (Nestle 
et al. 1994; Kikukawa et al. 2015; Tallima et al. 2018). 
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Figure 1.3 Cellular uses of FFA. FFAs are transported to the cell either bound to 
albumin or packed in lipoproteins, before being dissociated from their protein carriers 
by receptors on the outer face of the plasma membrane. The FFAs are then taken up 
into the cell and activated in the cytosol by the addition of a CoA (coenzyme A) group. 
Both FFA and fatty acyl-CoA (the activated form) can form precursors to lipid signalling 
molecules or can be converted to membrane lipid species (for incorporation into 
cellular membranes), at sites such as the ER and Golgi apparatus. Other uses of FFA, 
fatty acyl-CoA and fatty acid metabolites (such as ceramide) are to modulate gene 
expression in the nucleus or, in the case of fatty acyl CoA, to act as a source of fuel, 
being oxidised in the mitochondria to yield energy (in the form of adenosine 
triphosphate (ATP)) or converted to triglycerides for energy storage (Carta et al. 2017). 
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Recent advances in lipidomics have enabled the circulatory FFA profile to be 
characterised in both lean and obese individuals. In healthy lean individuals, the FFA 
plasma pool is  composed of more than 40 different fatty acid species, approximately 
78% of which are the long-chain free fatty acids (LC-FFAs) oleic acid (C18:1), palmitic 
acid (C16:0), and stearic acid (C18:0) (Quehenberger et al. 2010). In obese subjects, 
lipidomics has identified an elevation in the LC-SFAs C16:0 and stearic acid C18:0, 
whereas the LC-MUFA C18:1 is decreased (Sansone et al. 2016). C16:0 is consumed 
in the diet or synthesised endogenously from carbon substrates (such as 
carbohydrates) through the de novo lipogenesis (DNL) pathway. The homeostatic 
control of C16:0 in tissue is highly regulated and kept within a strict physiological 
range. The accumulation of C16:0 is prevented by desaturation to C16:1, and/or 
elongation to C18:0 with further desaturation to C18:1 (Silbernagel et al. 2012). In 
hyperglycaemic conditions (for example T2D), an overproduction of C16:0 by DNL has 
been observed to contribute towards dyslipidaemia, insulin resistance and the 
dysregulation of fat storage and distribution (Donnelly et al. 2005).  
1.5.2 The effect of FFA on glucose metabolism 
First suggested by Randle et al. (1963), the “glucose-FFA cycle” is a system in 
mammals whereby glucose and fatty acids compete to be oxidised in tissue such as 
muscle and adipose. It is proposed that a disruption to the glucose-FFA cycle by 
obesity and insulin resistance, results in high plasma concentrations of FFA (Hue, 
2009). In a healthy lean individual, FFA bound to albumin is the form in which stored 
body fat from adipose tissue is transported to tissue. The FFA plasma pool plays an 
essential role in metabolic regulation during feeding and fasting, as when blood 
glucose concentrations are low FFA act as a major fuel source for many tissues. Based 
on their observations in isolated rat cardiac muscle, Randle et al. (1963) proposed that 
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when blood glucose levels are elevated, FFA oxidation is inhibited, thereby enhancing 
FFA storage, glucose oxidation and glucose storage in muscle and adipose. 
Conversely, when blood FFA levels are elevated, glucose oxidation is inhibited from 
increasing FFA oxidation (Randle, 1963). This hypothesis was later confirmed by the 
work of Boden et al. (1994) who demonstrated that increased FFA oxidation 
decreased glucose oxidation in human skeletal muscle 1h post-acute lipid infusion.  
At a cellular level, Randle proposed that glucose and FFA metabolic pathways could 
be regulated by nutrients, depending on whether glucose or FFA was in excess. 
Randle proposed that an increase in FFA oxidation would ultimately lead to the 
inhibition of the glucose sensor, hexokinase, causing a reduction in the uptake of 
glucose (Randle et al. 1963). In later years, it was identified that an increase in glucose 
oxidation subsequently elevates malonyl-CoA production which acts to inhibit carnitine 
acyltransferase I (CPT-1). Inhibition of CPT-1 reroutes FFA into cytosolic esterification 
pathways; storing FFA as triglycerides to be used in periods when glucose 
concentrations are low (McGarry et al.1977). 
The glucose-FFA cycle is particularly important in pancreatic β-cells. In response to 
elevated glucose, FFA are rerouted into esterification pathways which is vital to enable 
glucose-stimulated insulin secretion (GSIS) to occur (Prentki et al. 2013). The 
rerouting of FFA not only enables GSIS but also amplifies GSIS via the generation of 
lipid signalling molecules (see section 1.6.1) (Prentki et al. 2013). In T2D however, 
hyperglycaemia combined with excess fatty acids is thought to contribute towards β-
cell death via the mass accumulation of esterified FFA in the cytoplasm (as reviewed 
by Kim & Yoon, 2011). 
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1.6 Pancreatic β-cells 
Pancreatic β-cell dysfunction and death is a major feature of T2D. Beta-cells are 
located in the endocrine tissue of the pancreas within cell aggregates named the ‘islets 
of Langerhans’ (islets henceforth) (as reviewed by Kulkarni, 2004) (figure 1.4). The 
main function of the pancreatic β-cell is to secrete the hormone insulin, the primary 
regulator of blood glucose concentrations.  
1.6.1 Insulin secretion  
Pancreatic β-cells secrete insulin in response to a range of stimuli, the primary 
modulator being glucose. The full mechanisms by which insulin is secreted remains 
unclear although insulin secretion is believed to occur via KATP-dependent and KATP-
independent pathways (as reviewed by Jenson et al. 2008).  The canonical pathway 
of GSIS is the KATP-dependent pathway, where glucose is metabolised in the cytosol 
and mitochondria to generate ATP. The increase in ATP is sensed by ATP-sensitive 
K+ channels on the plasma membrane, causing KATP-channels to close and 
consequently the plasma membrane to depolarise. Depolarisation of the plasma 
membrane opens voltage-gated Ca2+ channels, resulting in an influx of Ca2+ which 
leads to the exocytosis of insulin-containing secretory granules (as discussed by Fu 
et al. 2013).  
Insulin secretion, however, is not triggered solely by glucose. Malaisse et al. (1967) 
were the first to observe that β-cells secrete insulin in response to FFA, with later 
research establishing that FFA can stimulate insulin secretion through their oxidation, 
or by potentiating GSIS (Prentki et al. 2013). FFA-induced insulin secretion occurs via 
metabolic pathways and membrane receptor activation (figure 1.5). Similarly to  
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Figure 1.4: Islets of Langerhans 
The β-cells are one of five cell types contained in the islets of Langerhans. β-cells 
secrete the hormone insulin, whereas α-cells secrete glucagon, δ-cells secrete 
somatostatin, Ɛ-cells secretes ghrelin, and PP-cells secrete polypeptide (Kulkarni, 
2004).  
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Fig. 1.5 The role of fatty acids in insulin secretion. LC-FFA can stimulate insulin 
secretion through: (A) their oxidation which subsequently leads to an increase in ATP 
production causing the KATP channels to close, voltage-gated Ca2+ channels to open 
and leading ultimately to increased insulin secretion. (B) An increase in glucose 
concentrations can cause malonyl-CoA concentrations to rise, which blocks CPT-1. 
This re-routes FFA into esterification pathways to generate lipid droplets and lipid 
signalling molecules (such as long chain coenzyme A (LC-CoA)) which can act as 
signalling molecules to amplify GSIS. Moreover, stored FFA derived from this pathway 
can act as autocrine signalling molecules which activate certain G protein-coupled 
receptors (GPR) such as free fatty acid receptor 1 (FFAR1). (B, C) FFA (specifically 
medium and long-chain FFA) can activate FFAR1 (also known as GPR40) which can 
either (C) cause the release of Ca2+ from the endoplasmic reticulum (ER), thereby 
triggering insulin secretion, or (D) generate lipid signalling molecules (such as 
diacylglycerol (DAG)) which potentiates insulin secretion (Prentki, 2013; Amisten, 
2013). 
Glucose 
Insulin 
Ca2+ 
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glucose, however, the mechanisms by which FFA trigger insulin secretion are still to 
be fully characterised (Nolan et al. 2006). 
1.6.2 FFA induced β-cell dysfunction 
Prior to β-cell death, the pancreatic β-cells undergo a period of dysfunction, in which 
fatty acids play a contributory role (Weir & Bonner-Weir, 2004). In pre-diabetes and 
the early stages of T2D, β-cells increase their secretion of insulin as an adaptive 
response to elevated blood glucose (β-cell compensation). In rodent models, this 
compensation is accompanied by an increase in β-cell number (hyperplasia) and size 
(hypertrophy) (as reviewed by Chang- Choi et al. 2008). Whether β-cell compensation 
and an increase in β-cell mass occur in humans, and by what mechanisms, is however 
currently under investigation. Following β-cell compensation, it is thought that the β-
cells begin to decompensate, and may dedifferentiate into progenitor-like endocrine 
cells (Talchai et al. 2012). Ultimately, severe decompensation and β-cell death ensue, 
in part due to functional exhaustion (as discussed by Acilli et al. 2016; Weir & Bonner-
Weir, 2004), leading to a reduction in β-cell mass. Interestingly, it has been proposed 
that the reduction in β-cell mass may be due to dedifferentiation (Talchai et al. 2012). 
However, there is also a body of literature that supports β-cell apoptosis as a primary 
cause (Wang et al. 2014; Butler et al. 2003; Jurgens et al. 2011). 
In vitro and in vivo studies have ascertained that chronic exposure to LC-SFA leads to 
an elevation in basal insulin secretion by β-cells and a blunted insulin secretory 
response to glucose (Malmgren et al. 2012). Further, fatty acids have been shown to 
cause β-cell compensation independently of glucose as, when fed a high-fat diet, the 
β-cell mass of animal models increases even when glucose is within the physiological 
range (Chang-Chen et al. 2008; Van Citters et al. 2002; Steil et al. 2001). The 
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molecular mechanisms of fatty acid-induced compensation are yet to be elucidated 
but rat islets cultured in FFA for 4 days exhibit enrichment in actin along their plasma 
membrane, an increase in DNA synthesis and a reduction in insulin content (Vernier 
et al. 2012). There are extensive theories as to how chronic exposure to fatty acids 
causes a direct decrease in insulin secretion at both the transcriptional and proteome 
level (reviewed in Sharma & Alonso, 2014) although it is beyond the scope of this 
study to discuss them in detail. Instead, the remainder of this thesis will discuss the 
role fatty acids play in β-cell death.  
1.7 The role of FFAs in β-cell death 
Elevated FFAs are believed to be a causative factor in β-cell death, a process that has 
been termed lipotoxicity. The mechanisms by which beta-cell lipotoxicity occur remain 
unclear. Lipotoxicity is dependent upon the FFA concentration, exposure duration, and 
strikingly the carbon chain length and degree of saturation of the FFA (Sharma & 
Alonso, 2014). The work of Welters et al. (2004), Diakogiannaki et al. (2007) and 
others such as Maedler et al. (2001) have repeatedly demonstrated that in rodent β-
cells and human islets, it is the LC-SFA (such as C16:0 and C18:0) that are most toxic 
to pancreatic β-cells whereas short to medium chain FFA is less toxic. Moreover, the 
LC-MUFA (for example C18:1) do not cause β-cell death and can even exert a 
protective effect against their LC-SFA counterparts (Mika et al. 2016; Maedler et al. 
2001; Welters et al. 2004). Furthermore, under certain circumstances, lipotoxicity can 
be aggravated by high concentrations of glucose (glucolipotoxicity) (as discussed by 
Poitout et al. 2010). In subjects with T2D, both hyperglycaemia and elevated FFA are 
often present in the extracellular milieu. Glucolipotoxicity is considered to contribute 
towards decreased insulin secretion, impaired insulin gene expression, and eventually 
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β-cell death in T2D (Poitout et al. 2010). This thesis, however, is principally concerned 
with the phenomena of lipotoxicity in pancreatic β-cells. 
The mechanisms by which lipotoxicity occurs is highly debated. There is a wealth of 
literature which suggest that processes such as ceramide accumulation (Shimabukuro 
et al. 1998), ER stress (Cunha et al. 2008), oxidative stress (Elsner et al. 2011), 
mitochondrial dysfunction (Molina et al. 2009) and autophagy (Choi et al. 2009) 
mediate LC-FFA-induced β-cell death (Sharma & Alonso, 2014). Further, LC-FFA 
seemingly triggers β-cell death via the apoptotic pathway (Diakogiannaki et al. 2007). 
1.7.1 Ceramide accumulation 
Ceramide consists of a sphingosine and LC-FFA side-chain (figure 1.6) and is 
biosynthesised via a de novo pathway (as discussed by Hannun & Obeid, 2018). 
Serine palmitoyl-transferase (SPT), the enzyme which catalyses the first step of de 
novo ceramide synthesis, has a high affinity for its substrates l-serine and palmitoyl-
CoA (the activated form of C16:0). As such, any increase in C16:0 availability can 
induce an aberrant production of ceramide via the de novo pathway, leading to 
ceramide accumulation (Veret et al. 2013). 
Ceramide accumulation is one potential mechanism by which LC-FFA induce β-cell 
death. It has been observed that in individuals with T2D there is a marked increase in 
sphingolipids in the blood (Haus et al. 2009). Sphingolipids are a diverse group of 
lipids which act as cell signalling molecules, regulating such cellular processes as 
apoptosis, inflammatory responses and senescence (Hannun & Obeid, 2018). It is well 
documented that nearly all stress stimuli (including obesity) induce sphingolipid 
synthesis which can lead to the intracellular accumulation of the sphingolipid ceramide  
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Figure 1.6 Chemical structure of C16-ceramide. A sphingoid base linked to C16:0 
by an amide bond, yielding C16-ceramide. The sphingoid base may be linked to fatty 
acids which vary in carbon chain length to form a ceramide molecule, although C16:0 
has been included within this schematic (adapted from Becam et al. 2017). 
 
in β-cells (Bikman & Summers, 2011). Yano et al. (2011) suggest that an accumulation 
of ceramide can affect mitochondrial membrane integrity, inducing an excessive 
production of reactive oxygen species (ROS) which disrupt insulin secretion and 
promote apoptosis in β-cells. Shimabukuro et al. (1998) were the first to identify the 
involvement of ceramide in FFA-induced β-cell death. Using the SPT inhibitor, 
fumonisin B1, to block ceramide de novo synthesis, they showed attenuation of C16:0 
induced β-cell death in Zucker diabetic fatty (ZDF) rats (Shimabukuro et al. 1998). 
Subsequent studies identified various possible mechanisms of C16:0/ceramide 
induced β-cell death including impaired protein trafficking, ER stress, mitochondrial 
dysfunction and alterations in ion-channel activity (Boslem et al. 2011; Zhang et al. 
2009; Giussani et al. 2006; Hannun & Obeid, 2018). Collectively, these studies support 
a role for ceramide in β-cell lipotoxicity.  
It can be argued, however, that the deleterious effects of ceramide depend on the 
model being used. For example, Shimabukuro et al. (1998) used ZDF rats which could 
be considered as an extreme case of ceramide accumulation as this model has 
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extremely high concentrations of circulating lipids (>1mM) (Boslem et al. 2013). 
Conversely, only a modest increase in ceramide accumulation was observed in the β-
cells of the POKO mouse, a murine model with chronic dyslipidaemia (>1mM) 
generated in part to investigate the effects of lipotoxicity (Medina-Gomez et al. 2007; 
Medina-Gomez et al. 2009). The modest increase in β-cell ceramide led Medina-
Gomez et al. to speculate that β-cells may be more resistant to lipid overloading 
compared to other cell types (for example hepatocytes) (Medina-Gomez et al. 2007; 
Medina-Gomez et al. 2009). In the RINm5F β-cell line, inhibition of de novo ceramide 
synthesis with l-cycloserine or fumonisin B1 failed to attenuate C16:0 induced cell 
death (Baldwin et al. 2012). Work is ongoing to identify the role of ceramide in β-cell 
lipotoxicity, and with the generation of the human EndoC-βH1 cell line, this can now 
be determined in a human model.  
1.7.2 Endoplasmic reticulum (ER) stress 
Accumulating evidence links chronic ER stress to lipotoxicity in pancreatic β-cells (Han 
& Kaufman, 2016). The ER plays an important role in Ca2+ homeostasis, lipid 
metabolism, protein synthesis and the posttranslational modification and trafficking of 
proteins (as reviewed by Han & Kaufman, 2016). A disturbance of ER homeostasis by 
excess fatty acids or other physiological or pharmacological stressors triggers ER 
stress. ER stress causes unfolded or misfolded proteins to accumulate, activating ER 
stress sensors which trigger the unfolded protein response (UPR) signalling pathway 
(figure 1.7) (as reviewed by Fonseca et al. 2012). The UPR is mainly activated to 
restore ER function, although, it can act as a binary switch between cell survival and 
cell death (Tse et al. 2016). Acute ER stress induces a regulated UPR which promotes 
cell viability, whereas chronic ER stress causes the UPR to become hyperactivated, 
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leading to apoptosis through the activation of the transcription factor C/EBP-
homologous protein (CHOP) (as reviewed by Fonseca, 2012).  
Prolonged β-cell exposure to LC-SFA induces ER stress in vitro and in vivo, although 
the mechanisms are still under investigation (Boslem et al. 2013). Chronic 
administration of LC-SFA selectively enhances the PERK (PRKR-like endoplasmic 
reticulum kinase) arm of the UPR in rodent β-cells and human islets (Cunha et al. 
2008). Specifically, when rodent clonal β-cells are treated for 4-72hrs with C16:0 there 
is an upregulation of activating transcription factor 4 (Atf4), eukaryotic translation 
initiation factor 2α phosphorylation (eIF2α), and CHOP, leading to apoptosis (Boslem 
et al. 2013; Cunha et al. 2008; Laybutt et al. 2007; Karaskov et al. 2006; Diakogiannaki 
et al. 2007). In those studies which reduce ER stress by exposing rodent-derived β-
cells to small molecules or chemical chaperones that prevent misfolding (such as 
tauroursodeoxycholic acid (TUDCA)), C16:0-induced β-cell death was prevented 
(Chen et al. 2013; Tran et al. 2014). Conversely, when assessed directly, C16:0 did 
not appear to promote protein misfolding of a reporter protein (mutant vesicular 
stomatitis virus G protein (VSVG)), in the rodent β-cell line, MIN6 (Preston et al. 2009). 
Rather, it is thought that C16:0 acts to slow protein trafficking out of the ER, thereby 
triggering ER stress though protein overloading (Boslem et al. 2013; Preston et al. 
2009). Trafficking defects have been linked to alterations in sphingolipid metabolism 
where a C16:0 induced loss of the sphingolipid, sphingomyelin, disrupts ER lipid rafts. 
ER lipid rafts are thought to be essential for packaging secretory cargo into export 
vesicles, and their disruption contributes towards defective protein trafficking and ER 
stress in rodent β-cells (Boslem et al. 2013).  
A further hypothesis for the mechanism by which LC-SFA induce ER stress is by 
altering the activity of the Ca2+ pump, SERCA (sarcoendoplasmic-reticulum pump 
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Ca2+-ATPase), which depletes ER Ca2+ stores thereby triggering ER stress (Cunha et 
al. 2008). However, the depletion of ER Ca2+ stores by FFA is not universally 
observed, with Karaskov et al. (2006) failing to identify alteration in ER Ca2+ 
concentrations in INS-1E cells exposed to C16:0 for 6hrs. 
Protein palmitoylation is also believed to play a role in C16:0 induced ER-stress in β-
cells. Protein palmitoylation is a major posttranslational modification where C16:0 is 
added to a protein to affect its function (including protein trafficking and stability) (as 
reviewed by Linder & Deschenes, 2007). Using the protein palmitoylation inhibitor, 2-
bromopalmitate, Baldwin et al. (2012) observed an attenuation in C16:0-induced ER 
stress, coupled with a reduction in β-cell death. This indicated that FFA-induced β-cell 
death might be mediated by unregulated palmitoylation of proteins, stimulating ER 
stress (Baldwin et al. 2012).   
Collectively, these studies indicate that ER stress and the UPR can mediate LC-SFA 
induced lipotoxicity in β-cells, with possible mechanisms including LC-SFA induced 
ER Ca2+ store depletion, defective ER-Golgi protein trafficking and C16:0 induced 
unregulated palmitoylation. Further investigations are required however to elucidate 
the mechanism by which LC-SFA trigger ER stress.  
1.7.3 Oxidative stress and lipotoxicity 
One school of thought is that β-cell lipotoxicity occurs due to enhanced ROS formation 
by the oxidation of FFA in the mitochondria and peroxisomes (Elsner et al. 2011). 
Clinical studies suggest that individuals with T2D are subject to chronic oxidative 
stress, with markers of oxidative damage (such as 8-OH-deoxyguanine) being present 
in pancreatic biopsies of patients with T2D (Sakuaba et al. 2002; Robertson et al. 
2004). Oxidative stress refers to the imbalance of excess ROS and insufficient  
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 ER stress and the UPR cascade. ER stress is activated by such factors 
as a prolonged exposure to excess LC-SFA, leading to the accumulation of unfolded 
or misfolded proteins in the ER lumen. The unfolded/misfolded proteins bind to and 
sequester immunoglobulin heavy-chain binding protein (BiP; also known as GRP78) 
which triggers the activation of inositol-requiring enzyme 1α (IRE1), protein kinase-like 
eukaryotic initiation factor 2α kinase (PERK) and ATF6α (activating transcription factor 
6α). The activation of these ER transmembrane ER stress sensors activates the UPR 
signalling pathway, which, downstream results in the alleviation of ER stress, restored 
homeostasis or apoptosis (Fonseca et al. 2012).  
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capacity of the cell to mount an effective antioxidant response (Ray et al. 2012). 
Pancreatic β-cells are highly susceptible to oxidative stress as they lack a 
comprehensive antioxidant system. Compared to the liver, β-cells express ~50% less 
of the antioxidant enzyme, superoxide dismutase (SOD), and only ~1% of the 
proportion of catalase (CAT) (Pi et al. 2010). It is proposed that low levels of 
antioxidant enzymes in β-cells enable ROS to act as metabolic signalling molecules 
for GSIS (Pi et al. 2010). A sustained elevation of ROS, however, causes lipid 
peroxidation, oxidation of proteins and DNA damage to the β-cell, which are thought 
to contribute significantly to β-cell death (Lenzen, 2008).  
The LC-SFA C16:0 and long-chain monounsaturated fatty acids (LC-MUFA) C18:1 
have both been shown to stimulate ROS production in rodent-derived pancreatic β-
cells (Maestre et al. 2003). The main ROS in β-cells includes superoxide (O2-•), 
hydroxyl radicals (•HO), and hydrogen peroxide (H2O2); which are mostly derived from 
nutrient oxidation (as reviewed by Wojtczak, 2008). Mitochondrial oxidation of LC-FFA 
produces ROS via complex I and III of the electron transport chain, whereas 
peroxisomal oxidation produces ROS as a bi-product of β-oxidation (Elsner et al. 
2011). Consequently, an increase in LC-FFA oxidation can increase ROS formation, 
potentially leading to oxidative stress and β-cell death. 
It has been proposed that long-term overloading of LC-FFA oxidation by the 
mitochondria can cause increased ROS production (Koshkin et al. 2003). LC-FFA 
induced increases in ROS production can increase mitochondrial DNA damage in the 
rodent-derived INS-1 β-cell line, which ultimately leads to apoptosis (Rachek et al. 
2006). Researchers, however, demonstrated that ROS-induced mitochondrial DNA 
damage could be overcome by transfecting INS-1 cells with a vector for the DNA repair 
enzyme, hOGG1 (human 8-oxoguanine DNA glycosylase/apurinic lyase). An increase 
46 
 
in the expression of hOGG1 successfully minimised the induction of apoptosis in LC-
FFA treated INS-1 cells, reducing cytochrome c release from the mitochondria 
(Rachek et al. 2006; Newsholme et al. 2007). This indicates that mitochondrial DNA 
damage, induced by LC-FFA derived ROS, may be a component of lipotoxicity in β-
cells.  
It has been proposed, however, that β-cells have a protective mechanism which 
prevents ROS induced β-cell death due to elevated LC-FFA oxidation, namely 
uncoupling protein-2 (UCP2). UCP2 is located in the inner mitochondrial membrane 
and acts to uncouple the electron transport chain, lowering the mitochondrial 
membrane potential to decrease ATP production when there is a surplus of LC-FFA 
being oxidised. The activation of UCP2 by ROS in the mitochondrion is considered to 
be a cellular protective mechanism which stops ROS production and enables harmful 
peroxides to be exported from the mitochondrion (Poitout et al. 2010). This theory is 
supported by Lee et al. (2001) who observed that overexpression of UCP2 protects 
against ROS induced cell death in the rodent-derived INS-1 β-cell line. However, the 
decrease in ATP production caused by LC-FFA induced UCP2 activity may be a 
detrimental process to β-cells as it also attenuates insulin secretion, which if sustained 
can contribute to β-cell dysfunction (Fariss et al. 2005).  
LC-SFA such as C16:0 and C18:0 can also initially undergo β-oxidation in the 
peroxisomes, before being transported to the mitochondria to complete their oxidation 
(Wanders et al. 2010). In contrast to the mitochondria, peroxisomal β-oxidation is not 
linked to ATP production but rather generates the ROS, H2O2. In β-cells, the 
antioxidant enzyme catalase is virtually absent, thereby leaving β-cells vulnerable to 
elevated concentrations of H2O2 (Lenzen et al. 1996). This has led to the theory that 
C16:0 induced β-cell lipotoxicity could be due to an excess of H2O2 arising from 
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peroxisomal β-oxidation (Elsner et al. 2011). Further, using the H2O2-sensitive 
fluorescent protein, HyPer, Elsner et al. (2011) showed that the peroxisomes were the 
major site of H2O2 formation in rodent β-cells, with the mitochondria being a minor site 
of H2O2 production. Subsequently, it has been proposed that peroxisomal LC-FFA β-
oxidation contributes towards ROS-induced lipotoxicity more so than mitochondrial 
LC-FFA oxidation (Gehrmann et al. 2010).  
In summary, the metabolism of LC-FFA may trigger β-cell death through oxidative 
stress. Although currently, the role of oxidative stress is still under investigation, 
especially considering that elevated ROS in response to LC-FFA is not always 
observed in β-cells (Moore et al. 2004). 
1.7.4 Mitochondrial dysfunction and lipotoxicity 
Given the central role for mitochondria in insulin secretion and the apoptotic pathway, 
it is unsurprising that emerging literature has identified mitochondrial aberrations in β-
cell lipotoxicity (Stiles & Shirihai, 2012). Mitochondria are highly dynamic organelles 
which constantly fuse (fusion) and divide (fission) to form interconnecting networks in 
cells, evenly distributing metabolites, lipids and proteins to facilitate metabolic 
efficiency (as discussed by Wiederkehr & Wollheim, 2009). The disruption of 
mitochondrial networks (for example by LC-FFA) has, however, been shown to have 
a profound effect on β-cell function and can lead to apoptosis (Molina et al. 2009; Suen 
et al. 2008). For example, an increase in fission frequency causes a deterioration in 
mitochondrial signal generation and insulin secretion in β-cells, potentially leading to 
apoptosis (Park et al. 2008). Consequently, mitochondrial morphology is indicative of 
fusion/fission dynamics which is intimately linked with mitochondrial function. There is 
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limited evidence however for the underlying mechanisms of β-cell mitochondrial 
defects in the pathophysiology of T2D although LC-FFA is known to play a role.  
When investigating the effects of LC-SFA directly on β-cell mitochondrial dynamics, 
Molina et al. (2009) reported that C16:0 caused an arrest of mitochondrial fusion 
activity, with the complete fragmentation of the mitochondria in INS-1 β-cells in as little 
as 4hrs. When inhibiting mitochondrial fission, Molina and colleagues preserved the 
mitochondrial morphology of INS-1 cells and prevented apoptosis (Molina et al. 2009). 
The complete mitochondrial fragmentation induced by C16:0, however, does not 
correlate with those studies which observed mitochondrial swelling in response to LC-
FFA in pancreatic β-cells (Fex et al. 2007; Anello et al. 2005; Diakogiannaki et al. 
2008). This discrepancy warrants further investigation.  
In islets isolated post mortem from overweight individuals with T2D, β-cell 
mitochondrial density volume is significantly higher compared to individuals without 
T2D (Anello et al. 2005). Similarly, Fex et al. (2007) observed swollen mitochondria in 
insulin-resistant mice fed a high-fat diet. Further, Diakogiannaki et al. (2008) have 
identified mitochondrial enlargement accompanied by apoptosis in the rat-derived 
BRIN-BD11 β-cell line, treated with C16:0 for 18hrs. Mitochondrial swelling may be 
due to the induction of the mitochondrial permeability transition (MPT) pore (Koshkin 
et al. 2008). The MPT is a Ca2+-dependent nonspecific pore in the mitochondrial inner 
membrane. In rat β-cell lines, C16:0 has been shown to promote the opening of the 
MPT pore causing mitochondrial swelling and the release of proteins capable of 
inducing apoptosis (Koshkin et al. 2008).  
C16:0 is known to induce the release of the apoptogenic factor, cytochrome c, from 
the mitochondria of human islets (Maedler et al. 2003). Cytochrome c is anchored to 
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the inner mitochondrial membrane by the phospholipid cardiolipin, which may play a 
significant role in LC-SFA induced β-cell death. Cardiolipin contains four unsaturated 
fatty acid molecules in its structure, although the fatty acid species incorporated into 
cardiolipin during its synthesis and remodelling, will be altered by the prevailing fatty 
acid milieu (Wahjudi et al. 2011). If saturated fatty acid species are incorporated into 
cardiolipin, there will be an alteration in its binding properties, and a reduced affinity 
for cytochrome c. This may promote the dissociation of cytochrome c from cardiolipin 
which can then trigger apoptosis (Iverson & Orrenius, 2004). Incorporation of LC-
MUFA into cardiolipin, however, would not exert this effect, offering a possible 
explanation as to why LC-MUFA are better tolerated than LC-SFA by β-cells. However, 
the role of cardiolipin synthesis and remodelling with saturated fatty acid species has 
received very little attention as a possible mediator of LC-SFA induced apoptosis in β-
cells (Newsholme et al. 2007; Iverson & Orrenius, 2004).  
In summary, the LC-FFA induced: disruption to mitochondrial networks, mitochondrial 
swelling and mitochondrial remodelling may play a pivotal role in lipotoxicity.  
1.7.5 The role of fatty acid metabolism in causing lipotoxicity 
The oxidation of LC-FFA is thought to play a key role in mediating LC-SFA induced 
toxicity in pancreatic β-cells, although research is conflicting as to how this occurs. 
Certain studies indicate that increased oxidation of LC-FFA is cytotoxic to β-cells 
(Graciano et al. 2011), whereas other results suggest that the metabolism of LC-FFA 
prevents the toxicity of the FFA (Lee et al. 2014). For example, supplementing β-cells 
with tricarboxylic acid cycle (TCA) intermediates was shown to decrease C16:0 
induced β-cell death (Lee et al. 2014). Further, when LC-FFA oxidation is blocked 
using etomoxir, a pharmacological inhibitor of CPT-1, there is an increase in C16:0 
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induced cell death according to some authors (El-Assad et al. 2003; Sargsyan et al. 
2011), and an attenuation according to our group (Diakogiannaki et al. 2007). The LC-
MUFA, C18:1, is not toxic to β-cells (Maedler et al. 2003), despite being metabolised 
by the same pathways as LC-SFA, again suggesting that metabolism of LC-FFA is not 
directly responsible for causing cell death. This contradicts studies which suggest that 
metabolism of LC-FFA is cytotoxic to cells. For example, the non-oxidisable C16:0 
analogues, methyl ester and bromo-C16:0, which are not transported into the 
mitochondria by CPT-1, do not cause cell death (Newsholme et al. 2007). Additionally, 
increased fatty acid oxidation also increases the production of ROS, which β-cells are 
ill-equipped to process as they lack a comprehensive antioxidant system; leading to 
β-cell death (Graciano et al. 2011).  
In summary, studies are conflicting as to whether LC-FFA oxidation plays a role in β-
cell lipotoxicity and consequently, further investigations are necessary to clarify the 
role of fatty acid metabolism in β-cell death. 
1.7.6 Autophagy 
Exposure of rodent β-cells and human islets to LC-FFA is widely reported to induce 
autophagy (Ebato et al. 2008; Oh, 2018; Las & Shirihai, 2010). Macroautophagy 
(hereafter named ‘autophagy’) is a major intracellular degradation pathway. By this 
mechanism, cytoplasmic material such as lipids, are sequestered in double-
membrane vesicles and delivered to the lysosomes for degradation (figure 1.8) 
(Kurokawa & Kornbluth, 2012). Post-degradation, the material is released back into 
the cell in its constituent parts, producing a source of energy and new building blocks 
for cellular homeostasis (Singh & Cuervo, 2012; Las & Shirihai, 2010). Under basal 
conditions, autophagy contributes towards cellular homeostasis, whereas under cell 
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stress, autophagy can also act to mediate cell survival or cell death (Singh & Cuervo, 
2012; Oh et al. 2018).  
Autophagy is known to occur during LC-FFA induced β-cell lipotoxicity in T2D 
although, whether autophagy has a protective or detrimental role remains a matter of 
debate (Oh et al. 2018; Ebato et al. 2008; Las et al. 2010). A protective role for 
autophagy against C16:0-induced β-cell death was proposed by Choi et al. (2009). In 
the rat-derived INS-1 β-cell line, it was suggested that increasing autophagosome 
formation using rapamycin reduced C16:0-induced β-cell death. Conversely, 
decreasing autophagosome formation increased C16:0-induced β-cell death (Choi et 
al. 2009). Further, upon alleviating ER stress with 4-phenylbutyrate (4-PBA), a 
chemical chaperone which prevents protein aggregation, Choi et al. observed a 
reduction in C16:0-induced autophagic vesicles implying that ER stress may play a 
role in driving C16:0-induced autophagy (Choi et al. 2009).  
The body of literature supporting a detrimental role for C16:0-induced autophagy, 
however, is much greater. Beta-cell death and glucose intolerance have been 
observed in mice deficient for β-cell Atg7, an essential gene for autophagosome 
formation (Ebato et al. 2008). The loss of autophagy in the β-cells of Atg7-deficient 
mice fed a high-fat diet, significantly increased oxidative stress and was coupled with 
the accumulation of ubiquitinated proteins and damaged organelles, which it was 
speculated contributed towards β-cell degeneration (Ebato et al. 2008). Further, in 
human islets and INS-1 β-cells, prolonged exposure to elevated concentrations of 
C16:0 increased the accumulation of overloaded autophagosomes, with suppression 
of autophagic degradation. This disruption to autophagic flux led to an impairment in 
insulin secretion and β-cell death (Las et al. 2011; Mir et al. 2015; Masini, 2009). A 
large number of overloaded autophagosomes has also been observed in the β-cells 
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of individuals with T2D (Masini et al. 2009). Coupled to overloaded autophagosome 
accumulation in post mortem β-cells and islets post LC-FFA treatment, was a reduced 
expression of lysosome-associated membrane protein 2 (LAMP2) and cathepsin B 
and D. LAMP2 and cathepsin B and D are involved in protein degradation and in 
lysosomal fusion of the autophagic pathway (Masini et al. 2009). This suggests that 
an increase in overloaded autophagosomes in β-cells exposed to LC-FFA may be due 
to a decrease in autophagic flux because of decreased lysosome fusion and 
autophagosome degradation. This decrease in autophagic flux may then contribute to 
β-cell lipotoxicity rather than exerting protection (Las et al. 2010; Masini et al. 2009).  
In summary, the majority of evidence supports C16:0-induced autophagy being 
detrimental to pancreatic β-cell viability. Further, the interruption to autophagic flux by 
C16:0 and subsequent β-cell death, support the theory that autophagy-associated 
death occurs as a result of a blockage of autophagic flux rather than an induction of 
autophagosome formation (Las et al. 2010). 
1.8 Monounsaturated fatty acids and β-cell cytoprotection 
As discussed earlier, the toxicity of LC-FFAs depends on their degree of saturation. 
The literature clearly shows LC-SFA (such as C16:0) to induce apoptosis in pancreatic 
β-cells, whereas the effects of LC-MUFA (for example C18:1) on β-cell viability are 
less clear. Certain studies have shown C18:1 to increase apoptosis in INS-1 and MIN6 
cells, preceded by the induction of ER stress markers (Wrede et al. 2002; Martinez et 
al. 2008; Yuan et al. 2010). There is a larger body of literature however, which supports 
the view that C18:1 is not toxic to pancreatic β-cells and, when co-incubated with 
C16:0, completely attenuates C16:0-induced toxicity in rodent-derived β-cells and  
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Figure 1.8 Autophagy pathway. Autophagy can be stimulated by ROS, ER stress 
and LC-FFA. The initiation of autophagy is the generation of an isolated membrane. 
The isolated membrane engulfs cytosolic proteins and organelles. Upon completion of 
the membrane, an autophagosome is formed which transports its cargo to lysosomes. 
The fusion of the autophagosome to a lysosome forms an autolysosome. Hydrolases 
from the lysosome subsequently break down the inner membrane and cytoplasmic 
contents of the autophagosome, releasing the constituent parts back into the 
cytoplasm for use by the cell (Hannigan &Gorski, 2009).  
 
human islets (Welters et al. 2004; Maedler et al. 2003; Maedler et al. 2001; Nemcova-
Furstova et al. 2011; Plotz et al. 2016). Further, in rodent β-cell lines, contrary to C16:0, 
C18:1 does not activate pro-apoptotic enzymes such as the apoptogenic kinases 
protein kinase C delta type (PKC-δ) and c-Jun N-terminal kinase (JNK) (Eitel et al. 
2003; Cunha et al. 2008). Further, C16:0-induced caspase 3/7 activity is abolished 
immediately upon addition of the LC-MUFA, C16:1, promoting β-cell survival (Dhayal 
et al. 2008). The differential effects of C16:0 and C18:1 on β-cell viability, and the 
mechanisms by which C18:1 attenuates C16:0-induced β-cell death have been 
investigated for a number of years, and is in part the subject of this study.  
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Dhayal et al. 2008 have found that the anti-apoptotic protection exerted by C18:1 does 
not require the activation or metabolism of the LC-MUFA by pancreatic β-cells. 
Blocking the uptake of LC-MUFA into the mitochondria using etomoxir, which inhibits 
CPT-1, does not prevent C18:1 attenuating C16:0-induced β-cell death. This suggests 
that mitochondrial entry and subsequent mitochondrial oxidation of LC-MUFA is not a 
pre-requisite for the protective action of C18:1. Similarly, the non-metabolisable methyl 
ester C16:1 attenuates C16:0-induced β-cell death, thereby indicating that formation 
of acyl-CoA is not necessary for the LC-MUFA protective response, as the presence 
of a methyl moiety will prevent acyl-CoA formation (Dhayal et al. 2008). 
C16:0 is well documented to activate ER stress and the UPR signalling pathways 
(figure 1.7), which can lead to apoptosis. Seemingly, C18:1 does not activate ER 
stress and the UPR signalling pathways in β-cells (Karaskov et al. 2006; Sommerweiss 
et al. 2013). Moreover, Diakogiannaki et al. (2008) have observed that C16:1 markedly 
suppresses the induction of ER stress markers in C16:0-treated β-cells. Attenuated 
ER stress markers included elf2α phosphorylation and the induction of ATF4 and 
CHOP. Further, in a recent proteomic analysis, when C16:0 and C18:1 were co-
exposed to β-cells, there was a differential expression of proteins compared to those 
cells expressed in the presence of C16:0 alone. Differentially expressed proteins 
included those involved in the ER stress response and proteins with antioxidant activity 
and an anti-apoptotic function (Sargsyan et al. 2016). The expression of proteins with 
antioxidant activity, triggered by C18:1, may offer an explanation for the observation 
that C18:1 prevents C16:0-induced peroxisomal H2O2 production in β-cells (Gehrmann 
et al. 2015). Moreover, contrary to C16:0, C18:1 does not trigger peroxisomal H2O2 
generation (Gehrmann et al. 2015). Whether this phenomenon is due to C18:1 not 
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being oxidised by peroxisomes or C18:1 increasing the activity of antioxidant proteins 
is unknown.  
Emerging evidence has identified that C18:1, but not C16:0, can generate lipid 
droplets in rodent β-cells (Gehrmann et al. 2015; Plotz et al. 2016). When C16:0 is co-
incubated with C18:1 however, lipid droplet formation increases in β-cells (Gehrmann 
et al. 2015; Plotz et al. 2016). It has been proposed that C18:1 rescues C16:0 induced 
apoptosis by channelling C16:0 into triglyceride pools and away from pathways which 
lead to apoptosis (Gehrmann et al. 2015). When triglyceride synthesis is impaired, 
C18:1 has been shown to induce lipotoxicity (Listenberger et al. 2003). However, the 
contribution of lipid droplet formation to C18:1 induced C16:0 triglyceride formation is 
uncertain. Pancreatic β-cell exposure to C18:1, and C16:0 together with C18:1, 
increases expression of both the mRNA and protein of perilipin, a protein involved in 
lipid droplet formation (Plotz et al. 2016). Upon silencing of perilipin however, C18:1, 
or C18:1 combined with C16:0, is still not toxic to rodent β-cells, implying that perilipin 
synthesis is not essential for the protective effect of C18:1 (Plotz et al. 2016). 
C18:1 has been shown to protect against C16:0-induced β-cell death at concentrations 
as low as 100μM, under conditions, when the concentration of C16:0 is five times 
higher than that of C18:1 (Plotz et al. 2016). In rodent β-cells, C16:1 attenuates C16:0-
induced β-cell death even when C16:1 is introduced as late as 10h after the initial 
treatment with C16:0 (Dhayal et al. 2008). The potency and rapid action of C18:1 
suggests that LC-MUFA may prevent C16:0-induced β-cell death through a receptor-
mediated process. One potential candidate is the intracellular receptors, peroxisome 
proliferator-activated receptors (PPAR), a family of transcription factors whose ligands 
include FFA, and which act to regulate lipid homeostasis (Grygiel-Gorniak, 2014). In 
rodent β-cells, C18:1 but not C16:0, increase the activity of PPARδ, leading to the 
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induction of genes involved in fatty acid oxidation (Ravnskjaer et al. 2010). However, 
C18:1 has been shown to have no effect on the gene expression of other PPAR 
isoforms expressed in β-cells (Nolan & Larter, 2009). Consequently, there is 
insufficient evidence to conclusively show a role for PPAR activity in the protective 
effect of C18:1. A further receptor candidate for the protective mechanism of C18:1 
against LC-SFA induced β-cell death, is the cell-surface G-protein coupled receptor, 
FFAR1 (free fatty acid receptor 1). The endogenous ligands for β-cell FFAR1 
(previously known as GPR40) include unsaturated and saturated LC-FFA (Stoddart et 
al. 2008; Wang et al. 2018). Upon binding to FFAR1 on the β-cell plasma membrane, 
LC-FFA can act to stimulate insulin secretion, but with chronic exposure, it has been 
suggested that they may induce apoptosis. However, whether FFAR1 plays a pro- or 
anti-lipoapoptotic role remains a matter of debate. Certain studies have proposed that 
FFAR1 may contribute to C16:0 induced rodent β-cell death by contributing towards 
the phosphorylation of the apoptogenic kinases JNK and p38 mitogen-activated 
protein kinase (MAPK) (Natalicchio et al. 2013). Conversely, Zhang et al. (2007) 
reported that silencing of FFAR1 suppressed the anti-apoptotic activity of C18:1 in 
response to C16:0. Researchers identified that the activation of the extracellular 
signal-regulated kinase (ERK)/MAPK pathway was required for C18:1 to attenuate 
C16:0-induced murine β-cell apoptosis (Zhang et al. 2007). The differential effects of 
LC-FFA on FFAR1 and the fact that FFAR1 appears to bind LC-SFA and LC-MUFA 
with almost equal affinity indicates that FFAR1 is unlikely to be the receptor which 
mediates the cytoprotective properties of C18:1 in β-cells (Newsholme et al. 2007). 
The role of other FFAR subtypes (such as GPR119 and GPR120) in β-cells are yet to 
be characterised fully, but potentially other FFARs may play a role in the protective 
effect of C18:1 against C16:0-induced β-cell lipotoxicity.  
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In summary, there is a large body of literature which supports a role for C18:1 in 
preventing C16:0-induced apoptosis of pancreatic β-cells. Mechanisms by which 
C18:1 may protect the β-cell from lipoapoptosis include attenuating ER stress, 
cardiolipin, increasing the expression of those proteins with anti-oxidant activity, 
rerouting C16:0 into triglyceride pools, and through an unknown receptor-mediated 
process.  
1.9 Gaps in research 
The cause of LC-SFA induced β-cell death remains unclear, as do the mechanisms 
by which C18:1 acts to attenuate LC-SFA induced β-cell apoptosis. Literature supports 
the role of ER stress, autophagy, ceramide metabolism, mitochondrial dysfunction and 
intracellular fatty acid storage, in the cytotoxic and cytoprotective mechanisms of LC-
FFA. It is likely that the mechanism of LC-SFA induced β-cell death and the 
cytoprotective mechanism of C18:1 is multifaceted, although the interplay of these 
processes is yet to be determined. 
There are numerous discrepancies in the literature which can, in part, be attributed to 
the model being used. The majority of research investigating the mechanism of 
lipotoxicity has been conducted in rodent β-cells or human islets. Rodent β-cells have 
been shown to differ in: their expression of genes for insulin as rodent β-cells have 
two genes and humans have one (Shiao et al. 2008), glucose transporters (De Vos et 
al. 1995) and islet structure (Brissova et al. 2005); which raises questions as to 
whether rodent β-cells are a suitable model to study T2D. Moreover, human islets 
contain β-cells as well as α-cells, δ-cells, pancreatic polypeptide (PP) cells and Ɛ-cells 
(figure 1.4) (Elayat et al. 1995; Wierup et al. 2002); which makes them an unsuitable 
model for specifically studying β-cells. Further, post-mortem pancreatic tissue has 
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been used to study lipotoxicity although post-mortem tissue can only offer insight into 
the end point of T2D and not the progression of β-cell dysfunction and death. Although 
these models have played a critical role in the exploration and characterisation of β-
cell LC-FFA lipotoxicity, it is imperative that the mechanisms of lipotoxicity be 
investigated in a cell and species-specific model, namely live human pancreatic β-
cells. By gaining insight into the mechanisms of lipotoxicity in a live human β-cell, only 
then can strategies be devised which reduce the toxicity of LC-SFA in β-cells by 
therapeutic intervention. Researchers have long attempted to generate a human-
derived pancreatic β-cell for use in the field of diabetes research. Ravassard et al. 
have finally achieved this, developing the EndoC-βH1 cells, a stable insulin-secreting 
human-derived β-cell line which was made available to study in 2011 (Ravassard et 
al. 2011). Studies which have characterised the functionality of EndoC-βH1 cells have 
identified that they function in a manner similar to human islets. However, EndoC-βH1 
cells consist only of β-cells, unlike human islets which comprise of a number of 
different cell types (Andersson et al. 2015; Gurgul-Convey et al. 2015). There are a 
limited number of studies which have investigated the effect of C16:0 and C18:1 on 
EndoC-βH1 cell viability (Tsonkova et al. 2018; Krizhanovskii et al. 2017; Plotz et al. 
2017). To the best of our knowledge, however, we are the first to study lipotoxicity in 
a human-derived β-cell line using a range of LC-FFA. 
The LC-SFA C16:0 and C18:0 are the most abundant circulating fatty acids and as 
such C18:0, and particularly C16:0, are most often employed when investigating β-cell 
lipotoxicity (Abdullah et al. 2015). However, C16:0 and C18:0 are not the only LC-SFA 
in circulation, pentadecanoic acid (C15:0), heptadecanoic acid (C17:0) and 
nonadecanoic acid (C19:0) are also present in blood plasma and as such merit further 
investigation into their toxicity profile in β-cells (Abdelmagid et al. 2015; Forouhi et al. 
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2014). A recent epidemiological study shows that higher circulating concentrations of 
C15:0 and C17:0 are associated with a lower the risk of developing T2D. This implies 
that C15:0 and C17:0 may exert a positive effect on β-cell survival, although this is yet 
to be tested directly (Forouhi et al. 2014). 
Extensive work has been conducted into the mechanisms underlying LC-SFA-induced 
β-cell death and the cytoprotective properties of LC-MUFA. Insight into these 
mechanisms have been gained predominantly using molecular biology and multi-
omics techniques (including lipidomics, proteomics and transcriptomics); identifying 
many of the intracellular signalling pathways which contribute towards β-cell 
lipotoxicity, more often than not with conflicting results. A feature of many of these 
mechanisms is that they are compartmentalised, occurring at subcellular organelles 
such as the ER, mitochondria, lipid droplets, cell membrane etc. Subsequently, the 
work of this thesis proposes to investigate lipotoxicity by ‘zooming out’ of the molecular 
mechanisms, in favour of studying the subcellular organelle distribution of LC-FFA. 
We predict that by studying lipotoxicity in this manner will provide new insight on how 
lipotoxicity occurs. Investigating the disposition of LC-FFA in β-cells may also serve to 
elucidate the extent to which each subcellular organelle contributes towards 
lipotoxicity. For example, if LC-FFA accumulates in the ER and alters ER morphology, 
it can be assumed that the ER may play a greater role in β-cell lipotoxicity compared 
to fully functioning mitochondria with no alterations in morphology and no 
accumulation of LC-FFA. Further, by studying the distribution of LC-FFA, it can be 
determined how β-cells handle LC-FFA, if this differs with fatty acid chain length and 
degrees of saturation, and if there are interspecies differences in the handling of LC-
FFA. Ultimately, these investigations will serve as a means to devise a strategy to 
reduce the toxicity of LC-SFA in β-cells by therapeutic intervention.   
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1.10 Thesis aims and objectives 
The overall aim of this thesis is to elucidate the mechanisms of lipotoxicity in human 
pancreatic β-cells. The objectives of this study are, therefore: 
1. To characterise the toxicity profile of LC-FFA (odd and even LC-SFA, and LC-
MUFA) in the human-derived EndoC-βH1 cell line 
2. Compare the effects of LC-FFA on the viability of EndoC-βH1 cells with those 
in the rat-derived INS-1E β-cell line.  
3. To elucidate the mechanisms of lipotoxicity by studying the subcellular 
distribution of LC-FFA in both human-derived EndoC-βH1 and rodent-derived 
INS-1 β-cell lines.  
In order to meet these objectives, pancreatic β-cell viability will be assessed using a 
vital dye stain and flow cytometry. The distribution of LC-FFA will be studied with the 
aid with fluorescent dyes and confocal and electron microscopy. Further, the Seahorse 
extracellular flux analyser will be employed to measure the oxidation of unlabelled LC-
FFA in real time. In this way, the mechanisms underlying β-cell lipotoxicity can be 
elucidated. 
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Chapter 2. 
Materials and Methods 
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2.1 Source of reagents 
The sources of all reagents are stated in table 2.1.  
The contents of all buffers are stated in table 2.2. 
Table 2.1 Sources of reagents 
Processes Reagent with manufacturer 
Cell culture Bovine fraction V (fatty acid free) (Roche Diagnostics);  
β-mercaptoethanol (Fisher);  
Extracellular Matrix (ECM) (Sigma); 
Fetal bovine serum (FBS) (Gibco);  
Fibronectin from bovine plasma (Sigma);  
High glucose DMEM (Gibco);  
L-glutamine (Gibco). 
Low glucose Dulbecco’s Modified Eagles Medium 
(DMEM) (Gibco);  
Nicotinamide (VWR);  
Penicillin-streptomycin (Life Technology);  
Phosphate buffered saline (PBS) (Lonza);  
RPMI-1640 (Lonza);  
Sodium selenite (Sigma);  
Transferrin (Sigma);  
0.05% Trypsin (v/v) 0.53mM EDTA (Life Technologies);  
Fatty acids All fatty acids were purchased from Sigma, except 
heptadecanoic acid, 9,11-CLA and 10,12-CLA which 
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were purchased from Cayman Chemicals. Bovine 
fraction V (fatty acid-free) (Roche Diagnostics). 
Viability assays Glucose, propidium iodide and trypan blue were 
purchased from Sigma. All other flow cytometer reagents 
were purchased from BD Biosciences.  
Microscopy BODIPY FL C16 (ThermoFisher Scientific),  
CellLight Golgi-RFP, BacMam 2.0 (ThermoFisher 
Scientific).  
Radioimmunoassay All reagents purchased from Sigma 
Seahorse XF96e All reagents purchased from Agilent.  
 
Table 2.2 Buffers 
Krebs Ringer bicarbonate buffer 
(McClenaghan, 1996) 
115mM NaCl, 4.7mM KCl, 1.2mM 
MgSO4, 10mM NaHCO3, 20mM 
HEPES, and 1.28mM CaCl2. 
Insulin assay buffer 40mM Na2HPO4, 10mM KH2PO4, 
150mM NaCl, 10mM EDTA and 5% 
(w/v) BSA. 
FACS buffer PBS with 2% (w/v) BSA 
Antibody diluting solution (ADS) 0.1M lysine, 10% (v/v) donor calf 
serum 0.02% (w/v) sodium azide, 
made up in PBS 
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2.2 Cell lines 
Immortalised clonal β-cell lines, the rodent-derived INS-1 (INS-1E and INS-1 823/13) 
and human-derived EndoC-βH1 cells, were used in this study. The INS-1 rodent beta 
cell line originated from cells that had been isolated from an x-ray induced rat 
insulinoma, with continuous growth requiring thiol β-mercaptoethanol (Asfari et al. 
1992). Hohmeirer et al. (2000) stably transfected the INS-1 cell line with a human 
proinsulin gene to enhance their response to glucose, thereby generating INS-1 
823/13 cells. Merglen et al. (2004) isolated INS-1E cells from parental INS-1 cells, 
based on their responsiveness to glucose and insulin content. The EndoC-βH1 
human-derived beta cell line was established using targeted oncogenesis of human 
foetal tissue. Briefly, this consisted of transducing human foetal pancreatic buds with 
a lentiviral vector encoding the oncoprotein, SV40LT. The oncoprotein SV40LT was 
under the control of the insulin promoter, thereby facilitating proliferation. The 
transduced buds were then grafted into mice to facilitate their development and 
differentiation into mature β-cells. The β-cells proliferated and formed insulinomas, 
which were subsequently transfected with human telomerase reverse transcriptase 
(hTERT) (to immortalise the cell line) and expanded in vitro (Ravassard, 2011).  
INS-1 and EndoC-βH1 cells were both found to secrete insulin and express β-cell 
markers, such as the transcription factor PDX1 (Wang, 2001; Ravassard, 2011). 
2.2.1 Cell culture conditions 
Clonal INS-1E cells were cultured in RPMI-1640 medium containing 11mM glucose, 
supplemented with 10% (v/v) foetal bovine serum, 100U/ml penicillin and 100μg/ml 
streptomycin, 2mM L-glutamine and 50mM/L β-mercaptoethanol. INS-1 823/13 cells 
were cultured in the same media as INS-1E cells but with a further supplement of 
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10mM HEPES and 1mM sodium pyruvate. Cells were cultured in complete medium 
(containing supplemental reagents to facilitate growth) which had been pre-warmed to 
37ºC. Cells were maintained in 75cm2 flasks at 37°C in a 5% CO2 humidified 
atmosphere. Culture medium was changed twice weekly.  
EndoC-βH1 were seeded into flasks that were coated 1h prior to seeding in DMEM 
(25mM glucose) supplemented with 1% (v/v) penicillin/streptomycin (P/S), 2µg/ml 
fibronectin, 1% (v/v) extracellular matrix (ECM). Coating medium was kept at 4ºC while 
coating the flasks, and at 37°C for the 1h incubation period before cell seeding. 
EndoC-βH1 were cultured in DMEM medium containing 5.6mM glucose, 
supplemented with  2% (w/v) bovine serum fraction V (BSA), 100U/ml penicillin and 
100μg/ml streptomycin, 10mM Nicotinamide, 5.5µg/ml transferrin, 50mM/L β-
mercaptoethanol, and 2.7nM sodium selenite. Cells were maintained in 25cm2 flasks 
at 37°C in a 5% CO2 humidified atmosphere. Culture medium was changed twice 
weekly. 
2.2.2 Cell passage 
Both cell lines were subcultured when they reached a confluency of approximately 
80%.  
INS-1 cells were detached from the culture vessel with the aid of 0.05% trypsin-
0.53mM EDTA for 5min at 37°C. Trypsin was neutralised with culture medium 
containing 10% (v/v) FBS and centrifuged at 200g for 5min. INS-1 cells were seeded 
into a fresh flask at one-tenth of the original growing population.  
To aid the detachment of EndoC-βH1 cells from the culture vessel, cells were washed 
twice in PBS and then incubated in 0.05% (v/v) trypsin-0.53mM EDTA for 5min at 
37°C. The trypsin was then neutralised in 20% FBS/ 80% (v/v) PBS and centrifuged 
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at 700g for 4min. To maintain the cell line, EndoC-βH1 cells were seeded into a fresh 
flask at 2.5x106 cells per flask. 
2.2.3 Cell Seeding  
In this study, cells were seeded in a monolayer at the densities stated in Table 2.3. 
Table 2.3 Cell seeding densities 
Cell line Plate size Seeding density (per well) 
EndoC-βH1 6-well plates 1x106 
EndoC-βH1 12-well plate 0.5x106 
EndoC-βH1 24-well plates 0.25x106 
EndoC-βH1 FluoroDish sterile 
microscopy culture 
dishes 
0.5x106 
EndoC-βH1 Seahorse XF96e 96-well 
cell culture plates 
0.06x106 
INS-1 cell lines FluoroDish sterile 
microscopy culture 
dishes 
0.5x106 
INS-1 cell lines 6-well plate 1x106 
INS-1 cell lines 12-well plate  0.5x106 
INS-1 cell lines 24-well plates 0.25x106 
INS-1 cell lines Seahorse XF96e 96-well 
cell culture plates 
0.02x106 
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In those experiments which used fixed cells for microscopy, cells were seeded onto 
glass coverslips that had been sterilised in 95% (v/v) ethanol (EtOH) for 30min, 
repeated three times. 
2.3 Preparation of fatty acids and treatment of cells 
All fatty acids were dissolved in 90% (v/v) EtOH, except oleic (C18:1) and palmitoleic 
(C16:1) acids which were dissolved in 50% (v/v) EtOH. Fatty acids were dissolved in 
EtOH by heating at 70ºC for 10min. The dissolved fatty acids were then conjugated to 
albumin by combining the fatty acids with a 10% (w/v) bovine fatty acid-free albumin 
solution for 1h at 37ºC, at a 1:10 dilution. The fatty acids conjugated to BSA were then 
added to BSA free media at a 1:10 dilution. This gave a final concentration of either 
0.9% (v/v) or 0.5% (v/v) EtOH and 1% (w/v) BSA. Cells were seeded (Table 2.3) 24h 
before being treated with the fatty acid-BSA complexes. EndoC-βH1 cells were 
exposed to fatty acid-BSA complexes for 72h, whereas INS-1 cells were treated for 
only 24h (shown to be a sufficient time for lipotoxicity to occur in INS-1 cells by Kwak 
et al. (2017)). Controls received vehicle alone which consisted of a final concentration 
of 0.9% (v/v) or 0.5% (v/v) EtOH, 1% (w/v) BSA, and no fatty acids. 
2.4 Bafilomycin  
Bafilomycin A1 is an inhibitor of vacuolar (H+)-ATPase (V-ATPases), which play a role 
in receptor-mediated endocytosis, intracellular membrane trafficking and protein 
degradation (Toei, 2011; Xu, 2003). In this study, bafilomycin A1 was used to 
investigate the role of specific fatty acid trafficking pathways (such as lipophagy) inside 
the cell. Bafilomycin A1 (Sigma) was prepared in 100% EtOH and applied to the culture 
medium at a concentration of 100nM, 1h before being treated with fatty acid-BSA 
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complexes (see section 2.3). A concentration of 100nM bafilomycin was used as 
recommended in the literature (Yamamoto et al. 1998).  
2.5 Cell viability assays  
2.5.1 Vital dye staining  
Trypan blue is a dye commonly used to assess cell viability. In living cells, where the 
membrane is intact, trypan blue is excluded causing the cell to have a clear cytoplasm. 
In dead cells, where the membrane has been damaged, the dye is retained causing 
the cell to have a blue cytoplasm (Strober, 1997). In this study, cells were treated with 
fatty acid-BSA complexes (see section 2.3) and subsequently harvested by collecting 
adhered and floating cells from each well. Cells were then centrifuged (INS-1 were 
centrifuged at 200g for 5min, EndoC-βH1 at 700g for 4min), the supernatant removed 
and the cell pellet resuspended in 500µl culture medium and 500µl trypan blue (0.4% 
(w/v) in PBS) and incubated at room temperature for 5min. The total number of dead 
(blue) and live (yellow) cells were then counted on a haemocytometer (figure 2.1) 
under a light microscope, enabling the percentage of dead cells in each well to be 
determined.   
2.5.2 Propidium iodide staining 
Propidium iodide (PI) is a red-fluorescent stain which, when the plasma membrane 
integrity is lost in cell death, intercalates with DNA. Adhered and floating cells were 
harvested as described for vital dye staining (see section 2.4.1). The pellet was 
resuspended in 200µl medium. The PI staining solution was prepared by combining 
20μg/ml propidium iodide (PI) suspended in FACS buffer (PBS and 2% (v/v) FBS). 
200µl of PI solution was then added to each sample, and the samples incubated at 
4ºC for 15min. Following this, the PI-stained cells were assessed using a BD AccuriTM 
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C6 Plus flow cytometer. PI stain was excited at 535nm, with a gate created to aid in 
the identification of dead cell populations. The gate was defined to differentiate cells 
with high PI fluorescence intensity, increased granulation and small size, which are 
indicative of reduced viability (figure 2.2) (Cummings et al. 2013).  
All viability experiments were performed a minimum of three occasions with either 
duplicate or triplicate wells for each experimental condition.  
2.6 Determining the action of fatty acid uptake and distribution 
2.6.1 Imaging with BODIPY-labelled palmitic acid 
BODIPY FL C16 (4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-
hexadecanoic acid) is a fluorescent C16:0 analogue, employed to study the subcellular 
disposition of fatty acids (Ziessel et al. 2007). BODIPY FL C16 (Life Technologies, 
USA) was prepared in 100% EtOH. When preparing the fatty acid-BSA complexes 
(see section 2.3) BODIPY FL C16 was also added and the fatty acid-BSA-BODIPY FL 
C16 complex incubated for 1h at 37ºC. The bound fatty acid-BSA-BODIPY FL C16 
complexes were then applied to cells at a final exposure concentration of 250µM FFA, 
1% (w/v) BSA and 400nM BODIPY FL C16. Cells were seeded on coverslips in a 24 
well plate (section 2.2.3) 24h before fatty acid-BSA-BODIPY FL C16 treatment.  
The subcellular disposition of the fatty acids was discovered by exposing cells to 
500μM C16:0 containing 400nM BODIPY FL C16, or 250μM C16:0 plus 400nM 
BODIPY FL C16 plus either 250 μM C17:0, 250 μM C19:0, 250 μM C18:1 or 250 μM 
methyl C18:1; for 2, 6 and 24hrs. Control cells received 400nM BODIPY FL C16 bound 
to BSA only. Cells were maintained at 37°C in a 5% CO2 humidified atmosphere. 
To image the BODIPY FL C16, cells were fixed in 250µl 4% (w/v) paraformaldehyde 
(at 4ºC) and incubated at room temperature for 15min. Fixed cells were then washed 
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three times in PBS, and mounted on coverslips with the aid of a fluorescent mounting 
medium (Dako, Denmark). Images were captured with a Leica DMI8 confocal 
microscope (63x/1.40 oil immersion objective) with excitation at 488-552nm, using 
Leica Application Suite X software. Intracellular BODIPY FL C16 accumulation 
(identified in the study as cytosolic puncta) was quantified using FIJI software 
(Schindelin, 2012). Using FIJI software, a region of interest (ROI) was drawn around 
the plasma membrane to identify the total cell area (figure 2.3a). ROI were drawn 
around the cytosolic puncta to identify the total area occupied by the puncta in the cell 
(figure 2.3b). The area of the cell covered by cytosolic puncta was then divided by the 
total cell area, and the results expressed as a percentage of the total. This was 
repeated for each individual cell and a minimum of 5 cells per condition. All 
experiments were performed on either two or three separate occasions using either 
two or three replicate wells for each experimental condition. Statistical analysis was 
carried out as described in section 2.10.  
The results from each experimental condition in each cell line are expressed as mean 
± SEM, with each data point representing an individual well containing a monolayer of 
cells at the seeding densities specified in Table 2.3. 
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Figure 2.1 Counting dead and live cells on a haemocytometer. (A) Dead (blue) 
and live (yellow) cells were counted by eye in all four large squares (red) of a 
haemocytometer. The number of dead cells was expressed as a percentage of total 
cells counted in all four squares. (B) Trypan blue stained and healthy cells, imaged 
and recorded with the x4 objective on a Zeiss Primovert inverted microscope with an 
Axiocam camera.  
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Figure 2.2 Detection of cell death using flow cytometry. (A) Cell death was induced 
in β-cell lines using fatty acid-BSA complexes. (B) Cells treated with vehicle control 
did not undergo cell death. Cells were stained with PI. The gate was established to 
differentiate dead (and dying) from live cells as shown.  
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Figure 2.3 Determining the total area of the cell covered by cytosolic puncta 
(BODIPY FL C16 accumulation) in ImageJ/FIJI software. (A) A region of interest 
was drawn around the plasma membrane and (B) cytosolic puncta. The area of the 
cell covered by cytosolic puncta was then divided by the total cell area to determine 
the total area (%) of the cell occupied by the puncta.  
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2.6.2 Golgi-BODIPY FL C16 co-localisation 
Cells were transfected with CellLight Golgi-RFP, BacMam 2.0 (Life Technologies), a 
fusion construct of a red fluorescent protein and human Golgi resident enzyme (N-
acetylgalactosaminyltransferase) to identify co-localisation. Golgi-RFP was prepared 
according to the manufacturer’s instructions and added to cells at 50 viral particles per 
cell (100μl reagent in 1.5ml culture medium) directly in culture medium 24hrs after 
seeding. Fatty acid-BSA complexes containing BODIPY FL C16 (see section 2.6.1), 
were added after 24hr and fixed in 4% (v/v) PFA (as described in section 2.6.1) for 1 
hr. To image the Golgi-RFP and BODIPY FL C16 treated cells, images were taken 
using confocal microscopy as described in section 2.6.1 above. Golgi-RFP was 
excited at 555-584nm. Cells were maintained at 37°C during imaging and imaged 
directly in culture medium or Live Cell Imaging Solution (Life Technologies). These 
experiments were conducted in collaboration with and by Dr Jenna Corcoran, 
University of Exeter.  
A quantitative colocalisation analysis was conducted using the fluorescent intensity 
analysis (FIA) plugin (as described in Dunn et al. 2011) in FIJI software (Schindelin et 
al. 2012). Briefly, the FIA plug-in converts the microscopy image into two RGB 
matrices: a pixel array of the Golgi-RFP red channel and a pixel array of the BODIPY 
FL C16 green channel. The fluorescent intensity analysis then overlaps the matrices to 
measure the degree of an overlay of the red and green pixels. The degree of 
colocalisation is then expressed as Pearson's correlation coefficient, where a value 
close to 1 is indicative of a high degree of co-localisation. 
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2.7 Transmission electron microscopy 
INS-1 and EndoC-βH1 cells were seeded on coverslips in a 6 well plate (refer to Table 
2.3 for seeding density) and exposed to 500µM C16:0, 500µM C18:1 or C16:0 co-
incubated with C18:1 (final concentration of 500µM) (as fatty acid-BSA complexes 
described in section 2.3) for 6h. Control cells were treated with BSA vehicle only. INS-
1 and EndoC-βH1 cells were then fixed in an osmium tetroxide fixative before being 
imaged with TEM. Fixing of the cells and TEM was undertaken within the Bioimaging 
Unit at the University of Exeter.  
2.7.1 Immunogold labelling with transmission electron microscopy 
Cryo-immunogold electron microscopy was used to determine the localisation of 
proinsulin and insulin in the EndoC-BH1 cell line. EndoC-βH1 cells were seeded in 
10cm dishes at 5x106 cells per dish. Cells were exposed to 500µM C16:0 or vehicle 
control (as fatty acid-BSA complexes described in section 2.3) for 6h. Cells were then 
treated as described in Slot et al. (2007). Briefly, this included fixing the cells in 4% 
(v/v) PFA supplemented with 0.1% (v/v) glutaraldehyde, scraping the cells in fixative, 
centrifuging at 800g for 30min to form a pellet, and embedding the pellet in 12% (w/v) 
gelatin. The gelatin embedded pellet was then immersed in 2.3M sucrose (made up in 
PBS at 4ºC) before being frozen in liquid nitrogen and cryo-sectioned. The sections 
were then incubated for 45min at room temperature in PBS containing 1% (w/v) BSA 
and the appropriate antibodies (insulin or proinsulin). The sections were then washed 
in PBS and incubated for 20 min in protein A-gold labelled antibodies (5nm or 20nm 
diameter gold spheres; G. Posthuman, Utrecht) diluted in 0.1% (w/v) BSA and PBS. 
The 5nm protein A-gold labelled antibody bound to the insulin antibody, and a bridging 
antibody was used to increase the stability of binding the 20nm protein A-gold label to 
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the proinsulin antibody. The sections were then incubated briefly in 1% (v/v) 
glutaraldehyde to stabilise the interactions and stained with 2% (w/v) neutral uranyl 
acetate (to stabilise the membrane lipids and enhance the final contrast) in water for 
5 minutes. Sections were then embedded for 10 minutes on ice with 2% (w/v) 
methylcellulose supplemented with 0.4% uranyl acetate (w/v) and imaged with a Jeol 
1400 microscope. Cryosectioning, immunolabelling and imaging were kindly 
conducted by Dr Varpu Marjomӓki at the University of Jyvӓskyla, Finland.  
2.8 Insulin secretion 
2.8.1 Insulin secretion assay 
INS-1 and EndoC-βH1 cells were seeded in a 24 well plate (table 2.3) 24h before the 
experiment. Cells were washed and pre-incubated for 1h in Krebs Ringer bicarbonate 
buffer (Krebs henceforth) (table 2.2) supplemented with 0.1% (w/v) BSA and 2mM D-
glucose. The medium was then removed, and cells were treated for 1.5h (at 37ºC) 
with Krebs buffer supplemented with: 
1. 0.1% (w/v) BSA and 2mM D-glucose  
2. 0.1% (w/v) BSA and 20mM D-glucose 
3. 0.1% (w/v) BSA and 25mM KCl (30mM final concentration as Krebs recipe 
contained 5mM KCl).  
4. 20mM D-glucose and 500µM of either C16:0, C17:0, C18:0, C18:1 or vehicle 
only (as fatty acid-BSA (1% w/v) complexes described in section 2.3) 
EndoC-βH1 cells did not secrete insulin in response to 20mM glucose. To amplify the 
release of insulin from the cells, test reagents were applied with and without 100µM 
IBMX (3-isobutyl-1-methylxanthine) in the incubation medium. IBMX was used to raise 
the level of cAMP, which amplifies the release of insulin (Siegal, 1980). After the 1.5h 
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treatment period, 500µl of the supernatant was removed from each well and insulin 
levels determined by radioimmunoassay.  
2.8.2 Radioimmunoassay  
Crystalline human insulin (8ng/ml) was serially diluted to create a standard curve. To 
each of the standards and samples, 50µl guinea pig anti-bovine insulin antibody 
(1:20,000 in insulin assay buffer) and 50µl of 125I insulin (0.5µCi in 10ml insulin assay 
buffer) was added, and the tubes incubated overnight at 4°C. 1ml of precipitating 
reagent (PBS with 2mg/ml γ-globulins plus 30% PEG 6000 (w/v) (1:1) and 0.05% (v/v) 
Tween) was added to precipitate the insulin bound to the Ab. This was collected by 
centrifugation and the radioactivity of each pellet measured using a Perkin Elmer 2470 
Automatic Gamma Counter with Wizard2 software. A standard curve was constructed 
and used to calculate the insulin concentration of each experimental sample. Results 
were standardised by expressing insulin secretion as a fold change relative to those 
cells treated with either 2mM D-glucose alone (which acted as a control for 20mM 
glucose and 30mM KCl) or fatty acid vehicle control (see section 2.3).  
All insulin secretion experiments were performed a minimum of three times with either 
duplicates or triplicates for each experimental condition.  
2.8.3 EndoC-βH1 pseudoislet insulin secretion  
To generate pseudoislets, EndoC-βH1 cells were grown as described in section 2.2, 
omitting the Matrigel-fibronectin from the culture flasks before seeding. The growing 
cells formed pseudoislets over a 72h period (figure 2.4). 
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Figure 2.4 Pseudoislet formation after 72h. EndoC-βH1 were seeded in cell culture 
flasks that had not been coated with Matrigel-fibronectin before seeding. Cells were 
left to form pseudoislets over a 72h period. The formation of pseudoislets after this 
period was documented using a Leica DMi8 Widefield and Live Cell microscope 
(images courtesy of Dr Holly Hardy, University of Exeter).  
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EndoC-βH1 pseudoislet insulin secretion was determined by perfusion. Perfusion 
experiments were undertaken by Dr Mark Russell (University of Exeter) as described 
in Russell et al. (2011). Briefly, this consisted of suspending pseudoislets on a pre-
wetted glass wool plug (in tubing) inside a Stuart bench incubator at 37ºC. Warm Krebs 
buffer (supplemented with 0.1% (w/v) BSA and 2mM D-glucose) was pumped over the 
pseudoislets at a rate of ~1ml/min for 1h before the start of the experiment. Insulin 
release was stimulated by adding 20mM glucose and ~20mins later, 30mM KCl. The 
supernatant was collected every minute for 50min. At the end of the assay, the glass 
wool was examined by eye under a Zeiss Primovert inverted microscope, to confirm 
that the islets were still present. The insulin content of the supernatant was determined 
by radioimmunoassay as described in section 2.2.  
2.8.4 Immunocytochemistry  
INS-1 and EndoC-βH1 cells were seeded on coverslips in a 24-well plate (Table 2.3) 
and left to adhere for 24hrs. Cells were exposed to the fatty acid-BSA complexes 
(section 2.3) for 4h before being fixed with 4% (v/v) PFA (as described in 2.6.1). Cells 
were then treated for 30min with antibody diluting solution (ADS) (table 2.2) 
supplemented with 0.2% (v/v) Triton X-100 (ADST) to permeabilise the cell membrane. 
The ADST was removed, and the cells probed with a primary insulin antibody 
(polyclonal guinea pig IgG anti-insulin [Dako, Agilent] at a 1:400 dilution in ADST) and 
incubated for 1h. The cells were washed five times in PBS and incubated for 1hr with 
the secondary antibody (anti-guinea pig 568nm (Thermo Fisher) at a 1:400 dilution in 
ADST) and DAPI (4’,6-Diamidino-2-Phenylindole, Dihydrochloride) (Thermo Fischer) 
(at a 1:1000 dilution in ADST) to stain the nucleus. Cells were washed a further five 
times in PBS and mounted face down onto 3µl of fluorescent mounting medium 
(DAKO, Agilent). Samples were then viewed under a Leica DM4000 B LED 
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Fluorescent microscope, where DAPI was excited at 400nm and anti-guinea pig IgG 
at 568nm. Images were captured using Leica Application Suite X software.  
2.9 Mitochondrial respiration 
In this study, the Seahorse XF96e flux analyser was used to measure the oxygen 
consumption rate (OCR) (pmol/minute) of live β-cells in response to an acute injection 
of glucose or fatty acid-BSA complexes (as described in section 2.3). INS-1 and 
EndoC-βH1 cells were seeded in a Seahorse XF96e 96-well cell culture plate (table 
2.3) 24h prior to running the assay. The 96-well culture microplate was coated in 
100µg/ml poly-D-lysine (Sigma) 30 minutes prior to seeding cells to facilitate adhesion. 
As per the manufacturer instructions, a Seahorse XF96e sensor cartridge was 
hydrated (to hydrate the solid sensor probes which monitor changes in O2) in Seahorse 
XF calibrant (200μl/well) and incubated overnight at 37°C with only atmospheric CO2. 
Cell media were replaced 2h before running the assay with Krebs-Ringer buffer (table 
2.2) supplemented with 1mM pyruvate, 2mM L-glutamine and either 0mM or 10mM 
glucose, and the pH adjusted to 7.4. Cells were further incubated at 37°C without CO2 
for 1h before the XF assay. Reagents to be injected were adjusted to a pH 7.4. 
Reagents were loaded into the injection ports of the sensor cartridge (25µl per port) 
ready for sequential injection during the assay. After injection, the machine mixed the 
well for 3 minutes, rested for 2 minutes, and took measurements for 3 minutes. The 
total assay time was between 60-90 minutes, including 20 minutes for reading basal 
respiration. The Seahorse instrument maintained the cells at a pH of 7.4 and at 37°C 
for the duration of the experiment. Each experiment was repeated a minimum of three 
times and eight replicates were included for each experimental condition.  
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2.9.1 Mito stress test 
A Seahorse XF Cell Mito Stress Test kit was used to produce a mitochondrial 
bioenergetic profile of INS-1 and EndoC-βH1 cells, as an indicator of the metabolic 
function and bioenergetic health of the β-cell lines (figure 2.5). As per the 
manufacturer’s instructions, oligomycin, FCCP (fluoro-carbonyl cyanide 
phenylhydrazone) and rotenone/antimycin A mix were reconstituted in supplemented 
Krebs buffer (Table 2.2). Compounds were loaded into the injection ports in the sensor 
cartridge (25µl per port) ready for sequential injection during the assay. Oligomycin 
was injected after 15 minutes (with the first 15mins measuring basal respiration), 
FCCP was injected after 35mins and the rotenone/antimycin mix after 61mins. 
Respiration was measured for approximately 20mins after each injection. The cells 
were exposed in the well to a final concentration of 1µM oligomycin, 1µM FCCP and 
0.5µM rotenone/antimycin mix. 
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Figure 2.5 Agilent Seahorse XF Cell Mito Stress Test. The mitostress test produces 
a mitochondrial energetic profile of cells. (A) Oligomycin, FCCP and rotenone 
antimycin mix are sequentially injected during the assay which facilitates the 
measurement of ATP production, proton leak, maximal respiration and the spare 
metabolic capacity of cells. (B) Oligomycin inhibits ATP synthase, FCCP disrupts the 
proton gradient of the ETC, rotenone and antimycin A inhibit complex I (NADH 
Coenzyme Q oxidoreductase) and complex III (ubiquinol-cytochrome c 
oxidoreductase), respectively (adapted from Agilent, 2017). 
 
A. 
B. 
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2.9.2 Seahorse statistical analysis 
All statistical analysis was conducted using the R statistical language, and GraphPad 
software. To standardise the data, all experimental values were normalised to baseline 
and loge transformed. The area under the curve was calculated by taking the sum of 
all data points recorded after the substrate injection. The statistical differences 
between groups was conducted as described in section 2.10.  
2.10 Statistical Analysis 
Statistical significance was established using the R statistical language, and 
GraphPad software. Experimental replicates from each independent experiment were 
collated and the statistical difference between groups calculated using an analysis of 
variance (ANOVA) (Box, 1954). To compare differences between all treatment groups, 
a Tukey post-hoc (Tukey, 1949) test was used. The difference between groups or 
control was regarded as significant if P< 0.05. 
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Chapter 3. 
Effects of long-chain fatty acids on human β-cell viability 
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3.1 Introduction 
Fatty acids (FFA) are mainly bound to serum albumin in the blood and are present at 
total concentrations between 100µM-1mM (Ralston et al. 2013). The concentration of 
circulating FFA is tightly regulated, but with metabolic disturbances (such as insulin 
resistance) circulating FFA concentrations can become elevated and their circulating 
profile altered (Mika et al. 2016). When sustained, the dysregulation and elevation of 
circulating FFA are linked with an increase in an individual’s risk of developing T2D 
(Mooradian, 2009; Fourouhi et al. 2014).  
Lee et al. (1994) was one of the earliest studies to recognise that elevated FFA and 
triglyceride levels in the pancreas caused β-cell dysfunction and death. However, in 
subsequent years it has been realised that not all FFAs exert the same toxic effects 
on pancreatic β-cells. The LC-SFA C16:0 and C18:0 are the most abundant LC-SFAs 
in the human body (Mika et al. 2016), and it is widely understood that in excess they 
are extremely toxic to rodent β-cells and human islets at least, in vitro (Maedler et al. 
2003; Welters et al. 2004). The short to medium chain SFAs (such as myristate; C14:0) 
however are much less toxic (Welters et al. 2004). Moreover, a recent epidemiological 
study revealed that higher levels of circulating C16:0 and C18:0 correlate with an 
increased risk of developing T2D, whereas an elevation in certain odd numbered LC-
SFA (C15:0 and C17:0) is associated with a decreased risk (Fourouhi et al. 2014). 
This might suggest that C15:0 (pentadecanoic acid) and C17:0 (heptadecanoic acid) 
exert a positive effect on β-cell survival, although this has yet to be tested directly. 
Therefore, this evidence poses the following questions: 1) does LC-SFA toxicity 
correlate with carbon chain length in β-cells? 2) are the odd-chain FFA cytoprotective 
to β-cells?  
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Strikingly, the long-chain monounsaturated fatty acids (LC-MUFA) (such as oleic 
(C18:1) and palmitoleic acid (C16:1)) are well tolerated by β-cells, and even have the 
ability to attenuate C16:0 induced toxicity in rodent β-cells and human islets (Maedler 
et al. 2003; Maedler et al. 2001; Welters et al. 2004). It has been suggested that LC-
MUFA may inhibit C16:0 induced cell death as a protective mechanism against 
lipotoxicity in tissues such as the liver (Silbernagel et al. 2012). In the liver and 
pancreas, C16:0 can be desaturated to yield C16:1 by SCD-1 (stearoyl-CoA 
desaturase) and this could be a mechanism to prevent C16:0 accumulation 
(Silbernagel et al. 2012; Hellemans et al. 2009). Interestingly, SCD1 has been shown 
to be upregulated in specific clones of rodent-derived β-cells which are resistant to 
C16:0-induced apoptosis (Busch, 2005). Further, inducing SCD1 expression protects 
against C16:0-induced cell death in rodent and human β-cells (Hellemans et al. 2009). 
Thus, the balance between the levels of various long-chain FFA (LC-FFA) species, 
particularly LC-SFA and LC-MUFA, is likely to be critical to the health of β-cells, as is 
the activity of desaturase enzymes such as SCD1.  
Investigating the lipotoxic profile of individual FFAs in human β-cells has proved 
challenging. Isolating homogenous populations of β-cells is difficult due to the fact that 
β-cells comprise only 1-2% of the total pancreatic mass and they are located in islets 
of Langerhans, which also contain other cell types (Weir et al. 2011). With recent 
developments in florescence activated cell sorting (FACS) however, it is becoming 
increasingly feasible to purify β-cell populations (Basu et al. 2010), but accessing 
human islets remains a challenge in many countries as the majority of viable human 
islets are used in transplant programmes. Until recently, reliance has been placed on 
rodent models, post-mortem pancreatic sections and isolated human islets to study 
the pathophysiology of T2D. Although rodent models have historically played a critical 
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role in the exploration and characterisation of diabetes, there are marked interspecies 
differences between rodent and human β-cells. For example, the principal glucose 
transporter expressed in rodent β-cells is GLUT2 (glucose transporter 2), whereas in 
human β-cells GLUT1 and GLUT3 are the main glucose transporters (Chandrasekera 
et al. 2013). Interspecies differences call into question whether rodent cells are an 
appropriate model to study human β-cell lipotoxicity. However, investigating β-cell 
lipotoxicity in human islets also has limitations, as the islets consist of a number of cell 
types in addition to β-cells. In order to understand the impact of elevated FFAs on 
human pancreatic β-cells, it is essential to determine the mechanisms by which 
lipotoxicity occurs. For the first time, however, lipotoxicity in human β-cells can now be 
addressed as, in 2011, the stable insulin-secreting human-derived β-cell line, EndoC-
βH1, was generated and has subsequently been made available for study (Ravassard 
et al. 2011).  
With access to the EndoC-βH1 cell line, glucolipotoxicity can also be investigated. 
Human islets and rodent β-cells are well documented to undergo cell death when 
exposed to C16:0, although whether C16:0-induced β-cell death is affected by the 
presence of elevated glucose concentrations is species dependent. C16:0-induced 
cell death in isolated human islets does not increase when glucose concentrations are 
raised from 5.5mM to >20mM (Sargsyan et al. 2011; Poitout et al. 2010). Conversely, 
an increase in C16:0-induced cell death is observed when rodent β-cells are exposed 
to >11mM glucose (Sargsyan et al. 2011). Therefore, with the availability of EndoC-
βH1 cells, it is now possible to establish whether human β-cells are sensitive to C16:0 
and, if so whether cell viability is adversely affected by glucose concentrations. 
The aim of the studies presented in this chapter is to characterise the toxicity profile 
of LC-FFA. Specifically, we wanted to determine which LC-FFA are toxic to human-
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derived β-cells and over which concentration range. The studies further determined if 
toxicity correlates with FFA carbon chain length, if the odd-chain LC-SFA are 
cytoprotective to β-cells, and whether the presence of high glucose accentuates 
C16:0-induced cell death. Moreover, to assess whether lipotoxicity in rodent β-cells is 
reflective of the human situation, a comparison of the LC-FFA toxicity profile of the 
rodent-derived INS-1E β-cell line with that of the human-derived EndoC-βH1 cells 
were also made. 
3.2 Methods 
EndoC-βH1 and INS-1E cell lines were used in all experiments described in this 
chapter. The cells were cultured as described in section 2.2 and seeded into 6 or 12 
well plates at a seeding density given in table 2.3. Cells were seeded 24h prior to 
treatment with fatty acid-BSA complexes (see section 2.3). Vital dye staining and 
propidium iodide were used to estimate cell death (see section 2.5).  
Foetal bovine serum (FBS) is a necessary constitute of INS-1E culture medium, 
although it contains varying fatty acids (mainly polyunsaturated FFA) (Stoll, 1984). All 
experiments described in this chapter, therefore, were conducted in FBS FFA free 
media to ensure that FFA concentrations were not altered in an uncontrolled manner. 
Moreover, fatty acids were conjugated to fatty acid-free bovine serum albumin (BSA).  
3.3 Results 
3.3.1 Effects of the LC-SFA C16:0 on human β-cell viability 
It is well understood that the LC-SFA C16:0 causes a loss of viability in rodent β-cells 
cultured for periods of 24-96h (Welters et al. 2004; Dhayal et al. 2011). Accordingly, 
in this study when INS-1E cells were exposed to increasing concentrations of C16:0 
(0-500µM), there was a dose-dependent increase in cell death within 24h as judged 
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by vital dye staining. Cell death was significantly increased in INS-1E cells with 
concentrations of ≥250µM C16:0 after a 24h period of exposure (figure 3.1). To 
investigate the effects of C16:0 on the human-derived EndoC-βH1 cell line, EndoC-
βH1 cells were also treated with increasing concentrations of C16:0 (0-500µM). 
Surprisingly, after 24, 48, and 72h there was no increase in cell death as assessed by 
flow cytometry (only 72h data shown) (figure 3.2). EndoC-βH1 cells exposed to 500µM 
C16:0 for 72h, also showed no significant increase in cell death when viability was 
estimated by vital dye staining (appendix 1). EndoC-βH1 cells, therefore, were more 
resistant to the toxic effects of C16:0 than rodent β-cells.  
To investigate if the human-derived β-cell line, EndoC-βH1, undergoes cell death 
when exposed to C16:0 in the presence of glucose at high concentrations 
(glucolipotoxicity), EndoC-βH1 cells were treated with 500µM C16:0 in both low 
(5.5mM) and high (20mM) glucose for 72h. Compared to vehicle controls, there was 
no increase in cell death when EndoC-βH1 cells were exposed to 500µM C16:0 with 
low (5.5mM) or high (20mM) glucose in the extracellular medium (figure 3.3).  
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Figure 3.1 Effect of increasing concentrations of C16:0 on the viability of INS-1E 
cells. INS-1E cells were treated with 0µM, 125µM, 250µM and 500µM C16:0 for 24h. 
Cell death was estimated using vital dye staining. Dots represent data points from four 
independent experiments. Data are expressed as the mean values with error bars 
representing the SEM. *** p<0.001 relative to 0µM. 
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Figure 3.2 Effect of increasing concentrations of C16:0 on the viability of EndoC-
βH1 cells. EndoC-βH1 cells were treated with 0µM, 125µM, 250µM and 500µM C16:0 
for 72h. Dots represent data points from four independent experiments. Cell death was 
estimated using flow cytometry. Data are expressed as the mean values with error 
bars representing the SEM. 
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Figure 3.3 Effect of C16:0 on the viability of EndoC-βH1 cells in the presence of 
low and high glucose. EndoC-βH1 cells were treated with 0.5mM C16:0 in the 
presence of 5.5mM or 20mM glucose, for 72h. Control cells were treated with BSA 
vehicle only, with either 5.5mM or 20mM glucose in the extracellular medium. Cell 
death was estimated using flow cytometry. Dots represent data points from three 
independent experiments. Data are expressed as the mean values with error bars 
representing the SEM 
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3.3.2 Effects of fatty acid chain length on human β-cell viability 
Welters et al. (2004) have previously shown that SFAs with a chain length greater than 
14 carbon atoms are toxic to pancreatic β-cells, whereas SFAs with 14 carbon atoms 
or less are much less toxic to rodent β-cells. Moreover, it has been suggested that β-
cell lipotoxicity is induced to a greater extent by C18:0 compared to C16:0 (Lu et al. 
2016). Therefore, in this study, it was sought to explore if fatty acid chain length 
correlated with toxicity. The toxicity profile of C15:0, C16:0, C17:0, C18:0 and C19:0 
were determined in both rodent-derived INS-1E and human-derived EndoC-βH1 cells. 
Seemingly, this is the first time that the toxicity profile of odd-chain LC-SFA has been 
determined directly in pancreatic β-cells. 
In the rodent-derived INS-1E β-cell line, when used at 500µM and after an exposure 
time of 24h, C15:0, C16:0, C17:0, C18:0 and C19:0 all significantly increased β-cell 
death relative to control (figure 3.4). C19:0, however, was the most efficacious LC-
SFA when used at 500µM, triggering cell death in almost 100% of cells. The odd-chain 
LC-SFA C15:0, C17:0 and C19:0 are therefore toxic to rodent INS-1E cells. LC-SFA 
toxicity, however, did not correlate directly with carbon chain length (i.e. there was no 
increase in cell death with increased chain length) since C15:0 caused a greater 
degree of INS-1E cell death compared to C17:0. Importantly, C17:0 and C19:0 were 
both found to cause cell death in a dose-dependent manner (figure 3.5 and 3.6). After 
24h exposure, C17:0 induced INS-1E cell death at concentrations as low as 125µM 
(figure 3.5) with >50% of cells losing viability at concentrations ≥250µM. After 24h 
treatment, C19:0, however, caused >50% cell death at a concentration as low as 
125µM (figure 3.6). In the INS-1E cell line, therefore, all LC-SFA are toxic, with C19:0 
causing the greatest loss in viability even at lower concentrations.  It must be noted 
that in figure 3.4, those cells treated with vehicle control had a higher amount of cell 
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death relative to those cells treated with vehicle control in figure 3.1. This was due to 
using a different method to estimate cell death, where flow cytometry gives a greater 
percentage cell death in the vehicle control-treated group compared to vital dye 
staining.  
In the human-derived EndoC-βH1 cell line, C19:0 (500µM) was the only LC-SFA to 
significantly induce cell death over 72h, causing cell death in a dose-dependent 
manner (figure 3.7 and figure 3.8). Approximately 50% of total EndoC-βH1 cells 
underwent cell death after being treated with C19:0 for 72h at a concentration of 
500µM, although there was no significant increase in cell death at concentrations 
<500µM. EndoC-βH1 cells are therefore resistant to the toxic effects of C15:0, C16:0, 
C17:0 and C18:0, but undergo cell death with exposure to high concentrations of 
C19:0.  
C16:0 is present in the blood in combination with other FFA (Abdelmagid et al. 2015; 
Mika et al. 2016). To study the toxicity profile of LC-SFAs in combination, EndoC-βH1 
cells were simultaneously treated for 72h with 250µM C16:0 and either 250µM C17:0 
or 250µM C19:0 (total concentration of LC-SFA per well, 500µM) (figure 3.9). 
Individually and in combination, C16:0 and C17:0 did not increase EndoC-βH1 cell 
death relative to vehicle control. Conversely, C19:0 significantly increased β-cell death 
but surprisingly, when in combination with C16:0, C19:0-induced EndoC-βH1 cell 
death was significantly decreased. This may indicate that C16:0 exerts a protective 
effect against C19:0-induced EndoC-βH1 cell death. Alternatively, EndoC-βH1 cells 
may not have undergone C19:0-induced cell death as cells were treated with only 
250µM C19:0 (and 250µM C16:0) which, as shown in figure 3.8, is not a sufficient 
concentration to induce cell death. In summary, human-derived EndoC-βH1 cells 
appear to respond differently to LC-SFA (C15:0-C18:0) compared to rodent-derived  
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Figure 3.4 Effect of increasing chain length LC-SFA on the viability of INS-1E 
cells. INS-1E cells were treated with 500µM C15:0, C16:0, C17:0, C18:0 and C19:0 
for 24h. Control cells were treated with BSA vehicle only. Cell death was estimated 
using flow cytometry. Dots represent data points from three independent experiments. 
Data are expressed as the mean values with error bars representing the SEM. 
*p<0.05, ***p<0.001 relative to vehicle.  
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Figure 3.5 Effect of increasing concentrations of C17:0 on the viability of INS-1E 
cells. INS-1E cells were treated with 0µM, 125µM, 250µM and 500µM C17:0 for 24h. 
Cell death was estimated using flow cytometry. Dots represent data points from four 
independent experiments. Data are expressed as the mean values with error bars 
representing the SEM. **p<0.01,***p<0.001 relative to 0µM. 
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Figure 3.6 Effect of increasing concentrations of C19:0 on the viability of INS-1E 
cells. INS-1E cells were treated with 0µM, 125µM, 250µM and 500µM C19:0 for 24h. 
Cell death was estimated using flow cytometry. Dots represent data points from four 
independent experiments. Data are expressed as the mean values with error bars 
representing the SEM. *p<0.05, ***p<0.001 relative to 0µM. 
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Figure 3.7 Effect of increasing chain length of LC-SFA on the viability of EndoC-
βH1 cells. EndoC-βH1 cells were treated with 500µM C15:0, C16:0, C17:0, C18:0 and 
C19:0 for 72h. Control cells were treated with BSA vehicle only. Cell death was 
estimated using flow cytometry. Dots represent data points from three independent 
experiments. Data are expressed as the mean values with error bars representing the 
SEM. **p<0.01 relative to the vehicle. 
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Figure 3.8 Effect of increasing concentrations of C19:0 on the viability of EndoC-
βH1 cells. EndoC-βH1 cells were treated with 0µM, 125µM, 250µM and 500µM C19:0 
for 72h. Cell death was estimated using flow cytometry. Dots represent data points 
from four independent experiments. Data are expressed as the mean values with error 
bars representing the SEM. ***p<0.001 relative to 0µM. 
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Figure 3.9 Effect of combined LC-SFA on the viability of EndoC-βH1 cells. 
EndoC-βH1 cells were treated with either 500µM C16:0, C17:0 and C19:0 (circles) for 
72h, or  250µM C16:0 in combination with 250µM C17:0 or C19:0 (diamonds) (total 
concentration per well 500µM) for 72h. Control cells were treated with BSA vehicle 
only. Cell death was estimated using vital dye staining. Dots represent data points from 
three independent experiments. Data are expressed as the mean values with error 
bars representing the SEM. *p<0.05 
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INS-1E cells. C19:0, however, is the most efficacious LC-SFA causing the loss of 
viability in both EndoC-βH1 and INS-1E cells. EndoC-βH1 cells, however, appear 
more resistant to the toxic effects of C19:0 only losing viability with high concentrations 
(≥500µM) and with exposure periods extending up to 72h. 
3.3.3 Effects of co-incubating LC-SFA with LC-MUFA on human β-cell viability 
Contrary to LC-SFA, LC-MUFA have mostly proven to be benign in rodent β-cells and 
human islets. Strikingly, LC-MUFA have been shown to completely attenuate the 
cytotoxic effects of C16:0 in rodent β-cells and human islets (Maedler et al. 2003; 
Maedler et al. 2001). In confirmation of previous in vitro experiments (Welters et al. 
2004), INS-1E cells were treated simultaneously with C16:0 and C18:1 and cell 
viability monitored. As previously observed in rodent β-cells, C18:1 was not toxic to 
INS-1E cells. Further, C18:1 completely attenuated C16:0 induced cell death, with the 
extent of cell death being even lower than in cells treated only with vehicle (figure 
3.10). C16:0-induced INS-1E cell death was also attenuated by C18:1 methyl ester 
(figure 3.10). Due to the carboxyl group of the C18:1 being esterified to a methyl group, 
methyl-C18:1 cannot be further esterified to Co-enzyme A and is therefore 
metabolically inert. Thus, this result is indicative of C18:1 promoting β-cell viability by 
a mechanism that does not require its metabolism, as the non-metabolised methyl-
C18:1 also mitigates C16:0-induced cell death in rodent-derived β-cells.  
To determine if C18:1 blocks only C16:0-induced cell death in rodent-derived β-cells, 
INS-1E cells were treated simultaneously for 72h with C18:1 and either C15:0, C17:0 
or C19:0. The LC-MUFA C18:1 completely attenuated cell death induced by each odd-
chain LC-SFA in INS-1E cells (figure 3.11). In rodent-derived INS-1E cells, therefore, 
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LC-SFAs cause extensive cell death, except when simultaneously exposed to certain 
LC-MUFA.  
To determine the effect of co-incubating C16:0 with LC-MUFA on the viability of 
EndoC-βH1 cells, these were simultaneously exposed to C16:0 and C18:1 (figure 
3.12). Surprisingly, unlike in rodent β-cells, C18:1 modestly (18%) increased cell death 
relative to vehicle control, at a concentration of 500µM and an exposure time of 72h. 
Interestingly, methyl-C18:1 did not induce EndoC-βH1 cell death (figure 3.12), 
indicating that the toxic effects of C18:1 were due to a mechanism that requires its 
activation. To investigate if other LC-MUFA were also toxic to human-derived β-cells, 
EndoC-βH1 cells were treated for 72h with increasing concentrations of the LC-MUFA, 
palmitoleate (C16:1) (figure 3.13). No increase in cell death was observed in EndoC-
βH1 cells treated with concentrations as high as 500µM C16:1 during an exposure 
period of 72h.  
In summary, the LC-MUFA C18:1 can completely attenuate rodent β-cell death 
induced by the LC-SFA C15:0, C16:0, C17:0 and C19:0. Further, the cytoprotective 
effect of C18:1 in rodent-derived β-cells does not require its activation. Conversely, 
C18:1 causes a modest increase in human-derived β-cell death, but this is not 
reproduced by the methyl ester of C18:1. Unlike C18:1 however, the LC-MUFA C16:1 
does not induce EndoC-βH1 cell death.  
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Figure 3.10 Effect of C16:0 in the presence or absence of C18:1 and C18:1 methyl 
on the viability of INS-1E cells. INS-1E cells were treated with either 500µM C16:0, 
500µM C18:1, 500µM methyl C18:1 (C18:1m), or 250µM C16:0 combined with either 
250µM C18:1 or 250µM methyl-C18:1 (final total concentration 500µM); for 24h. 
Control cells were treated with BSA vehicle only. Cell death was estimated using vital 
dye staining. Dots represent data points from four independent experiments. Data are 
expressed as the mean values with error bars representing the SEM. ***p<0.001.  
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Figure 3.11 Effect of varying chain length LC-SFA in combination with C18:1 on 
the viability of INS-1E cells. INS-1E cells were treated for 24h with 500µM C15:0, 
C16:0, C17:0, C18:0 and C19:0, or 250µM C15:0, C16:0, C17:0, C18:0 and C19:0  in 
combination with 250µM C18:1., giving a final total concentration of 500µM fatty acids 
in each well. Control cells were treated with BSA vehicle only. Cell death was estimated 
using flow cytometry. Dots represent data points from three independent experiments. 
Data are expressed as the mean values with error bars representing the SEM. 
*p<0.05, **p<0.01, ***p<0.001 relative to vehicle. 
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Figure 3.12 Effect of C16:0 in combination with C18:1 and methyl-C18:1 on the 
viability of EndoC-βH1 cells. EndoC-βH1 cells were treated for 72h with 500µM 
C16:0, 500µM C18:1, 500µM C18:1 methyl or 250µM C16:0 in combination with 
250µM C18:1 (500µM total final concentration). Control cells were treated with BSA 
vehicle only. Cell death was estimated using flow cytometry. Dots represent data points 
from four independent experiments. Data are expressed as the mean values with error 
bars representing the SEM. **p<0.01. 
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Figure 3.13 Effect of increasing concentrations of C16:1 on the viability of 
EndoC-βH1 cells. EndoC-βH1 cells were treated with 0µM, 125µM, 250µM and 
500µM C16:1 for 72h. Cell death was estimated using flow cytometry. Dots represent 
data points from three independent experiments. Data are expressed as the mean 
values with error bars representing the SEM. 
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3.3.4 Effects of bafilomycin A1 on human β-cell viability in cells exposed to LC-
SFA 
Bafilomycin A1 is an inhibitor of vacuolar H+-ATPase (V-ATPase), an electrogenic H+ 
pump which regulates the pH of intracellular compartments including 
autophagosomes, endosomes and lysosomes (Maxson et al. 2014). V-ATPase, 
therefore, plays a regulatory role in intracellular processes including intracellular 
membrane trafficking, endocytosis and protein degradation (Jefferies et al. 2008). The 
effect of inhibiting these processes on EndoC-βH1 cell viability was investigated with 
the rationale that EndoC-βH1 cells may be resistant to the toxic effects of C16:0 
through increased activity of V-ATPase dependent processes (e.g. autophagy). 
Inhibiting V-ATPase dependent mechanisms using 100nM bafilomycin alone 
significantly increased EndoC-βH1 cell death during an exposure time of 72h (figure 
3.14). Moreover, bafilomycin-induced β-cell death was not altered in the presence of 
500µM C16:0 or 500µM C18:1. Strikingly, treatment of EndoC-βH1 cells with both 
C16:0 and C18:1 for 72h (total concentration of LC-FFA per well, 500µM) caused a 
marked decrease in bafilomycin-induced β-cell death. This indicates that the 
combination of C16:0 and C18:1 is cytoprotective against bafilomycin-induced EndoC-
βH1 cell death.  
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Figure 3.14 Effects of bafilomycin A1 on EndoC-βH1 cells exposed to LC-SFA. 
EndoC-βH1 cells were incubated for 1h with 100nM bafilomycin in the extracellular 
medium. 500µM C16:0, 500µM C18:1, or 250µM C16:0 combined with 250µM C18:1 
was then added to cells which had previously been treated with and without 
bafilomycin. Control cells were treated with BSA vehicle only. EndoC-βH1 cells were 
treated with vehicle or LC-FFA for 72h, and cell death was estimated using flow 
cytometry. Dots represent data points from three independent experiments. Data are 
expressed as the mean values with error bars representing the SEM. **p<0.01, 
***p<0.001 relative to vehicle (without bafilomycin). 
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3.3.5 The effect of conjugated linoleic acid (CLA) on human β-cell viability 
The results obtained so far have shown that the human-derived EndoC-βH1 β-cell line 
is resistant to LC-SFA-induced β-cell death, whereas the rodent-derived INS-1E β-cell 
line is more susceptible. It was next investigated if EndoC-βH1 cells were resistant to 
the toxic effects of C16:0 through an increase in SCD1 activity; SCD1 being a 
desaturase enzyme which catalyses the biosynthesis of LC-MUFA from LC-SFA (as 
reviewed by Paton, 2009). Transcriptomic analyses of rodent β-cells rendered 
resistant to the toxic effects of C16:0 have shown an upregulation of SCD1 (Busch et 
al. 2005), and in rodent and human β-cells the overexpression of SCD1 protects 
against C16:0-induced apoptosis (Hellemans et al. 2009). Subsequently, cells were 
treated with the selective SCD1 inhibitor, cis-10,12-conjugated linoleic acid (10,12-
CLA), to determine if EndoC-βH1 cells would undergo cell death when exposed to 
C16:0 in the presence of 10,12-CLA. The effects of SCD1 inhibition by 10,12-CLA 
were also compared with those of the structural analogue, cis-9, trans-11-conjugated 
linoleic acid (9,11-CLA), which does not inhibit SCD1 (Busch et al. 2005). 
Investigations using the SCD1 inhibitor were also undertaken in the rodent-derived 
INS-1E cell line. This was to compare the effects of SCD1 inhibition on cell viability in 
a cell line which is known to undergo C16:0-induced cell death (INS-1E) and one which 
is resistant to the toxic effects of C16:0 (EndoC-βH1 cells).  
Initially, rodent-derived INS-1E cells were treated with increasing concentrations of 
either 9,11-CLA or 10,12-CLA for 24h. There was no significant increase in cell death 
in INS-1E cells treated with 0-80µM 10,12-CLA. Moreover, 10,12-CLA did not protect 
against C16:0-induced INS-1E cell death at 10,12-CLA concentrations ≤80µM (figure 
3.15). The non-functional analogue, 9,11-CLA also did not increase INS-1E cell death 
with increasing concentrations (0-80µM). Surprisingly, however, 9,11-CLA significantly 
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decreased C16:0-induced cell death (compared to C16:0 alone) at concentrations 
≥40µM. This unexpected result indicates that 9,11-CLA is cytoprotective against the 
toxic effects of C16:0 at concentrations ≥40µM  (figure 3.16). Subsequently, 9,11-CLA 
and 10,12-CLA do not alter the viability of INS-1E cells, and 9,11-CLA is cytoprotective 
against C16:0-induced rodent-derived β-cell death at concentrations ≥40µM.  
Human-derived EndoC-βH1 cells were also treated with increasing concentrations (0-
80µM) of either 9,11-CLA or 10,12-CLA for 72h with and without 250µM C16:0. 
Strikingly EndoC-βH1 cells treated with ≥40µM 10,12-CLA had a significant increase 
in cell death relative to cells treated with 0µM 10,12-CLA. Moreover, EndoC-βH1 cells 
treated with ≥20µM 10,12-CLA in the presence of C16:0 also had significantly more 
cell death compared to cells treated with C16:0 only (figure 3.17). Thus, inhibiting 
SCD-1 with ≥40µM 10,12-CLA causes an increase in EndoC-βH1 cell death both in 
the presence and absence of C16:0. Conversely, the structural analogue, 9,11-CLA 
did not promote cell death in the absence or presence of C16:0 (figure 3.18) in EndoC-
βH1 cells. This indicates that 9,11-CLA is not toxic to EndoC-βH1 cells. It can, 
therefore, be inferred that inhibiting SCD1 activity is detrimental to EndoC-βH1 cell 
viability.  
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Figure 3.15 Effect of 10,12-conjugated linoleic acid (CLA) with and without C16:0 
on the viability of INS-1E cells. INS-1E cells were treated with 0µM, 5µM, 20µM, 
40µM or 80µM 10,12-CLA with (mauve) and without (turquoise) 250µM C16:0; for 24h. 
Cell death was estimated using flow cytometry. Data points are from five independent 
experiments. Data are expressed as the mean values with error bars representing the 
SEM. ***p<0.001  
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Figure 3.16 Effect of 9,11-conjugated linoleic acid (CLA) with and without C16:0 
on the viability of INS-1E cells. INS-1E cells were treated with 0µM, 5µM, 20µM, 
40µM or 80µM 9,11-CLA with (purple) and without (green) 250µM C16:0; for 24h. Cell 
death was estimated using flow cytometry. Data points are from three independent 
experiments. Data are expressed as the mean values with error bars representing the 
SEM. **p<0.01, ***p<0.001. 
 
 
 
 
 
 
 
 
 
** 
*** 
*** 
 
IN
S
-1
 c
e
ll 
d
e
a
th
 (
%
 t
o
ta
l)
 
[9,11-CLA]µM 
9,11-CLA 
9,11-CLA+C16:0 
113 
 
 
 
 
 
 
 
 
Figure 3.17 Effect of 10,12-conjugated linoleic acid (CLA) with and without C16:0 
on the viability of EndoC-βH1 cells. EndoC-βH1 cells were treated with 0µM, 5µM, 
20µM, 40µM or 80µM 10,12-CLA with (mauve) and without (turquoise) 250µM C16:0; 
for 72h. Cell death was estimated using flow cytometry. Data points are from four 
independent experiments. Data are expressed as the mean values with error bars 
representing the SEM. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 3.18 Effect of 9,11-conjugated linoleic acid (CLA) with and without C16:0 
on the viability of EndoC-βH1 cells. EndoC-βH1 cells were treated with 0µM, 5µM, 
20µM, 40µM or 80µM 9,11-CLA with (purple) and without (green) 250µM C16:0; for 
72h. Cell death was estimated using flow cytometry. Data points are from three 
independent experiments. Data are expressed as the mean values with error bars 
representing the SEM. 
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3.4 Discussion  
The aim of this study was to characterise the toxicity profile of LC-FFA in human-
derived β-cells. The LC-FFA chosen for these investigations were C15:0, C16:0, 
C17:0, C18:0 and C19:0, in order to elucidate the role of chain length in toxicity and 
whether the odd-chain LC-FFA are cytoprotective to human-derived β-cells.  
3.4.1 Effects of the LC-SFA C16:0 on human β-cell viability 
It is well understood that the LC-SFA C16:0 induces cell death in both rodent-derived 
β-cells and human islets (Welters et al. 2004; Maedler et al. 2004). In this study, 
exposing rodent pancreatic β-cells to C16:0 caused a significant increase in cell death 
compared to vehicle, confirming previous observations (Dhayal et al. 2011; Welters et 
al. 2004). In contrast, EndoC-βH1 cells were found to be resistant to the toxic effects 
of C16:0. This finding is supported by the work of Tsonkova et al. (2018) and 
Krizhanovskii et al. (2017), who conducted their studies while the work of this study 
was taking place. Tsonkova et al. (2018) treated EndoC-βH1 cells with 100-700µM 
C16:0 for 72h and observed no increase in cell death relative to control. Krizhanovskii 
et al. (2017) treated EndoC-βH1 cells with 1mM C16:0 for 24h and failed to induce cell 
death. Conversely, however, another group treated EndoC-βH1 cells with 500µM 
C16:0 for 48h and reported a significant increase in cell death compared to cells 
treated with vehicle only (Plotz et al. 2017). Thus, three groups have found that EndoC-
βH1 cells are resistant to the toxic effects of C16:0 even when treated at 
concentrations as high as 1mM and for an exposure period of 72h. This result, 
however, is not universally observed, and thus the ongoing ambiguity is yet to be 
resolved.  
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Next, we investigated whether EndoC-βH1 cells maintain viability when co-treated with 
C16:0 and high concentrations of glucose (glucolipotoxicity). Glucolipotoxicity is a 
phenomenon whereby the combination of C16:0 and high glucose synergistically 
cause β-cell death (Poitout et al. 2010). As described in the results of this study, 
EndoC-βH1 cells do not die when exposed to 20mM glucose either in the presence or 
absence of C16:0. These findings correlate with that of Tsonkova and colleagues 
(Tsonkova et al. 2018) who also observed no increased cell death in EndoC-βH1 cells 
treated with 100-700µM C16:0 for 72h in the presence of 20mM glucose (Tsonkova et 
al. 2018). Likewise, Krizhanovskii et al. (2017) found EndoC-βH1 viability to be 
maintained when co-exposed to 1mM C16:0 and 22mM glucose for 24h. Studies which 
have characterised the functionality of EndoC-βH1 cells have reported that these cells 
function in a manner similar to human islets, for example in terms of insulin secretion 
and respiratory response to glucose (Andersson et al. 2015; Gurgul-Convey et al. 
2015). In human islets, Maedler et al. (2004) and Sargsyan et al. (2011) observed no 
further increase in cell death when human islets were treated with C16:0 in the 
presence of high glucose concentrations. Clearly, EndoC-βH1 cells do not respond to 
glucolipotoxic stress, and therefore, they appear to respond in a similar manner to 
human islets, whereby cell death is not exacerbated by co-treatment with high glucose 
and C16:0.  
3.4.2 Carbon chain length does not correlate with toxicity in human-derived β-
cells, and odd-chain LC-SFA are not cytoprotective in these cells 
The results described in this chapter do not support the hypothesis that LC-SFA 
induced cell death correlates with chain length. Previous studies have found C18:0 to 
cause a greater amount of cell death compared to C16:0 in the rodent-derived β-cell 
lines (Lu et al. 2016; Nemcova-Furstova et al. 2011). However, In this study treating 
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rodent-derived β-cells with C15:0, C16:0, C17:0 and C18:0 all caused a similar 
increase in cell death compared to INS-1 cells treated with vehicle only, with C15:0 
causing a greater degree of cell death compared to C17:0. In the rodent-derived INS-
1E cells, there was no significant difference in cell death in those cells treated with 
C16:0 compared to C18:0. In rodent-derived β-cells, increasing chain-length (above 
C16:0) is not associated with an increase in cell death.  
Similarly to C16:0, EndoC-βH1 cells did not die when exposed to C15:0, C17:0 or 
C18:0. Seemingly, this study is the first to identify that carbon chain length does not 
correlate with toxicity as LC-SFA molecules with 15-18 carbons had the same toxicity 
profile in rodent-derived (i.e. they all induced a comparable amount of cell death) and 
human-derived (i.e. viability was maintained) β-cells. This is important because 
epidemiological studies have identified a correlation between an increased 
concentration of odd-chained LC-SFA (C15:0 and C17:0) in the blood and a decreased 
risk of developing T2D (Forouhi et al. 2014; Santaren et al. 2014). From the results 
presented in this chapter, there was no difference in the toxicity profile of odd- and 
even-chained LC-SFA in rodent-derived or human-derived β-cells. This implies that if 
higher concentrations of circulating odd-chain LC-SFA do decrease the risk of 
developing T2D, it is unlikely to be through odd-chain LC-SFA exerting a protective 
effect on pancreatic β-cells.  
3.4.3 Effects of the LC-SFA C19:0 on human β-cell viability 
Strikingly, C19:0 was the most toxic LC-SFA in rodent β-cells. In addition, when used 
at a concentration of 500µM, C19:0 also caused EndoC-βH1 cell death. The effect on 
the viability of C19:0 has previously not been investigated in pancreatic β-cells. 
However, C19:0 was found to be toxic to the human macrophage cell line, THP-1, as 
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well as to a range of human cancer cell lines (Yoo et al. 2002). Collectively, this 
supports the view that C19:0 is toxic to a range of human-derived cell types including 
human-derived pancreatic β-cells, as shown in this study.  
In this study, all LC-FFA, including C19:0, was conjugated to bovine serum albumin 
(BSA) prior to being applied to β-cells. This is because LC-FFA is transported to the 
β-cell bound to albumin in vivo prior to their release from the protein carrier for uptake 
into the cell (Thompson et al. 2010). However, this study found that C19:0 was prone 
to precipitate in the BSA solution (potentially due to its chain length) as this 
phenomenon was not observed with other LC-SFA. Hence, the true concentration of 
C19:0 to which the β-cells were exposed may have been less than that for other LC-
SFA and cell death estimated less accurately.  
3.4.4 Effects of co-incubating LC-SFA with LC-MUFA on human β-cell viability 
Contrary to LC-SFA, LC-MUFA has mostly proven to be benign in rodent β-cells and 
human islets. A number of studies (Maedler et al. 2003; Maedler et al. 2001; Welters 
et al. 2004; Dhayal et al. 2008) have demonstrated that LC-MUFA can attenuate the 
cytotoxic effects of C16:0 in rodent β-cells and human islets. However, some studies 
have found LC-MUFA to promote β-cell death in immortal rodent-derived cell lines 
(Wrede et al. 2003; Martinez et al. 2008; Yuan et al. 2010). The results presented 
within this chapter verify previous observations (Dhayal et al. 2008). Namely, that 
C18:1 does not kill INS-1E cells and that it attenuates C16:0-induced cell death. 
Further, C18:1 also prevented cell death in INS-1E cells treated with either C15:0, 
C17:0, C18:0 or C19:0. This implies that in rodent-derived β-cells C18:1 can protect 
against the toxic effects of a range of LC-SFA, not just C16:0.  
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Surprisingly, in this study, when EndoC-βH1 cells were treated with 500µM C18:1 a 
modest but significant increase in cell death relative to control was seen. Another 
group have also noted that C18:1 can induce cell death in EndoC-βH1 cells (Plotz et 
al. 2017). Plotz and colleagues, however, also found EndoC-βH1 cells to undergo 
significant cell death when co-exposed to both C16:0 and C18:1 (Plotz et al. 2017), 
which differed from the observations detailed in the results section of this chapter. The 
difference observed between this study’s results and those of Plotz and colleagues 
was that a higher total concentration of LC-FFA was applied by Plotz et al. when co-
treating EndoC-βH1 cells with C16:0 and C18:1. In our investigations, we applied a 
combined concentration of C16:0 and C18:1 at 500µM, whereas Plotz et al. applied 
C16:0 combined with C18:1 at 1mM. It could be proposed, however, that these may 
be unphysiological concentrations which could account for the response. 
In summary, the human-derived EndoC-βH1 cell line appears to respond differently to 
rodent cells when exposed to C18:1. The modest increase in EndoC-βH1 cell death 
induced by C18:1 is apparently mediated by a metabolic process as methyl-C18:1 did 
not induce cell death. C16:1 was not toxic to EndoC-βH1 cells, but further work is 
required to determine whether LC-MUFA toxicity correlates directly with carbon chain 
length in these cells.  
3.4.5 The role of SCD1 in maintaining human-derived β-cell viability 
An interesting conclusion is that the desaturase enzyme, SCD1, may be necessary for 
maintaining EndoC-βH1 cell viability. As presented in the results section of this 
chapter, the SCD1 inhibitor 10,12-CLA induced cell death in the EndoC-βH1 cells both 
in the absence and presence of C16:0.  
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Increased SCD1 expression has been identified in rodent-derived β-cells resistant to 
the toxic effects of C16:0 (Busch et al. 2005). Rodent cells can contain sub-populations 
which are resistant to the toxic effects of C16:0. Busch et al. (2005) isolated 
populations of MIN6 cells which did not undergo cell death when treated with C16:0. 
They then analysed the transcriptome of the C16:0-resistant MIN6 cells and identified 
that SCD1 expression was significantly upregulated compared to MIN6 cells which die 
when exposed to C16:0 (Busch et al. 2005). Busch and colleagues (2005) 
subsequently inhibited SCD1 using 10,12-CLA and, similar to the observations 
detailed in this chapter, EndoC-βH1 cell death occurrs both in the absence and 
presence of C16:0 (Busch et al. 2005). This implies that in those β-cells which are 
resistant to the toxic effects of C16:0, the capacity for β-cells to desaturate LC-FFA is 
critical for their survival. Busch et al. (2005) further suggested that the increased 
activity of SCD1 causes the resultant excess unsaturated fatty acids to accumulate in 
neutral lipids which are stored intracellularly as lipid bodies (Busch et al. 2005). 
Whether the C16:0-resistant EndoC-βH1 cells store a greater amount of intracellular 
lipids compared INS-1 cells, which undergo C16:0-induced cell death, merits further 
investigation. The expression of SCD1 in EndoC-βH1 cells also requires 
characterisation.  
3.4.6 Effects of bafilomycin on human β-cell viability 
Bafilomycin is known to inhibit V-ATPase dependent processes. However bafilomycin 
is most commonly used to block late-stage autophagy, inhibiting autophagosome to 
autolysosomal fusion (Yamamoto et al. 1998). In β-cells, autophagy has shown to be 
an essential process in maintaining cellular function and viability (Twig et al. 2008; 
Jung et al. 2008). This coincides with the observations of this study whereby EndoC-
βH1 cell death was induced when the human-derived β-cells were exposed to 
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bafilomycin alone. This indicates that if bafilomycin does inhibit autophagy, then 
inhibiting autophagic flux is detrimental to EndoC-βH1 cell viability.  
In rodent-derived β-cells, LC-FFA has been shown to alter autophagic turnover (Las 
et al. 2011; Choi et al. 2009; Chu et al. 2018). However, whether LC-FFA increases 
or block autophagic flux, and if LC-FFA with varying degrees of saturation act on 
autophagy, in the same manner, remains a matter of debate. For example, in rodent-
derived β-cells, both C16:0 and C18:1 have both been shown to induce autophagy 
(Choi et al. 2009; Chu et al. 2018), with Choi et al. reporting that C16:0-induced β-cell 
death was augmented in the presence of bafilomycin A1. Conversely, our group have 
recently investigated the role of autophagy in rodent β-cell lipotoxicity and found that 
C16:0 actively increases autophagic flux while C16:1 decreases it (Dhayal S – 
personal communication). This observation is supported by the work of Wu et al. 
(2017) who found C16:0 to induce autophagy unlike C18:1 which inhibited autophagy 
in the human breast cancer cell line, MDA-MB-231. However, EndoC-βH1 cells had 
the same viability profile when treated with either C16:0 or C18:1 in the absence 
(viability was maintained) or presence (cell death was induced) of bafilomycin. This 
implies that C16:0 or C18:1 do not exert differential effects on autophagy in EndoC-
βH1 cells.  
Surprisingly, treating EndoC-βH1 cells with bafilomycin in combination with C16:0 and 
C18:1 led to a reduction in cell death compared to cells exposed to bafilomycin alone. 
This indicates that the inhibitory effects of bafilomycin on either autophagy or another 
V-ATPase dependent mechanism is overcome in EndoC-βH1 cells treated with both 
C16:0 and C18:1. Our investigations (Dhayal S – personal communication) show the 
co-incubation of C16:1 with C16:0 reduce autophagic flux in both rodent-derived β-
cells and human islets (unpublished data). This indicates that the presence of one LC-
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FFA can alter the activity of another LC-FFA in relation to autophagy. It is clear that 
the role of autophagy in EndoC-βH1 cell viability and β-cell lipotoxicity requires further 
investigation.  
3.4.7 Summary 
In summary, human-derived EndoC-βH1 cells appear to respond differently to C16:0 
and C18:1 compared to rodent-derived INS-1E β-cells. Moreover, EndoC-βH1 cells 
also respond differently to C15:0, C17:0 and C18:0 compared to INS-1E cells. 
Nonadecyclic acid (C19:0) is the most efficacious LC-SFA and causes loss of viability 
in both human and rodent β-cells. Finally, human-derived β-cells undergo cell death 
when SCD1 is inhibited, suggesting that EndoC-βH1 cells may be resistant to LC-SFA 
induced cell death through an increase in fatty acid desaturase activity. However, the 
potential protective role of SCD1 in EndoC-βH1 cells requires further investigation.  
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Chapter 4. 
The intracellular distribution of long-chain fatty acids in rodent and 
human β-cells 
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4.1 Introduction 
Historically, lipotoxicity research has focused on characterising the molecular 
pathways which lead to FFA-induced β-cell apoptosis in T2D (as discussed in section 
1.11). Mitochondrial dysfunction, ER stress, autophagy and the cytosolic accumulation 
of fatty acids have all been identified to play a role in the pathological process of β-cell 
lipotoxicity (reviewed in Sharma et al. 2014). A feature shared by these pathological 
processes is that they are often compartmentalised, occurring at organelles including 
the ER, mitochondria, lipid droplets and autophagosomes. Overloading of the β-cell 
with fatty acids is thought to disrupt the morphology, organisation and communication 
networks of these organelles. This leads to alterations in organelle biomechanics and 
in the activation of biochemical cascades (such as the unfolded protein response) 
which can ultimately lead to β-cell death (Chang et al. 2015).   
The evidence is conflicting, however, as to which organelles LC-FFA predominantly 
act upon to cause β-cell death. For example, it has been suggested that excess LC-
FFA metabolism in the mitochondria, leads to mitochondrial dysfunction and ultimately 
activation of the intrinsic arm of the apoptotic pathway, through the release of 
cytochrome c (Elsner et al. 2011; Maedler et al. 2003). However, an opposing 
argument is that high glucose concentrations, which are also present in the T2D milieu, 
increase the production of malonyl-CoA which inhibits CPT-1, thereby preventing the 
entry of LC-FFA into the mitochondria (McGarry et al. 1977). Rather, LC-FFA are 
rerouted into esterification pathways leading to the cytosolic accumulation of LC-FFA 
esters which eventually cause β-cell death (Kim et al. 2011; Cnop et al. 2001). There 
is, therefore, a need to characterise the intracellular distribution of exogenously 
applied LC-FFA, to determine which subcellular organelles are affected in β-cell 
lipotoxicity. 
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Past research has mostly studied the biochemical and biomechanical processes 
underlying LC-FFA induced β-cell death. Although this approach has played a critical 
role in the exploration and characterisation of β-cell LC-FFA lipotoxicity, new insight 
may also be gained from taking a more ‘birds eye’ view. To our knowledge, research 
is yet to simply apply LC-FFA to β-cells and monitor their distribution and the 
subsequent alterations in the morphology of organelles. This method, however, has 
only relatively recently become feasible with the development of lipid-bound probes 
(as reviewed in Daemen et al. 2016). BODIPY (boron-dipyrromethene) fluorophores 
are one such example; these dyes can be conjugated with certain FFA and are 
relatively insensitive to their environment (for example changes in pH), making them 
appropriate tools for studying the intracellular distribution of FFA in live and fixed cells 
(Loudet et al. 2007).  
In this study, the fluorescent C16:0 analogue, BODIPY FL C16, was applied to clonal 
β-cells to investigate the distribution of the LC-FFA, C16:0. In parallel, electron 
microscopy was conducted to determine the changes occurring in the subcellular 
morphology of β-cells upon exposure to C16:0. By studying the distribution of BODIPY 
FL C16, and changes to the morphology of β-cells after exposure to C16:0, we aimed 
to provide new insights into the mechanisms of lipotoxicity. A limitation of this study, 
however, is that BODIPY FL C16 is seemingly the longest LC-FFA BODIPY dye 
available and subsequently only the distribution of C16:0 could be analysed and not 
longer chain FFAs (for example C18:0). As shown in section 3.3.3, in combining C16:0 
and C18:1, cell death is attenuated in both INS-1 823/13 and EndoC-βH1 cells. 
Moreover, C19:0-induced cell death is inhibited in the presence of C16:0 in EndoC-
βH1 cells. Seemingly, there are currently no fluorescent derivatives routinely available 
for study of these other LC-FFA. Therefore, LC-FFA (C17:0, C19:0 and C18:1) were 
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applied in combination with BODIPY FL C16 to determine if their presence altered the 
intracellular distribution of BODIPY FL C16. Subsequently, the changes in β-cell 
morphology were also examined using electron microscopy after exposure to C16:0 
in the presence, or absence of C18:1.  
Investigations in this study were conducted in both the rodent-derived INS-1 823/13 
and the human-derived EndoC-βH1, clonal β-cell lines, to determine interspecies 
differences in the distribution and changes to β-cell morphology induced by C16:0.  
4.2 Methods 
EndoC-βH1 and INS-1 823/13 cell lines were used in all experiments described in this 
chapter. The cells were grown in culture and seeded onto 24 well plates for use in 
microscopy experiments as described in section 2.2. LC-FFA were dissolved in either 
50% or 90% EtOH (final concentration 0.5% (v/v) or 0.9% (v/v) respectively) and then 
bound to 10% (w/v) BSA 1h before the addition to cells. In those experiments using 
tracer BODIPY FL C16 (400nM) was also added to the fatty acid-BSA complex 1h prior 
to treating cells (section 2.6.1).  
The distribution of BODIPY FL C16 was measured in fixed cells (see section 2.6.1). 
Cells were imaged, and the total area covered by cytosolic puncta (BODIPY FL C16) 
was calculated as described in section 2.6.1. Throughout this thesis the accumulation 
of C16:0 is referred to as ‘cytosolic puncta’, as the presence of the BODIPY FL C16 
tracer within the C16:0 accumulated within the cytoplasm has a puncta-like 
appearance. 
The distribution of BODIPY FL C16 and its co-localisation with organelles was studied 
with the aid of fluorescent dyes and confocal microscopy (see section 2.6.1). The 
impact of LC-FFA on β-cell organelle morphology was analysed by TEM, as detailed 
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in section 2.7. All electron microscopy images were assessed by an expert (Dr 
Christian Hacker, University of Exeter) to identify intracellular structures, including the 
Golgi apparatus and endoplasmic reticulum. The insulin localisation in β-cells was 
investigated using TEM after immunogold labelling and by immunocytochemistry 
(section 2.7.1 and 2.8.4).  
4.3 Results 
4.3.1 C16:0 cytosolic distribution in rodent- and human-derived β-cells 
The following set of experiments were performed to determine the intracellular 
distribution of C16:0 with the tracer BODIPY FL C16 and whether C16:0 distribution 
was altered in the presence of other LC-SFA. INS-1 823/13 and EndoC-βH1 cells were 
treated with 500µM C16:0 plus 400nM BODIPY FL C16 for 2h, 6h and 24h. In INS-1 
823/13 cells treated with both C16:0 and BODIPY FL C16 cytosolic puncta were not 
detected after 2h, 6h, or in those cells which had not undergone cell death at 24h 
(figure 4.1a). Conversely, in EndoC-βH1 cells, there was a significant time-dependent 
increase in the total area of the cell covered by cytosolic puncta when cells were 
exposed to both C16:0 and BODIPY FL C16 for 2-24h (figure 4.1a). When treated with 
tracer only (400nM BODIPY FL C16), no cytosolic puncta were observed in either INS-
1 823/13 or EndoC-βH1 cells (figure 4.1b+c). This indicates that the cytosolic 
distribution of BODIPY FL C16 is dictated by C16:0 and not by the fluorophore. In 
summary, C16:0 accumulates in the cytoplasm in human-derived, but not in rodent-
derived, β-cells. 
To study whether the cytosolic distribution of C16:0 is altered in the presence of other 
LC-FFAs, INS-1 823/13 and EndoC-βH1 cells were treated with C16:0 and BODIPY 
FL C16 in combination with either C17:0, C19:0, C18:1 or the methyl ester of C18:1; for 
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2h, 6h and 24h (figure 4.2+4.3). Cytosolic puncta were not observed in INS-1 823/13 
cells treated with C16:0 and BODIPY FL C16 in the presence of C17:0 or C19:0 (figure 
4.2). Surprisingly, however, a significant increase in cytosolic puncta was observed in 
INS-1 823/13 cells treated for 24h with C16:0 and BODIPY FL C16 in combination with 
C18:1 (figure 4.3). Interestingly, an increase in cytosolic puncta was not observed in 
INS-1 823/13 cells treated for 24h with BODIPY FL C16 and the metabolically inert, 
methyl ester of C18:1. Collectively, this indicates that C18:1 reroutes C16:0 in INS-1 
823/13 cells, although, in order to do so it must be metabolised as this phenomenon 
does not occur with the metabolically inert, methyl ester of C18:1.   
In EndoC-βH1 cells, there was no significant increase in cytosolic puncta in those cells 
treated with both C16:0 and BODIPY FL C16 compared to those treated with C16:0 
and BODIPY FL C16 in the presence of C17:0, C19:0, C18:1 or the methyl ester of 
C18:1 (figure 4.4 and 4.5). Further, upon inspection, the distribution pattern of the 
cytosolic puncta in EndoC-βH1 cells is often polarised (for example in figure 4.4), 
accumulating in one region of the cell, and increased in size over time both with and 
without other LC-FFA being present. Collectively, this implies that C17:0, C19:0 and 
C18:1 do not alter the cytosolic distribution of C16:0 in EndoC-βH1 cells. 
In summary, C16:0 accumulates in the cytoplasm of human-derived but not rodent-
derived β-cells. C17:0 and C19:0 do not reroute C16:0 in either human-derived or 
rodent-derived β-cells. C18:1 does not alter the cytosolic distribution of C16:0 in 
human-derived β-cells. However, in rodent-derived β-cells the metabolism of C18:1 
acts to reroute C16:0 causing it to accumulate in the cytoplasm. It could be speculated 
that the cytosolic puncta observed are in fact lipid droplets. However, this is yet to be 
tested directly.  
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Figure 4.1: Intracellular distribution of BODIPY FL C
16
 in INS-1 823/13 and 
EndoC-βH1 cells after 2-24h exposure. (A) INS-1 823/13 and EndoC-βH1 cells 
were treated with 500μM C16:0 together with 400nM BODIPY FL C16 for 2, 6, and 24 
hours. Confocal microscopy used an excitation/emission of 488/552nm. (B) 
Quantification of BODIPY FL C
16 with 500µM C16:0 (blue) and BODIPY FL C16 (black) 
cytosolic puncta in EndoC-βH1 cells. (C) Quantification of BODIPY FL C
16
 (blue) with 
500µM C16:0 and BODIPY FL C16 only (black) cytosolic puncta in INS-1 823/13 cells. 
Confocal images were analysed using ImageJ/FIJI. Data points were cells from three 
separate experiments. Error bars represent the SEM. **<0.01, ***p<0.001 relative to 
BODIPY FL.   
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(A) INS-1 cells were treated for 2, 6 and 24h with BODIPY FL C
16 
in the presence or absence of C17:0 or C19:0. Images taken with a confocal 
microscope using an excitation/emission of 488/552nm. (B) Quantification of BODIPY FL C
16
,
 
cytosolic puncta in INS-1 cells. Confocal images were 
analysed using ImageJ/FIJI. Data points were cells from two separate experiments. Error bars represent the SEM.  
A. B. 
Figure 4.2: Intracellular distribution of BODIPY FL C16 in 
INS-1 cells after 2-24h exposure to BODIPY FL C16 in the 
presence of absence of C17:0 or C19:0. INS-1 cells were 
treated for 2, 6 and 24h with 400nM BODIPY FL C16 only, or 
400nM BODIPY FL C16 and 500µM C16:0,  or 400nM BODIPY 
FL C16 and 250µM C16:0 with either 250µM C17:0 or 250µM 
C19:0. 
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 (A) INS-1 823/13 cells treated for 2, 6 and 24h with BODIPY FL C
16 
in the presence or absence of C18:1 or C18:1m. Images taken with a confocal 
microscope using an excitation/emission of 488/552nm. INS-1 823/13 cells treated with C16:0+C18:1 for 2, 6 and 24h provided courtesy of Jenna 
Corcoran. (B) Quantification of BODIPY FL C
16
,
 
cytosolic puncta in INS-1 cells. Confocal images were analysed using ImageJ/FIJI. Data points were 
cells from three separate experiments. Error bars represent the SEM. ***p<0.001 relative to BODIPY FL C16. 
A. B. 
*** 
Figure 4.3: Intracellular distribution of BODIPY FL C16 in INS-
1 823/13 cells after 2-24h exposure to BODIPY FL C16 in the 
presence or absence of C18:1 or the methyl ester of C18:1 
(C18:1m). INS-1 823/13 cells were treated for 2, 6 and 24h with 
400nM BODIPY FL C16 only, or 400nM BODIPY FL C16 with 
500µM C16:0; or 400µM BODIPY FL C16 with 250µM C16:0 and 
either 250µM C18:1 or 250µM C18:1m. 
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 (A) EndoC-βH1 cells were treated for 2, 6 and 24h with BODIPY FL C
16 
in the presence or absence of C17:0 or C19:0. Images taken with a confocal 
microscope using an excitation/emission of 488/552nm. (B) Quantification of BODIPY FL C
16
,
 
cytosolic puncta in EndoC-βH1 cells. Confocal images 
were analysed using ImageJ/FIJI. Data points were cells from three separate experiments. Error bars represent the SEM.  
A. B. 
Figure 4.4: Intracellular distribution of BODIPY FL C16 in 
EndoC-βH1 cells after 2-24h exposure to BODIPY FL C16 in 
the presence of absence of C17:0 or C19:0. EndoC-βH1 cells 
were treated for 2, 6 and 24h with 400nM BODIPY FL C16 only, 
or 400nM BODIPY FL C16 with 500µM C16:0, or  400nM 
BODIPY FL C16 with 250µM C16:0 and either 250µM C17:0 or 
250µM C19:0. 
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 (A) EndoC-βH1 cells were treated for 2, 6 and 24h with BODIPY FL C
16 
in the presence or absence of C18:1 or C18:1m. Images taken with a confocal 
microscope using an excitation/emission of 488/552nm. (B) Quantification of BODIPY FL C
16
,
 
cytosolic puncta in EndoC-βH1 cells. Confocal images 
were analysed using ImageJ/FIJI. Data points were cells from three separate experiments. Error bars represent the SEM. ***p<0.001 relative to BODIPY 
FL C16. 
Figure 4.5: Intracellular distribution of BODIPY FL C16 in 
EndoC-βH1 cells after 2-24h exposure to BODIPY FL C16 in 
the presence of absence of C18:1 or the methyl ester of 
C18:1 (C18:1m). EndoC-βH1 cells were treated for 2, 6 and 24h 
with 400nM BODIPY FL C16 only, or 400nM BODIPY FL C16 with 
500µM C16:0, or 400nM BODIPY FL C16 with 250µM C16:0 with 
either 250µM C18:1 or 250µM C18:1m. 
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4.3.2 Investigating LC-FFA distribution in human-derived β-cells using 
transmission electron microscopy (TEM) 
Next, electron microscopy was employed to study the morphology of EndoC-βH1 cells 
and INS-1 823/13 cells after being exposed to LC-FFA (figure 4.6 and 4.7a). EndoC-
βH1 and INS-1 823/13 cells were exposed for 6h to 250µM C16:0, 250µM C18:1, or 
250µM C16:0 and 250µM C18:1 combined; and imaged using transmission electron 
microscopy (TEM).  
Upon examination of the INS-1 823/13 cells, cellular organelles were visible in the 
cytoplasm whereas strikingly, in the cytoplasm of EndoC-βH1 cells, there were also 
numerous granular structures (figure 4.7b). Seemingly, the granular structures were 
present in the EndoC-βH1 cells to a greater extent compared to the INS-1 823/13 cells.  
The work of Anderson et al. (2015) has found that EndoC-βH1 cells contain 3-times 
more insulin granules than INS-1 823/13 cells. Considering the lack of cytosolic 
granules in INS-1 823/13 cells, and the presence of the granules in EndoC-βH1 cells 
treated with vehicle only, it was hypothesised that the cytosolic granules were, in fact, 
insulin secretory granules.  
Electron microscopy-immunogold labelling for insulin and proinsulin was conducted in 
EndoC-βH1 cells for verification that the granules observed in the cytoplasm of EndoC-
βH1 cells were indeed insulin secretory granules. EndoC-βH1 cells were treated for 
6h with either 500µM C16:0 or vehicle only. Cells were then exposed to protein-A-gold 
labelled antibodies for either insulin or proinsulin and imaged with TEM (figure 4.8a). 
Proinsulin and insulin were shown to present in the cytosolic granules of EndoC-βH1 
cells treated with both C16:0 and vehicle only. Isotype controls for proinsulin were also 
applied to EndoC-βH1 cells as a negative control to determine whether non-specific 
135 
 
binding had occurred. Electron-microscopy immunogold images of EndoC-βH1 cells 
treated with isotype controls showed that non-specific binding had not occurred in 
those cells probed with the isotype control antibody. To further verify the presence of 
insulin granule stores, and their distribution pattern within EndoC-βH1 after being 
treated with LC-FFA, cells were probed for insulin using immunocytochemistry. 
EndoC-βH1 cells were treated for 6h with either vehicle, 250µM C16:0, 250µM C18:1, 
or 250µM C16:0 and 250µM C18:1. Cells were then stained with an insulin antibody.  
Insulin was found to be distributed throughout the cytoplasm of EndoC-βH1 cells, and 
there was no observable difference in the presence or distribution patterns of insulin 
in EndoC-βH1 cells treated with either vehicle or LC-FFA (figure 4.8b). Collectively, 
this indicates that the granular structures observed in the cytoplasm of EndoC-βH1 
cells after 6h treatment with vehicle or LC-FFA are insulin secretory granules.  
Upon further examination of the morphology of INS-1 823/13 cells, it was observed 
that the Golgi apparatus appeared swollen after the rodent-derived β-cells had been 
treated for 6h with C16:0 (figure 4.9; appendix 2). Conversely, when INS-1 823/13 
cells were treated with C16:0 in the presence of C18:1, the Golgi apparatus was not 
swollen (figure 4.9). Moreover, there was only a moderate swelling of the Golgi 
apparatus of EndoC-βH1 cells treated for 6h with C16:0 (figure 4.10). This implies that 
C16:0 is being trafficked to the Golgi apparatus in INS-1 823/13 cells to a greater 
extent relative to EndoC-βH1 cells. To verify these morphological observations, the 
Golgi apparatus of INS-1E and EndoC-βH1 cells were labelled with the red fluorescent 
marker, Golgi-RFP, to assess whether BODIPY FL C16 co-localised to the Golgi, 
BODIPY FL C16 co-localised with Golgi-RFP in INS-1E cells but not in EndoC-βH1 
cells (figure 4.11 and figure 4.12). An intensity correlation analysis (Schindelin et al. 
2012) was conducted to quantify the colocalisation of BODIPY FL C16 and Golgi-RFP 
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within these images (figure 4.11b and figure 4.12b). There was found to be a greater 
positive correlation for BODIPY FL C16 co-localising with Golgi-RFP in INS-1E 
(Pearson’s correlation: 0.61) compared to EndoC-BH1 cells (Pearson’s correlation: 
0.25). Collectively, this implies that C16:0 becomes concentrated in the Golgi 
apparatus in rodent-derived, but not in human-derived β-cells. 
A further observation in INS-1 823/13 cells treated with 250µM C16:0 for 6h and 
imaged with TEM was that the cells were torn in the region of the cell which 
corresponded with the endoplasmic reticulum (ER) (figure 4.13; appendix 3). This 
observation was interpreted as dilation of the ER as the same alterations in ER 
morphology have been observed previously by Diakogiannaki et al. 2008 who reported 
C16:0 to dilate the ER membrane and activate the ER stress response pathway of 
BRIN-BD11 cells treated with C16:0. Tears in the region of the ER in INS-1 823/13 
cells treated with C16:0 were not observed when cells were treated with C16:0 in the 
presence of C18:1. Moreover, no observable changes in morphology were noted in 
the ER of EndoC-βH1 cells treated with 500µM C16:0 (figure 4.14). Further, using 
Western blotting with densitometry, C16:0 was shown to cause a 5-fold increase in the 
phosphorylation of the ER stress marker eIF2α in INS-1E cells (figure 4.14b). The 
increase in eIF2α stimulated by C16:0 was similar to that of tunicamycin, a known 
inducer of ER stress (Guha et al. 2017), which also caused a 6-fold increase in the 
phosphorylation of eIF2α (figure 4.14b). This indicates that in rodent-derived β-cells 
C16:0 causes ER stress to occur. As no changes to ER morphology were observed in 
EndoC-βH1 cells, it could be assumed that C16:0 does not have the same deleterious 
effects to the ER in the human-derived β-cell line.
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Figure 4.6 INS-1 cell structure as visualised by transmission electron microscopy (TEM). INS-1 cells 
were treated for 6hrs with 250µM C16:0 or 250µM C18:1 or 250µM C16:0 with 250µM C18:1. Control cells 
were treated with BSA vehicle only. INS-1 cells were then fixed in an osmium tetroxide fixative before being 
imaged with TEM. Scale bar represents 1µm. 
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Figure 4.7 EndoC-βH1 cell structure as visualised by transmission electron microscopy (TEM). EndoC-βH1 cells were treated for 6hrs 
with 250µM C16:0, 250µM C18:1 or 250µM C16:0 with 250µM C18:1. Control cells were treated with BSA vehicle only. EndoC-βH1 cells were 
then fixed in an osmium tetroxide fixative before being imaged with TEM. Scale represents 1µm. 
E
n
d
o
C
-β
H
1
 
A. 
B. 
E
n
d
o
C
-β
H
1
 
E
n
d
o
C
-β
H
1
 
E
n
d
o
C
-β
H
1
 
Vehicle C16:0  
C18:1  C16:0 + C18:1  
6h 6h 
6h 6h 6h 
1µm 1µm 
1µm 1µm 
1µm 
1µm 
139 
 
 
 
  
A. 
B. 
Figure 4.8 EndoC-βH1 cells are positive for insulin and proinsulin. (A) EndoC-βH1 cells were treated for 6hrs with vehicle only, 
500µM C16:0 or isotype control. Insulin and proinsulin primary antibodies were then applied to cells. A 5nm protein A-gold labelled 
antibody was bound to the insulin antibody whereas a 20nm protein A-gold labelled antibody was bound the proinsulin antibody with 
the aid of a bridging antibody for stability. Cells were then imaged with electron microscopy to localise proinsulin and insulin. (B) EndoC-
βH1 cells were treated for 6h with 500µM C16:0, 500µM C18:1 or 250µM C16:0 with 250µM C18:1 (final concentration 500µM). Control 
cells were treated with BSA vehicle only. Cells were then immunolabelled using an anti-insulin antibody (shown in red). The nuclei of 
EndoC-βH1 cells were counterstained with DAPI (shown in blue). Cells were then imaged using a fluorescent microscope.  
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Figure 4.9 C16:0 causes the Golgi (G) apparatus to become swollen in 
INS-1 823/13 cells as visualised by TEM. INS-1 823/13 cells were treated for 
6hrs with 250µM C16:0 or 250µM C16:0 combined with 250µM C18:1. Control 
cells were treated with BSA vehicle only. INS-1 823/13 cells were then fixed in 
an osmium tetroxide fixative before being imaged with TEM. Scale represents 
1µm. 
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Figure 4.10 C16:0 does not cause the Golgi (G) apparatus to become 
swollen in EndoC-βH1 cells as visualised by TEM. EndoC-βH1 cells were 
treated for 6hrs with 250µM C16:0. Control cells were treated with BSA vehicle 
only. EndoC-βH1 cells were then fixed in an osmium tetroxide fixative before 
being imaged with TEM. Scale represents 1µm. 
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BODIPY FL C16                                    Golgi-RFP                                           Merge 
Figure 4.11 Colocalisation of BODIPY FL C16 with the Golgi apparatus in INS-1E cells. (A) INS-1E cells were incubated with 250μM 
C16:0 plus 400nM BODIPY FL and 50ppc (define ppc) Golgi-RFP for 24hr. Golgi-RFP was added 24 hours prior to BODIPY FL C16. 
Confocal microscopy used an excitation/emission of 555/584nm for the red channel and of 488/552nm for the green. (B) ImageJ/FIJI 
intensity correlation analysis showed that when plotted against each other, the green and red pixels overlap in INS-1E cell images, with a 
Pearson correlation coefficient of 0.61 for C16:0: Golgi colocalisation.  
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BODIPY-FL C16                                    Golgi-RFP                                             Merge 
A. B. 
Figure 4.12 BODIPY FL C16 does not colocalise with the Golgi apparatus EndoC-βH1 cells. (A) EndoC-βH1 cells were incubated 
with 250μM C16:0 plus 400nM BODIPY FL C16 and 50ppc Golgi-RFP for 24hr. Golgi-RFP was added 24 hours prior to C16:0 and BODIPY 
FL C16. Confocal microscopy used an excitation/emission of 555/584nm. (B) ImageJ/FIJI intensity correlation analysis showed that when 
plotted against each other, the green and red pixels overlap in EndoC-βH1 cell images, with a Pearson correlation coefficient  of 0.25 for 
C16:0: Golgi colocalisation.  
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  (B) INS-1E cells were incubated with 250µM C16:0 for 16hr. Protein extracts were probed with an antiserum to phosphorylated ElF2α (pEIF2α) or total 
EIF2α. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control and the bands were quantified by densitometry. 
Tunicamysin = 1µg/ml. Western blot courtesy of Catherine Arden, Newcastle University.  
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Figure 4.13 C16:0 dilates the ER membrane and EIF2α is 
phosphorylated in INS-1 823/13 cells. (A) INS-1 823/13 cells 
were treated for 6hrs with 250µM C16:0 or C16:0 with C18:1 
(500µM total concentration). Control cells were treated with 
BSA vehicle only. INS-1 823/13 cells were then fixed in an 
osmium tetroxide fixative before being imaged with TEM. Scale 
represents 1µm. 
145 
 
 
ER 
ER 
E
n
d
o
C
-β
H
1
 
Vehicle 
E
n
d
o
C
-β
H
1
 
C16:0 
6h 1µm 
6h 1µm 
C18:1 
6h 1µm 
ER 
1µm 
1µm 
1µm 
Figure 4.14 C16:0 does not dilate the ER membrane in EndoC-βH1 cells. 
EndoC-βH1 cells were treated for 6hrs with 250µM C16:0 or 250µM C18:1. Control 
cells were treated with BSA vehicle only. EndoC-βH1 cells were then fixed in an 
osmium tetroxide fixative before being imaged with TEM. Scale represents 1µm.  
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In summary, within rodent β-cells, C16:0 accumulates in the Golgi apparatus and 
seemingly causes dilation of the ER membrane. Conversely, in human β-cells, C16:0 
does not become concentrated at the Golgi and does not cause alterations to ER 
morphology. 
4.4 Discussion 
In this chapter, the distribution and changes to β-cell morphology induced by C16:0 
were investigated. It was also determined whether the distribution and changes in β-
cell morphology induced by C16:0 were altered in the presence of other LC-FFA. 
Moreover, investigations were conducted in both rodent- and human-derived β-cells 
to determine if there were interspecies differences in the way β-cells distribute LC-FFA 
within the cell.  
4.4.1 C16:0 cytosolic distribution in rodent- and human-derived β-cells 
It was observed that C16:0 accumulates in the cytoplasm of human but not rodent-
derived β-cells after 2-24h. Throughout this study, the accumulation of C16:0 is 
referred to as cytosolic puncta as the presence of the BODIPY FL C16 tracer within the 
C16:0 accumulated within the cytoplasm has a puncta-like appearance. In EndoC-βH1 
cells, C17:0, C19:0, C18:1 and the methyl ester of C18:1 did not alter the cytosolic 
distribution of C16:0 or the total area of the cell covered by cytosolic puncta.  
This is seemingly the first study to report the cytosolic distribution of C16:0 in EndoC-
βH1 cells. This study is not, however, the first to show the cytosolic distribution of 
C16:0 in rodent-derived β-cells. Using the lipophilic stain, Nile Red, Vernier and 
colleagues (2012) reported lipid droplet formation in rat β-cells treated with C16:0 in 
combination with C18:1, and these steadily increased in number over 4 days. Further, 
Plotz et al. (2016) analysed lipid droplet formation in rodent-derived β-cells (RIN-m5F) 
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using the lipid stain Oil Red O coupled with Western blotting for the lipid droplet specific 
proteins, perilipin 1 and 2. Plotz et al. (2016) reported that lipid droplets form in RIN-
m5F cells treated for <24h with C16:0 and C18:1, but not in those cells treated with 
C16:0 only. This correlates with our observations whereby cytosolic puncta formed in 
INS-1 823/13 cells when treated with both C16:0 and C18:1, but not when exposed to 
C16:0 only. However, contrary to Vernier et al. (2012) and Plotz et al. (2016) the work 
detailed in the results of this study is yet to verify whether the cytosolic puncta 
observed in either the INS-1 823/13 or EndoC-βH1 cells are lipid droplets.  
Previously BODIPY dyes have been named in certain methodological reviews 
(Listenberger et al. 2016; Elle et al. 2010) as a valid method for the visualisation of 
lipid droplets. However, fatty acids may be present in the cytoplasm in more organelles 
than just lipid droplets. For example, lipid droplets can be sequestered by 
autophagosomes so that lipids can be degraded within lysosomes and the fatty acids 
recycled (Singh et al. 2009). Further, fatty acids can be transported in early 
endosomes as part of membrane trafficking pathways (Liu et al. 2007). Therefore, it is 
not clear whether BODIPY FL C16 in the cytoplasm of EndoC-βH1 cells (and INS-1 
cells treated with both C16:0 and C18:1) is contained within lipid droplets or an 
alternative cytosolic vesicle. Further work is, therefore, necessary to characterise the 
mode of BODIPY FL C16 cytoplasmic accumulation in EndoC-βH1 cells.  
4.4.2 Investigating LC-FFA distribution in rodent- and human-derived β-cells  
The apparent dilation of the ER in INS-1 823/13 cells treated with C16:0 supports 
previous observations whereby BRIN-BD11 showed structural changes to the ER 
when exposed to C16:0 for 18h (Diakogiannaki et al. 2008). However, structural 
changes in the β-cells were examined when cells had been acutely exposed (6h) to 
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LC-FFA rather than after a prolonged exposure (>18h), indicating that the dilation of 
the ER occurs rapidly. Similar to our observation in INS-1 823/13 cells, Karaskov et al. 
(2006) found dilation of the ER in INS-1E cells exposed to 1mM C16:0 for as little as 
30min. Laybutt et al. (2007), Kharroubi et al. (2004) and Baldwin et al. (2012) also 
report a significant upregulation in genes associated with ER-stress in rodent-derived 
β-cells treated with C16:0 for a time period of ≤6h. Collectively, this suggests that the 
structure and function of the ER are altered with both acute (<6h) and prolonged 
(≥18h) exposure to C16:0 in rodent-derived β-cells. This indicates that alterations to 
the ER may play a role in the induction of LC-SFA induced β-cell death in rodent 
models.  
Interestingly, no alteration in ER morphology was observed when INS-1 823/13 cells 
were co-treated with C16:0 and C18:1 for 6h. This coincides with Diakogiannaki et al. 
(2008) whereby alterations to the ER morphology were also not observed in BRIN-
BD11 cells exposed for 18h to both C16:0 and C16:1 combined (Diakogiannaki et al. 
2008). This implies that the structure of the ER remains unaltered when rodent-derived 
β-cells are treated for ≤18h with C16:0 in combination with an LC-MUFA. Further, 
Sommerweiss et al. (2013) observed no increase in mRNA or protein expression of 
ER stress markers in INS-1E cells treated with C16:0 in combination with C18:1 at 1h, 
6h or 24h; relative to control. Conversely, Cunha et al. (2008) reported a 2-2.5 fold 
increase in the expression of the chaperone protein, BiP, in INS-1E cells treated with 
C16:0 only or C16:0 combined with C18:1, indicating the activation of the ER stress 
response. However, Cunha et al. (2008) also reported no increase in the expression 
of those genes associated with PERK pathway, and only a moderate increase in genes 
associated with the IRE1 pathway, in INS-1E cells treated with both C16:0 and C18:1 
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for 6-24h. Collectively, this indicates that the ER stress response induced by C16:0 in 
rodent-derived β-cells is counteracted by C18:1.  
This study is the first to report that LC-FFAs do not induce ER morphological changes 
in EndoC-βH1 cells. Similarly, in β-cell populations (MIN6 cells) resistant to the toxic 
effects of C16:0 it has been reported that genes associated with ER stress are not 
upregulated upon chronic exposure to C16:0 (Laybutt et al. 2007; Busch et al. 2005). 
Interestingly, Oleson et al. (2015) failed to activate ER stress in EndoC-βH1 cells using 
thapsigargin, a well-known activator of ER stress which acts to deplete ER Ca2+ stores. 
Oleson et al. (2015) reported EndoC-βH1 cells to have a dysfunctional ER stress 
response due to having high concentrations of basal Hsp70 (i.e. in the absence of cell 
stressors). In the same study, INS-1 823/13 cells were found not to have high 
concentrations of basal Hsp70, with thapsigargin inducing an ER stress response in 
as little as 6h (Oleson et al. 2015). Collectively, this indicates that, unlike rodent-
derived β-cells, EndoC-βH1 cells may be resistant to the toxic effects of LC-SFA 
through a failure of LC-SFA to stimulate ER stress due to high levels of Hsp70. Future 
experiments could aim to knock out Hsp70 in EndoC-βH1 cells to determine if C16:0 
is then toxic. 
Along with dilation of the ER membrane, the Golgi apparatus was also found to be 
swollen in INS-1 823/13 cells treated with C16:0 for 6h. Moreover, C16:0 was found 
to localise to the Golgi in INS-1E cells after a 24h treatment period. These results 
correspond with Karaskov et al. (2006) who reported an alteration in Golgi morphology 
in INS-1 cells treated for 30min with 1mM C16:0. Seemingly, however, the results 
detailed in this chapter are the first to observe that C16:0 truly accumulates at the 
Golgi, ultimately altering the organelle’s morphology.  
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Intracellular fatty acid trafficking is not well studied. However, it is thought that in fed 
states, intracellular fatty acids are stored in lipid droplets thus supporting the 
observations of this study. Conversely, in starvation, fatty acids are believed to be 
mobilised to the mitochondria for oxidation or alternatively, incorporated into the 
autophagy pathway to replenish lipid droplet stores (Rambold et al. 2015). Moreover, 
fatty acids and their derivatives (for example ceramide) are known to be trafficked from 
the ER to the Golgi for the synthesis of membrane phospholipids (as reviewed in 
Fagone et al. 2009). Subsequently, it was surprising to observe that C16:0 
accumulates at the Golgi in rodent-derived β-cells as detailed in the results section of 
this study. It suggests that C16:0 is being routed via the Golgi in rodent-derived β-cells 
which is most likely a consequence of ER stress. This coincides with the work of 
Phelps et al. (2016) who reported C16:0 to accumulate at the Golgi in the form of 
palmitoylated glutamate decarboxylase 65 (GAD65). GAD65 is a peripheral 
membrane protein which undergoes a cycle of palmitoylation to control its 
endomembrane distribution. Upon inducing ER stress using thapsigargin or C16:0, the 
palmitoylation cycle of GAD65 is disrupted resulting in its Golgi accumulation (Phelps 
et al. 2016). Potentially, the observation that C16:0 localises to the Golgi (figure 4.9 
and 4.11) may be palmitoylated GAD65 and thus requires further investigation. For 
example, using immunocytochemistry and confocal microscopy it could be determined 
if GAD65 localises to the Golgi apparatus.  
4.4.4 Summary 
In summary, C16:0 accumulates in the cytoplasm of human-derived β-cells and its 
cytosolic distribution is not altered by the presence of other LC-FFA. Conversely, 
C16:0 does not accumulate in the cytoplasm of rodent-derived β-cells unless C18:1 is 
present then, like human-derived β-cells, it accumulates within the cytoplasm. 
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Moreover, within rodent β-cells, C16:0 accumulates in the Golgi apparatus and 
seemingly causes dilation of the ER. Conversely, in human β-cells, C16:0 does not 
become concentrated at the Golgi and does not cause the ER to dilate.  
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Chapter 5. 
Measuring the mitochondrial bioenergetics profile of β-cells 
using the Seahorse Extracellular Flux assay  
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5.1 Introduction 
Since its introduction in 2006, the Seahorse Extracellular Flux Analyser (EFA) 
has been used in >2500 peer-reviewed publications. It is classed as the current 
gold standard for determining metabolic function in the fields of drug toxicology, 
biochemistry and genetics. The Seahorse EFA uses a respirometry assay and 
operates using a two sensor probe system, which simultaneously measures the 
extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) of 
live cells. The OCR and ECAR of cells are measured; allowing the impact of 
nutrients and metabolic inhibitors on these parameters to be measured in real 
time. The output of the Seahorse EFA is a trace, giving a reading of OCR or 
ECAR every 3-7mins, to determine the bioenergetic profile of cells (van der Windt 
et al. 2016).  
In the Seahorse EFA, the OCR is a measure of mitochondrial respiration; the 
amount of O2 consumed by the cells is recorded and used as an indicator of 
oxidative phosphorylation, the primary use of O2 in cells (figure 2.5) (Gerencser 
et al. 2009). The ECAR is determined by recording pH changes of the 
extracellular medium. ECAR can be used as a measure of anaerobic glycolysis 
as the extracellular medium is acidified predominantly from the release of lactic 
acid derived from the regeneration of NAD+ in the glycolytic pathway (TeSlaa & 
Teitell, 2014). However, a limitation of using the Seahorse EFA for investigating 
the bioenergetics of β-cells is that any rise in ECAR is unlikely to be derived from 
glycolysis. Pancreatic β-cells express low levels of lactate dehydrogenase, the 
enzyme which catalyses the conversion of pyruvate (the end product of 
glycolysis) to lactate, and they lack monocarboxylate transporters which export 
lactate across the plasma membrane (Zhao et al. 2001). Subsequently, 
acidification of the extracellular medium is unlikely to be due to β-cells exporting 
154 
 
lactate. However, a rise in ECAR in β-cells is regularly observed when using the 
Seahorse EFA technology (figure 5.1). ECAR rises following the injection of 
glucose, decreases upon the injection of oligomycin, which inhibits ATP 
synthase, and decreases further with rotenone/antimycin mix, which inhibits 
complex I and complex III of the electron transport chain (van der Windt, 2016). 
In β-cells, it is likely that the rise in ECAR is a bi-product of mitochondrial 
respiration of glucose. To facilitate postprandial glucose-stimulated insulin 
secretion (GSIS), β-cells express low levels of lactate dehydrogenase and high 
levels of pyruvate carboxylase and pyruvate dehydrogenase, driving pyruvate 
into mitochondrial metabolic pathways (Khan, 1996; Schuit, 1997). 
Consequently, the TCA cycle generates large quantities of CO2 as a byproduct 
of glucose (and FFA) oxidation which contributes towards a rise in ECAR by a 
reversible reaction, whereby CO2 is hydrated to H2CO3, which then dissociates 
to HCO3- + H+ (Mookerjee, 2015): 
H2O+CO2 ↔ H2CO3 ↔ HCO3- + H+ 
In the past, the contribution of mitochondrial CO2 to extracellular acidification has 
been overlooked in the Seahorse EFA literature (e.g. Cen et al. 2016). It is now 
however becoming common practice to omit ECAR data in studies using the 
Seahorse EFA to investigate the bioenergetics of β-cells (Andersson et al. 2015; 
Barlow et al. 2016). For this reason, this study only reports and discusses the 
OCR of pancreatic β-cells.  
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Figure 5.1 Typical extracellular acidification rate (ECAR) trace of INS-1E 
cells. Basal ECAR was recorded for 18mins, after which 28mM glucose was 
injected and respiration measured for approximately 31mins. At 49mins 2µg/mL 
oligomycin was introduced to inhibit ATP synthase, and respiration measured for 
approximately 20mins. At 69mins 2µM rotenone plus 2µM antimycin A (R/A) was 
added to inhibit mitochondrial respiration. Error bars represent SEM. Trace 
courtesy of Dr Charles Affourtit, University of Plymouth (Unpublished data).  
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In pancreatic β-cells, mitochondria oxidation of nutrients facilitates insulin 
secretion (Komatsu et al. 2013). Nutrient overloading of mitochondrial oxidative 
pathways, however, is well documented to contribute towards β-cell dysfunction 
and death in the pathophysiology of T2D (Stiles, 2012). Consequently, the 
Seahorse EFA is an ideal platform to study the mechanisms underlying nutrient-
induced β-cell dysfunction and death in T2D, which currently remain unclear. This 
includes studying the effects of overloading the mitochondria with fatty acids, to 
investigate the effects of lipotoxicity on the mitochondria.  
Mitochondrial dysfunction is thought to play a role in LC-FFA induced β-cell death 
(see section 1.7.4). However, literature is conflicting as to whether the 
mitochondrial oxidation of LC-FFA contributes towards β-cell death (see section 
1.7.5). By employing the Seahorse EFA to monitor cellular bioenergetics in real 
time, the O2 consumption of β-cells could be recorded, thereby providing a direct 
read-out of the oxidation rate of LC-FFA. By investigating the oxidation rate of 
LC-FFA species, it could be determined whether LC-FFA are indeed routed via 
the mitochondria in β-cells upon acute exposure. Moreover, by determining the 
OCR of both LC-SFA and LC-MUFA, it could be revealed whether a change in 
LC-FFA structure impacts on the efficiency of their oxidation in the mitochondria. 
By investigating these factors, it could be elucidated whether LC-FFA are routed 
to the mitochondria of β-cells upon acute exposure and if there was a link 
between LC-FFA mitochondrial oxidation and toxicity in pancreatic β-cells, which 
would merit further investigation. This work was conducted in the rodent-derived 
INS-1 and human-derived EndoC-βH1 cell lines, to determine if the two species 
respond similarly to LC-FFA mitochondrial oxidation.   
Seemingly, this is the first study to use the Seahorse EFA technology to record 
the oxidation of LC-FFA in β-cells following an acute injection. Further, there is 
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only one study (Andersson et al. 2015) which has assessed the mitochondrial 
bioenergetics of EndoC-βH1 cells; other studies have used rodent β-cells (e.g. 
Barlow, 2015; Barlow; 2016). As glucose-stimulated insulin secretion (GSIS) is 
tightly controlled by β-cell mitochondrial respiration, an insulin secretion assay 
was used to verify that the mitochondria of EndoC-βH1 and INS-1E cells were 
not dysfunctional. Next using the Seahorse EFA, the bioenergetics of the cells 
was studied to verify that the metabolic machinery of the β-cells was functional. 
Finally, the response of INS-1 and EndoC-βH1 cells to an acute injection of LC-
FFA species was conducted.  
5.2 Methods 
EndoC-βH1, INS-1E and INS-1 823/13 cell lines were cultured as described in 
section 2.2. The Seahorse EFA experiments were conducted as described in 
section 2.9. To ensure that the cells were metabolically responsive to glucose, 
insulin secretion assays were conducted as described in section 2.8. 
The XF96e 96-well cell culture plates were coated in 100µg/ml poly-D-lysine for 
30min prior to seeding of cells to facilitate cellular adherence. The cells were then 
seeded at a constant number. To further facilitate cellular adhesion, when 
aspirating the supernatant from each well a 200µl tip was attached to the aspirator 
and the plate tilted forward to minimise the risk of the aspirator coming into 
contact with the cells. To ensure that cells were not lost during the Seahorse EFA 
assay, cells were examined by eye under a Zeiss Primovert inverted microscope 
before and after the assay. 
Alterations in pH have the potential to alter cellular metabolic activity and thus 
OCR readings (Levin, 2013). Consequently, prior to running the Seahorse EFA, 
the media and compounds were all adjusted to a neutral pH of 7.4 at 37°C. The 
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temperature was maintained throughout the assay at 37°C by the Seahorse EFA 
machine. 
Statistical analysis was conducted as described in section 2.9.2. Statistical 
significance was determined as described in section 2.10. The difference 
between groups or control was regarded as significant if P<0.05. The Mito Stress 
test report generator (Agilent, 2016) automatically calculated the mito stress test 
parameters from the Seahorse EFA technology report data. Each experiment 
was repeated a minimum of three times and ≥6 replicates were included for each 
experimental condition.  
5.2.1 Optimising EndoC-βH1 cell seeding density 
A cell titration assay was conducted to determine the optimum seeding density of 
EndoC-βH1 cells. The manufacturers recommend a cell seeding density of 
5x103-40x103 cells per well (Agilent, 2017) and basal OCR should be kept 
between 100-200pmol/min for the best signal-noise ratio and to be within the 
dynamic range of the Seahorse instrument (Rogers et al. 2011). INS-1E cells 
were seeded at 20x103 cells per well to give a confluency of 70-80%, as 
recommended by Barlow et al. (2013), to give a basal respiration of approximately 
100 pmol/min. EndoC-βH1 cells were seeded at higher densities than INS-1E 
cells as EndoC-βH1 are smaller. EndoC-βH1 cells were therefore seeded at 
40x103, 60x103 and 80x103 cells per well. Basal respiration was measured before 
the sequential injection of 20mM glucose and oligomycin (figure 5.2).  Basal OCR 
was <100-200pmol/min when EndoC-βH1 cells were seeded at 40x103 per well, 
and >100-200pmol/min at seeding densities of 60x103 and 80x103 cells per well. 
OCR did not increase in response to glucose but efficiently decreased when ATP 
synthase was inhibited by oligomycin, in EndoC-βH1 cells seeded at 40x103, 
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60x103 and 80x103 cells per well (figure 5.2). A seeding density of 60x103 cells 
per well was chosen for the Seahorse EFA when using EndoC-βH1 cells, as OCR  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Raw OCR values for EndoC-βH1 cells to determine the optimum 
number of cells per well for the Seahorse EFA. EndoC-βH1 cells were seeded 
at either 40x103, 60x103 or 80x103 cells per well. EndoC-βH1 cells were starved 
of glucose for 2h and incubated for 1h at 37°C under air prior to transferring to an 
XF96e Seahorse analyser. Basal respiration (oxygen consumption rate (OCR)) 
was measured for 21mins. After 21mins, 20mM glucose was injected followed at 
47mins by 1μM oligomycin (Oli) to inhibit ATP synthase; respiration was 
measured every 6-7mins. Experimental points were the mean of 7 replicates. 
Error bars represent SEM.    
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was >100-200pmol/min for the full duration of the assay, whereas OCR was 
<100-200pmol/min with a seeding density of 40x103 cells per well. 
5.3 Results 
5.3.1 Glucose-induced insulin secretion of INS-1E and EndoC-βH1 cells 
To test that the INS-1E and EndoC-βH1 cell lines were responsive to glucose, 
and thus had functional mitochondria, the insulin secretory response of both INS-
1E and EndoC-βH1 was characterised. Insulin release was stimulated with either 
glucose (20mM) or KCl (30mM). Glucose-stimulated insulin secretion (GSIS) 
differed between the two cells lines. In the rodent-derived INS-1E cell line there 
was a 2-fold increase in insulin secretion at 20mM glucose compared to those 
cells treated with 2mM glucose (p<0.001). Moreover, depolarisation of the cells 
with 30mM KCl led to a 1.5-fold increase in basal insulin secretion (0mM glucose) 
in the INS-1E cell line (p<0.05) (figure 5.3).  
Surprisingly, when configured in a monolayer, EndoC-βH1 cells were 
unresponsive to 20mM glucose even when glucose was combined with 3-
isobutyl-1-methylxanthine (IBMX) which should amplify the release of insulin 
(figure 5.4).  The EndoC-βH1 cell line was however responsive to KCl, exhibiting 
an 8-fold increase in insulin secretion. Further, when EndoC-βH1 cells in a 
monolayer were stimulated with 20mM glucose in the presence of 500µM C16:0 
there was a 3.2-fold increase in insulin secretion in the presence of IBMX (figure 
5.5a). A significant increase in insulin secretion was not observed however when 
EndoC-βH1 cells were stimulated with either 500µM C17:0, C18:0 or C18:1; in 
the presence of IBMX. Further, C16:0 did not amplify GSIS when IBMX was not 
present in the extracellular medium (figure 5.5b).   
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It is has been suggested that in vitro insulin secretory responses of cultured β-
cells are greater when the cells are configured in a three-dimensional islet 
architecture (attributed to a greater degree of cell-cell communication) compared 
to when used as a monolayer (Green et al. 2015). To assess whether this was 
applicable to the EndoC-βH1 cell line, cells were configured as pseudoislets and 
insulin secretion quantified in response to 20mM glucose and 30mM KCl in a 
perifusion system. The insulin secretion trace (figure 5.6) revealed that neither 
20mM glucose nor 30mM KCl elicited a significant increase in insulin secretion 
from EndoC-βH1 pseudoislets. The reason why EndoC-βH1 cells were 
responsive to 30mM KCl when in a monolayer but not in a pseudoislet 
configuration remains unclear.  
In summary, the rodent-derived INS-1E cells have an intact GSIS response 
whereas the human-derived EndoC-βH1 cell line do not. Both cells lines were 
responsive to KCl indicating that both cell lines produce and secrete insulin, but 
EndoC-βH1 cells may be more reliant on canonical KATP-dependent pathways 
to secrete insulin. Moreover, secretion was increased by C16:0 in EndoC-βH1 
cells, although this required the presence of IBMX. 
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Figure 5.3 Glucose-induced insulin secretion of INS-1E cells. INS-1E cells 
were starved of glucose for 1.5h prior to being treated with 0mM glucose, 20mM 
glucose or 30mM KCl. Cells were treated for 1h and their insulin containing 
supernatant collected. A radioimmunoassay was then undertaken to measure the 
concentration of insulin in each sample. Data represent mean values from three 
independent experiments. Error bars represent SEM. *p<0.05, ***p<0.001 
relative to 0mM glucose. Insulin secretion assay conducted by Mark Russell, 
University of Exeter. 
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Figure 5.4 Glucose-induced insulin secretion in EndoC-βH1 cells. EndoC-
βH1 cells were starved of glucose for 1.5h prior to being treated with 2mM 
glucose, 20mM glucose or 30mM KCl with (+) or without 100µM IBMX for 1h. The 
supernatant was then collected for use in a radioimmunoassay to measure the 
presence of insulin in each sample. Data represent mean values from three 
independent experiments. Error bars represent SEM. * p<0.05 relative to 2mM 
glucose with (+) and without IBMX.   
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Figure 5.5 Fatty acid induced insulin secretion in EndoC-βH1 cells. EndoC-
βH1 cells were starved of glucose for 1.5h prior to being treated with 20mM 
glucose and either 500µM C16:0, C17:0, C18:0 or C18:1 with (A) or without (B) 
100µM IBMX. Control cells were treated with BSA vehicle only. Cells were treated 
for 1h and the supernatant collected. A radioimmunoassay was then undertaken 
to quantify the amount of insulin released. Data represent mean values from three 
independent experiments. Error bars represent SEM.  * p<0.05 relative to vehicle. 
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Figure 5.6 Insulin secretion profile of EndoC-βH1 pseudoislets during 
glucose and KCl perfusion. Pseudoislets were suspended inside a perifusion 
apparatus and warm Krebs buffer pumped over the pseudoislets at a rate of 
~1ml/min for 1h prior to insulin release being stimulated with 20mM glucose (5-
33mins) and 30mM KCl (33-50mins). Supernatant was collected every 1min for 
50min and insulin content quantified using a radioimmunoassay. Data points 
represent the mean of two independent experiments. Error bars represent SEM. 
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5.3.2 The bioenergetics of clonal β-cells 
A Mito Stress test (section 2.9.1) was conducted to verify that the mitochondrial 
machinery required for substrate oxidation in INS-1 and EndoC-βH1 cells were 
functional. The Seahorse EFA was used to record the OCR of cells after the 
sequential addition of mitochondrial inhibitors oligomycin, FCCP and a 
combination of rotenone and antimycin A. This enabled the mitochondrial 
respiration profile to be studied including ATP-linked respiration, respiration 
associated with the proton leak, and the maximal respiration rate (as reviewed by 
Brand, 2011). Healthy β-cell mitochondria will have a proton leak higher than 
other cell types as the proton leak is thought to be used by β-cells to regulate 
GSIS by decreasing ATP synthesis (Affourtit et al. 2011; Brand, 1993; Gohring, 
2013). Moreover, healthy β-cell mitochondria have the ability to respond to 
increased energy demands by maximising cellular respiratory activity (reviewed 
in Brand & Nicholls, 2011). 
INS-1 823/13 cells showed a decline in OCR upon inhibiting ATP synthase with 
oligomycin (figure 5.7a). From the trace, it could be determined that 55% of 
oxygen consumption is used by INS-1 823/13 cells to generate ATP, and the 
remaining 45% is associated with the proton leak (figure 5.7b). As shown in figure 
5.7b, uncoupling the inner mitochondrial membrane proton gradient with carbonyl 
cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP) caused INS-1 823/13 
cells to have an almost two-fold rise in OCR relative to basal respiration, 
demonstrating that INS-1 823/13 cells have the ability to respond to an increase 
in energy demand. Collectively, this indicates that the mitochondria of INS-1 
823/13 cells are functional and have the capacity to metabolise high 
concentrations of substrates.  
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Similarly to INS-1 823/13 cells, INS-1E cells had a decline in OCR upon inhibiting 
ATP synthase with oligomycin (figure 5.8). From the trace, it could be determined 
that 56% of oxygen consumption is used to generate ATP with the remaining 44% 
being associated with the proton leak. Unlike INS-1 823/13 cells, however, INS-
1E cells had a modest rise in OCR (one-fold increase relative to basal) upon 
uncoupling the inner mitochondrial membrane proton gradient with FCCP. 
Further, the spare capacity of INS-1E cells (5pmol/min) was substantially lower 
than INS-1 823/13 cells (95pmol/min). This indicates that INS-1E cells have a 
limited ability to respond to an increase in energy demand compared to INS-1 
823/13 cells. 
EndoC-βH1 cells had a marked decline in respiration upon the addition of 
oligomycin (figure 5.9), more so than INS-1 cells. Respiration associated with 
ATP generation accounted for 83% of basal respiration, whereas the proton leak 
only accounted for 17%. Respiration associated with ATP generation was much 
higher in the EndoC-βH1 cell line compared to INS-1 cells, and respiration 
associated with the proton leak was far less in EndoC-βH1 cells. Further, EndoC-
βH1 cells had a 2.2-fold increase in OCR with the addition of FCCP indicating 
that human-derived β-cells can also increase respiration to meet increased 
cellular energy requirements. The increase in OCR in response to FCCP was 
similar to the increase in OCR observed in INS-1 823/13 cells upon the 
uncoupling of their inner mitochondrial membrane proton gradient.  
In summary, the mitochondrial metabolic machinery of INS-1 823/13 and EndoC-
βH1 cells are fully functional, although rodent-derived β-cells seemingly have a 
greater proton leak relative to human-derived β-cells. Moreover, INS-1E cells 
have the capacity to produce ATP, but they are not able to meet an increase in 
energy demands due to having a modest spare respiratory capacity.  
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Figure 5.7 Bioenergetic profile of INS-1 823/13 cells. Cells were incubated in 10mM glucose for 2h and incubated for 1hr at 37°C 
under air prior to transferring to an XF96e Seahorse EFA analyser. During the assay, glucose was maintained at 10mM for the full 
duration. Basal respiration (oxygen consumption rate (OCR)) was measured for 21.3mins. At 21.3mins 1μM oligomycin was injected, 
at 34.5mins 1.0μM FCCP was injected and at 54.2mins 0.5 μM rotenone/antimycin (R/A) was injected; respiration was measured 
every 6-7mins. (A) Bioenergetics trace of INS-1 823/13 cells. Data was normalized to baseline and log-transformed. (B) Parameters 
of mitochondrial functioning as determined by the Mito Stress test report generator (Agilent, USA). Data was the mean from 3 
independent experiments. Error bars represent SEM.   *p<0.05. 
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Figure 5.8 Bioenergetic profile of INS-1E cells. Cells were incubated in 10mM glucose for 2h and incubated for 1h at 37°C under 
air prior to transferring to an XF96e Seahorse EFA analyser. During the assay, glucose was maintained at 10mM for the full duration. 
Basal respiration (oxygen consumption rate (OCR)) was measured for 21.3mins. At 21.3mins 1μM oligomycin was injected, at 
34.5mins 1.0μM FCCP was injected and at 54.2mins 0.5 μM rotenone/antimycin (R/A) was injected; respiration was measured every 
6-7mins. (A) Bioenergetics trace of INS-1E cells. Data was normalized to baseline and log-transformed. (B) Parameters of 
mitochondrial functioning as determined by the Mito Stress test report generator (Agilent, USA). Data was the mean from 3 
independent experiments. Error bars represent SEM.  
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Figure 5.9 Bioenergetic profile of EndoC-βH1 cells. Cells were incubated in 10mM glucose for 2h and incubated for 1h at 37°C 
under air prior to transferring to an XF96e Seahorse EFA analyser. During the assay, glucose was maintained at 10mM for the full 
duration. Basal respiration (oxygen consumption rate (OCR)) was measured for 21.3mins. At 21.3mins 1μM oligomycin was injected, 
at 34.5mins 1.0μM FCCP was injected and at 54.2mins 0.5 μM rotenone/antimycin (R/A) was injected; respiration was measured 
every 6-7mins. (A) Bioenergetics trace of EndoC-βH1 cells. Data was normalized to baseline and log-transformed. (B) Parameters 
of mitochondrial functioning as determined by the Mito Stress test report generator (Agilent, USA). Data was the mean from 3 
independent experiments. Error bars represent SEM. ***p<0.001. 
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5.3.3 Changes in β-cell respiration in response to glucose 
To verify that the INS-1E cell line had an increase in mitochondrial respiration in 
response to increasing glucose, OCR was measured in cells after an acute injection 
of 0mM, 16mM and 30mM glucose (figure 5.10). INS-1E cells oxidised glucose in a 
dose-responsive manner. With the injection of 0mM glucose, there was no rise in 
OCR. With the injection of 16mM glucose, there was a significant increase in OCR 
(18pmol/min) relative to 0mM. With the addition of 30mM glucose, there was also a 
significant elevation of OCR (41pmol/min) relative to 0mM. Moreover, 30mM glucose 
elicited a significant increase in OCR (23pmol/min) relative to 16mM glucose.  
Contrary to INS-1E cells, however, an acute injection of 10mM, 16mM, 20mM or 30mM 
glucose failed to stimulate an increase in OCR (compared to 0mM glucose) in EndoC-
βH1 cells (figure 5.11). This implies that glucose is not being oxidised by the 
mitochondria of EndoC-βH1 cells.  
In summary, using the Seahorse EFA technology to record OCR, INS-1E cells were 
found to oxidise glucose in a dose-responsive manner whereas EndoC-βH1 cells 
seemingly do not oxidise glucose through mitochondrial respiration pathways.  
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Figure 5.10 Cellular respiration upon acute injection of glucose in INS-1E cells. INS-1E cells were starved of glucose for 2h and 
incubated for 1h at 37°C under air prior to transferring to an XF96e Seahorse analyser. (A) Basal respiration (oxygen consumption 
rate (OCR)) was measured for 21.1mins. 16mM and 30mM glucose was injected at 21.1mins and respiration recorded every 6-7mins 
thereafter. Data was normalized to baseline and log-transformed. Experimental points were the mean of 7 replicates from 3 
independent experiments. (B) Area under the curve calculated by totaling the sum of data points post injection of glucose (i.e. those 
data points recorded after 21.1mins). Error bars represent SEM. **p<0.01, ***p<0.001.
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Figure 5.11 Cellular respiration upon acute injection of glucose in EndoC-βH1 cells. EndoC-βH1 cells were starved of glucose 
for 2h and incubated for 1h at 37°C under air prior to transferring to an XF96e Seahorse analyser. (A) Basal respiration (oxygen 
consumption rate (OCR)) was measured for 20mins. At 20mins 0mM, 10mM, 16mM, 20mM or 30mM glucose was injected and 
respiration recorded every 6-7mins thereafter. Data was normalized to baseline and log-transformed. Experimental points were the 
mean of 7-11 replicates from 3 independent experiments. (B) Area under the curve calculated by totaling the sum of data points post 
injection of glucose (i.e. those data points recorded after 21.1mins). Error bars represent SEM. ***p<0.001 relative to 0mM glucose.
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5.3.4 Changes in β-cell respiration in response to fatty acids 
The oxidation rate of LC-FFA species routed via the mitochondria was next assessed 
in INS-1E cells using the Seahorse EFA. In INS-1E cells, an acute injection of 125µM, 
250µM or 500µM C16:0 did not elicit a significant rise in OCR relative to control (figure 
5.12). Further, 125µM, 250µM or 500µM C17:0 also did not stimulate a significant rise 
in OCR relative to vehicle in INS-1E cells (figure 5.13). To assess whether it was only 
LC-SFA which were not oxidised by the mitochondria, the OCR of INS-1E cells after 
an acute injection of the LC-MUFA was also recorded. 125µM, 250µM or 500µM of 
the LC-MUFA, C16:1, did not cause a significant increase in OCR relative to control in 
INS-1E cells (figure 5.14). Therefore, LC-FFA did not cause a significant increase in 
mitochondrial oxidation in INS-1E cells even at concentrations as high as 500µM.  
It was observed in figure 5.8 that INS-1E cells have a modest mitochondrial spare 
capacity. Therefore, it could be inferred that INS-1E cells may not be able to increase 
their bioenergetic activity to oxidise the endogenous LC-FFA being acutely injected. 
Consequently, as an alternative to INS-1E cells the oxidation rate of LC-FFA was 
measured in INS-1 823/13 cells which are derived from the same parent cell line as 
INS-1E cells (Hohmeirer et al. 2000) but as shown in figure 5.7, have a greater spare 
respiratory capacity. Unlike INS-1E cells, INS-1 823/13 cells were responsive to an 
acute injection of LC-FFA (figure 5.15). After an acute injection of 500µM C16:0 there 
was no significant increase in OCR relative to vehicle control. However, with the 
injection of 500µM C18:1, there was a significant rise in OCR (19pmol/min) compared 
to vehicle and C16:0. Collectively, this shows that in INS-1 8233/13 cells C18:1 is 
routed to the mitochondria where it is oxidised. Conversely, C16:0 is not oxidised by 
the mitochondria of INS-1 823/13 cells.  
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Next, the oxidation rate of LC-FFA species routed via the mitochondria was assessed 
in EndoC-βH1 cells using the Seahorse EFA (figure 5.16). In my hands, no increase 
in OCR relative to control was observed after an acute injection of 500µM C16:0 or 
500µM C18:1. In summary, LC-FFA are not routed via the mitochondria for oxidation 
in EndoC-βH1 cells. 
In summary, no significant rise in OCR was observed in INS-1E or EndoC-βH1 cells 
in response to an acute injection of LC-FFA. Conversely, in INS-1 823/13 cells C18:1 
but not C16:0 was routed to the mitochondria for oxidation.  
 
 
 
 
 
 
 
 
 
 
 
 
176 
 
 
 
 
 
 
 
 
 
Figure 5.12 Cellular respiration upon acute injection of C16:0 in INS-1E cells. INS-1E cells were starved of glucose for 2h and 
incubated for 1h at 37°C under air prior to transferring to an XF96e Seahorse analyser. (A) Basal respiration (oxygen consumption 
rate (OCR)) was measured for 21.3mins. LC-FFA conjugated to BSA was injected at 21.3mins and respiration recorded every 
~6/7mins thereafter. Control cells received an injection of BSA vehicle only. (B) Area under the curve calculated by totaling the sum 
of data points post injection of C16:0 (i.e. those data points recorded after 21.1mins). Experimental points were the mean of 7 
replicates from 3 independent experiments. Data was normalized to baseline and log-transformed. Error bars represent SEM.  
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Figure 5.13 Cellular respiration upon acute injection of C17:0 in INS-1E cells. INS-1E cells were starved of glucose for 2h and 
incubated for 1h at 37°C under air prior to transferring to an XF96e Seahorse analyser. (A) Basal respiration (oxygen consumption 
rate (OCR)) was measured for 21.3mins. LC-FFA conjugated to BSA was injected at 21.3mins and respiration recorded every 
~6/7mins thereafter. Control cells received an injection of BSA vehicle only. (B) Area under the curve calculated by totaling the sum 
of data points post injection of C17:0 (i.e. those data points recorded after 21.1mins).  Experimental points were the mean of 7 
replicates from 3 independent experiments. Data was normalized to baseline and log-transformed. Error bars represent SEM. 
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Figure 5.14 Cellular respiration upon acute injection of C16:1 in INS-1E cells. INS-1E cells were starved of glucose for 2h and 
incubated for 1h at 37°C under air prior to transferring to an XF96e Seahorse analyser. (A) Basal respiration (oxygen consumption 
rate (OCR)) was measured for 21.3mins. LC-FFA conjugated to BSA was injected at 21.3mins and respiration recorded every 
~6/7mins thereafter. Control cells received an injection of BSA vehicle only. (B) Area under the curve calculated by totaling the sum 
of data points post injection of C16:1 (i.e. those data points recorded after 21.1mins). Experimental points were the mean of 7 
replicates from 3 independent experiments. Data was normalized to baseline and log-transformed. Error bars represent SEM. 
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Figure 5.15 Cellular respiration upon acute injection of LC-FFA in INS-1 823/13 cells. INS-1 823/13 cells were starved of glucose 
for 2h and incubated for 1h at 37°C under air prior to transferring to an XF96e Seahorse analyser. (A) Basal respiration (oxygen 
consumption rate (OCR)) was measured for 14.6mins. LC-FFA (500µM) conjugated to BSA was injected at 14.6mins and respiration 
recorded every ~6/7mins thereafter. Control cells received an injection of BSA vehicle only. (B) Area under the curve calculated by 
totaling the sum of data points post injection of LC-FFA (i.e. those data points recorded after 15mins). Experimental points were the 
mean of 7 replicates from 4 independent experiments. Data was normalized to baseline and log-transformed. Error bars represent 
SEM.  ***p<0.001. 
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Figure 5.16 Cellular respiration upon acute injection of LC-FFA in EndoC-βH1 cells. EndoC-βH1 cells were starved of glucose 
for 2h and incubated for 1h at 37°C under air prior to transferring to an XF96e Seahorse analyser. (A) Basal respiration (oxygen 
consumption rate (OCR)) was measured for 15mins. LC-FFA (500µM) conjugated to BSA was injected at 15mins and respiration 
recorded every ~6/7mins thereafter. Control cells received an injection of BSA vehicle only. (B) Area under the curve calculated by 
totaling the sum of data points post injection of LC-FFA (i.e. those data points recorded after 15mins).  Experimental points were the 
mean of 7 replicates from 3 independent experiments. Data was normalized to baseline and log-transformed. Error bars represent 
SEM.   
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5.4 Discussion 
The metabolic activity of INS-1 and EndoC-βH1 cells was studied by examining their 
insulin secretory responses, their bioenergetics profiles, and their respiratory 
responses to an acute injection of LC-FFA. 
5.4.1 Insulin secretion  
In this study, INS-1E cells were found to have a 2-fold increase in insulin secretion in 
response to 20mM glucose and a 1.5-fold increase in response to 30mM KCl. Insulin 
secretion by INS-1E cells in response to glucose and KCl was found to be less in this 
study compared to those reported by Merglen et al. (2004) who generated the INS-1E 
cell line. Merglen et al. (2004) provoked a 6.2-fold increase in insulin secretion in 
response to 15mM glucose and a 4.7-fold increase in response to 30mM KCl. 
Collectively, however, this supports the view that INS-1E cells secrete insulin in 
response to both glucose and KCl.  
However, as detailed in the results section of this chapter, EndoC-βH1 cells did not 
secrete insulin in response to 20mM glucose. This contradicts the work of Andersson 
et al. (2015) who found EndoC-βH1 cells to have a 2.4-fold increase in insulin 
secretion after treatment with 20mM glucose. The results detailed in this chapter also 
differ to the observations of Ravassard et al. (2011) and Gurgul-Convey et al. (2015) 
who reported EndoC-βH1 cells to secrete insulin in response to ≥11mM glucose. 
Gurgul-Convey et al. (2015) also found the insulin secretory response of EndoC-βH1 
cells to be amplified when cells were exposed to both 10mM glucose in combination 
with 100µM IBMX. In this study, EndoC-βH1 cells failed to secrete insulin in response 
to 20mM glucose in the presence of 100µM IBMX. However, 30mM KCl stimulated an 
8-fold increase in insulin secretion relative to control in EndoC-βH1 cells. This was 
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much higher than reported by Andersson et al. (2015) who found 35mM KCl to 
stimulate only a 2.8-fold increase in insulin secretion relative control. Both in this study 
and in the work of Andersson et al. (2015), EndoC-βH1 cells were found to secrete 
more insulin in response to KCl compared to glucose, whereas Gurgul-Convey et al. 
(2015) reported EndoC-βH1 cells to secrete a comparable concentration of insulin in 
response to glucose and KCl.  
Interestingly, a 3.2-fold rise in insulin secretion (relative to control) was observed after 
exposing EndoC-βH1 cells to 19mM glucose in combination with 500µM C16:0 and 
100µM IBMX for 1h. This finding supports those studies which have shown LC-FFA to 
augment GSIS (Prentki at al. 1992; Vara et al. 1986; Yaney et al. 2000). Gravena et 
al. (2002) also found human islets to have a marked increase in insulin secretion when 
treated with both 16.7mM glucose and 500µM C16:0, relative to control. Cen et al. 
(2016) also induced a 1.5-fold increase in insulin secretion after exposing human islets 
to both 5.5mM glucose and 500µM C16:0. This agrees with the observations detailed 
in the results section of this study, although EndoC-βH1 cells only secreted insulin in 
response to 20mM glucose and C16:0 in the presence of IBMX. Conversely, EndoC-
βH1 cells treated with 20mM glucose in combination with either C17:0, C18:0 or C18:1; 
did not have a significant increase in insulin secretion (relative to control) either in the 
presence or absence of IBMX. This result does not accord with Gravena et al. (2002) 
who stimulated insulin secretion from human islets after exposing islets to 16.7mM 
glucose in combination with either C18:0 or C16:1. Further, Cen et al. (2016) also 
found human islets to secrete insulin in response to C18:0 and C18:1 in the presence 
of 5.5mM glucose. The difference in insulin secretory response to C18:0 and C18:1 
between human islets and EndoC-βH1 cells may be due to EndoC-βH1 cells 
containing only β-cells whereas human islets also contain other cells types which may 
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release messengers in response to LC-FFA to amplify insulin secretion. Collectively, 
this implies that in my hands, EndoC-βH1 cells can secrete insulin via membrane 
depolarisation as evidenced by the 8-fold increase in insulin secretion relative to 
control induced by KCl. Moreover, insulin secretion can also be stimulated in EndoC-
βH1 cells when co-treated with C16:0, glucose and IBMX. The lack of insulin secretion 
in response to glucose may also imply that EndoC-βH1 cells have dysfunctional 
mitochondria.  
5.4.2 The mitochondrial bioenergetics of clonal β-cells 
The bioenergetic profile of INS-1E, INS-1 823/13 and EndoC-βH1 cells was studied to 
verify that the mitochondrial machinery required for oxidation in INS-1 and EndoC-βH1 
cells was functional. The most striking difference between the INS-1 and EndoC-βH1 
cell lines was that 44-45% of oxygen consumption in INS-1 cells was associated with 
the mitochondrial proton leak, whereas only 17% of oxygen consumption was 
associated with this proton leak in EndoC-βH1 cells. The mitochondrial proton leak 
acts to uncouple oxidative phosphorylation from ATP synthesis (Affourtit et al. 2011). 
Similar to what we observed, Andersson et al. (2015) also reported the relative proton 
leak of INS-1 823/13 cells to be greater than that of EndoC-βH1 cells.  
Affourtit et al. (2008) have shown INS-1E cells to have a proton leak four times higher 
than that of myoblasts, and Brand et al. (1993) have shown that only 30% of oxygen 
consumption is associated with the proton leak in hepatocytes. It has been proposed 
that pancreatic β-cells have a higher proton leak compared to other cell types (Affourtit 
et al. 2008) as the proton leak is thought to be used by β-cells to regulate GSIS by 
decreasing ATP synthesis (Affourtit et al. 2011). However, if a small proton leak 
increases GSIS, then it can be inferred that EndoC-βH1 cells should have secreted 
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more insulin in response to glucose relative to INS-1E cells as EndoC-βH1 cells had 
considerably less O2 consumption associated with the proton leak. As shown in 
section 5.3.1, EndoC-βH1 cells did not secrete insulin in response to glucose, unlike 
INS-1E cells. This indicates that the small proton leak in EndoC-βH1 cells is not the 
cause of the different insulin secretory responses to glucose by INS-1E and EndoC-
βH1 cells. The cause of impaired GSIS by EndoC-βH1 cells requires further 
investigation.  
The mechanism by which the proton leak regulates GSIS is currently the subject of 
ongoing investigation. Uncoupling protein-2 (UCP2) is thought to be a key regulator of 
the proton leak and its knock-down in INS-1E cells has been shown to enhance GSIS 
(Affourtit & Brand, 2008). Moreover, it has been proposed that UCP2 acts to attenuate 
GSIS by decreasing ROS production (Affourtit et al. 2011). The UCP2 associated 
decrease in ROS production would interfere with ROS metabolic signalling thereby 
attenuating insulin secretion (Pi et al. 2007) and would protect the β-cell from oxidative 
stress (Affourtit et al. 2011). The expression of UCP2 in response to LC-FFA therefore 
requires further investigation as if UCP2 is upregulated in INS-1 cells (which have an 
increased proton leak activity) then it could be inferred that an elevation in 
mitochondrial-derived ROS, produced by the increased oxidation of excess LC-FFA, 
is not the cause of LC-FFA induced β-cell death (as proposed by Graciano et al. 
(2011)). However, according to Barlow et al. (2015), the expression of UCP2 is 
challenging to quantify as commercially available UCP2 antibodies non-specifically 
bind to other proteins. However, Barlow et al. (2015) reported INS-1E cells exposed 
to C16:0 for 24h have an elevated concentration of mitochondrial-derived ROS 
(determined using MitoSOX oxidation) and a loss in viability. In their study knock down 
of UCP2 accentuated the protective effects of C18:1 against C16:0-induced β-cell 
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death (Barlow et al. 2015), implying that UCP2 was not protective against C16:0-
induced β-cell death. The high proton leak of INS-1 cells and, as detailed in chapter 3 
of this thesis, the fact that INS-1E cells undergo LC-SFA induced β-cell death support 
the work of Barlow et al. (2015) that the proton leak does not act to protect INS-1E 
cells from lipotoxicity.  
In summary, a higher degree of O2 is consumed by the proton leak in rodent-derived 
β-cells relative to human-derived β-cells. An increase in proton leak activity of INS-1 
cells relative to EndoC-βH1 cells does not offer an explanation however as to why 
INS-1E cells, but not EndoC-βH1 cells, secrete insulin in response to glucose. Further, 
the role of UCP2 in LC-FFA induced β-cell death requires further investigation.  
5.4.3 Glucose and fatty acid oxidation in rodent-derived β-cells  
The results detailed in this chapter have shown the metabolic machinery of INS-1E 
cells to be functional (albeit with a modest spare respiratory capacity). Consequently, 
INS-1E cells oxidise glucose in a dose-responsive manner, and in response to an 
acute exposure (1h) of glucose they secrete insulin. However, INS-1E cells were found 
not to route LC-SFA nor LC-MUFA to the mitochondria for oxidation. Conversely, INS-
1 823/13 cells, which are derived from the same parent cell line INS-1E cells but 
contain a human proinsulin gene (Hohmeirer, 2000); were found to oxidise C18:1 but 
not C16:0 upon acute exposure. The difference in the respiratory response to LC-FFA 
between INS-1E cells and INS-1 823/13 cells may be due to the difference in spare 
respiratory capacity between the cell types (figure 5.7 and 5.8). INS-1 823/13 cells 
have a much greater spare respiratory capacity (95.3pmol/min) compared to INS-1E 
cells (5.03pmol/min). Consequently, INS-1E cells may not be able to meet the 
increased energy demands imposed on the cell by the acute exposure of LC-FFA.  
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Seemingly, this study is the first to show that during acute exposure, C16:0 is not 
routed to the mitochondria in rodent-derived β-cells, whereas C18:1 is. Those studies 
which have previously investigated the effect of LC-FFA on mitochondrial 
bioenergetics of β-cells using the Seahorse EFA have pre-incubated β-cells in LC-FFA 
prior to running the Seahorse EFA (Barlow & Affourtit, 2013; Barlow et al. 2016; Cen 
et al. 2016). The observation that C18:1 but not C16:0 is routed to the mitochondria 
and oxidised in INS-1 823/13 cells agrees with the work of Cen et al. (2016). These 
authors preincubated human islets in 500µM LC-FFA for 1h before measuring OCR 
with the Seahorse EFA (Cen et al. 2016). Cen and colleagues (2016) reported OCR 
to be elevated by 50% in those islets treated with the LC-MUFA C16:1 and C18:1 
relative to control. In human islets pre-incubated with the LC-SFA C16:0 and C18:0, 
OCR was elevated 20% relative to control (Cen et al. 2016). The fact that human islets 
had an increase in OCR in response to C16:0 may be due to cells other than β-cells 
oxidising C16:0.  
In the work of Barlow et al. (2013) using Seahorse EFA technology, INS-1E cells were 
found to have defective mitochondria after they had been exposed to C16:0 for 24h. 
Mitochondrial defects included a dampening of the mitochondrial respiratory response 
to 28mM glucose (a 25% decrease) and a lower coupling efficiency compared to INS-
1E cells treated with vehicle only (Barlow et al. 2013). Barlow et al. (2016) also found 
the mitochondrial respiratory response to glucose to be impaired in mouse islets 
exposed to C16:0 for 48h, although the respiratory response to glucose was not 
impaired when mouse islets were exposed to C16:0 for 24h. Collectively, these results 
imply that C16:0 is not oxidised by the mitochondria in rodent-derived β-cells and that 
any mitochondrial defects generated by exposing β-cells to LC-SFA are not due to 
their oxidation but by an alternative mechanism. The ability of rodent-derived β-cells 
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to oxidise C18:1 may be a potential mechanism as to why C16:0 has been shown to 
kill rodent-derived β-cells whereas C18:1 is mostly benign.  
5.4.4 Glucose and fatty acids in human-derived β-cells  
EndoC-βH1 cells were found not to oxidise glucose or LC-FFA via mitochondrial 
oxidation pathways. Although, the metabolic machinery of EndoC-βH1 cells was 
functional and consequently EndoC-βH1 cells do have the capacity to oxidise glucose 
and LC-FFA. The observation that EndoC-βH1 cells do not oxidise glucose is 
supported by their not secreting insulin in response to an acute exposure to glucose. 
Conversely, Andersson et al. (2015) reported a modest but significant rise in OCR 
relative to control when measuring the respiration of 20mM glucose in EndoC-βH1 
cells.  
This study is the first to investigate the OCR of EndoC-βH1 cells after an acute 
injection of LC-FFA using the Seahorse EFA. According to the results in this study, 
EndoC-βH1 cells do not route LC-FFA to the mitochondria. These results do not 
accord with the work of Cen et al. (2016) who observed an increase in OCR of human 
islets following a 1h incubation in either LC-MUFA or LC-SFA.  
In summary, EndoC-βH1 cells appear not to oxidise glucose or LC-FFA via 
mitochondrial pathways. However, it can be questioned whether this is a true reflection 
of the oxidative capacity of EndoC-βH1 cells or whether it is due to the limitations of 
the Seahorse EFA.  
5.4.5 Limitations of the Seahorse EFA  
Initially, the Seahorse EFA was to be used within the work of this PhD as a tool for 
investigating the role of LC-FFA metabolism in β-cell death. The initial aim was to use 
the Seahorse EFA to investigate whether the structure or length of the LC-FFA 
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impacted on its ability to be metabolised by the mitochondria. Moreover, the Seahorse 
EFA was to be used to determine whether the presence of one LC-FFA altered the 
metabolic fate of another. However, the Seahorse EFA technology proved to be 
challenging. 
The Seahorse EFA technology has an accessible graphical user interface, and the 
machine itself is simple to operate. However, the preparatory steps of the Seahorse 
EFA increase the likelihood for error and the data output from the machine is timely to 
process (this was overcome by writing a Seahorse EFA script in the R statistical 
programming language). To obtain the results of section 5.3.3 and 5.3.4, it took a total 
of three years of intermittent work. In this time the advice of the Seahorse manufacturer 
and experts within the field was sought. In an attempt to record the oxidation rate of 
β-cells in response to an acute injection of glucose and LC-FFA the following steps 
were taken: 
 Optimised the time (1-24h) required to starve the cells of serum and glucose 
prior to running the Seahorse EFA 
 Devised a method to ensure the cells remained adhered to the Seahorse XF 
Cell Culture Microplate  
 Devised a method to deliver the fatty acids in a way which did not induce BSA 
bubble formation. This included: altering the BSA: fatty acid conjugation ratios, 
using the Seahorse XF Palmitate-BSA FAO substrate kit, varying the BSA 
solvent, and trialling pre-incubating the fatty acids instead of an acute injection.  
 Varying the usage of pipettes (i.e. manual, multi-dispenser and electronic) for 
each stage of the Seahorse EFA 
 Trialing a range of cell types including INS-1E, INS-1 823/13, EndoC-βH1, 
BRIN-BD11 and HEK cells 
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 Trialing compounds which alter glucose and LC-FFA metabolism including 
etomoxir, methyl succinate and 2-Deoxy-D-glucose (2DG) 
Consequently, due to the extensive optimisation steps required to obtain results from 
the Seahorse EFA, the number of repeats required in one experiment to obtain data, 
and the high degree of inter-experimental variability between wells; any results 
obtained from the Seahorse EFA technology require verification.  
As literature has shown (Barlow & Affourtit, 2013; Barlow et al. 2016; Cen et al. 2016), 
the Seahorse EFA technology is seemingly an ideal tool for measuring the extent of 
fatty acid-induced mitochondrial dysfunction in β-cells after they have been pre-
incubated in fatty acids. However, as a tool to measure changes in OCR of β-cells 
after an acute injection of fatty acids, the Seahorse EFA technology does not fit this 
purpose.  
Measuring changes in OCR of β-cells after an acute injection of glucose or fatty acids 
is also confounded by the design of the Seahorse EFA technology. The Seahorse EFA 
is a “semiclosed” design where the cells and the probes are exposed to leakage of 
atmospheric O2 (Gerencser et al. 2009). Moreover, the XF96e 96-well cell culture 
plates are also made of a polystyrene material which is permeable to, and stores 
substantial amounts of O2 further distorting OCR readings (Gerencser et al. 2009).  
A further limitation of the Seahorse EFA is that the assay medium requires 
supplementation with 1mM pyruvate (as sodium pyruvate) and 2mM L-glutamine. The 
Seahorse EFA manufacturer training manual recommends inclusion of pyruvate and 
L-glutamine in the assay medium as 'their consumption is necessary for mitochondrial 
respiration’ (Agilent, 2018). Furthermore, upon contacting the manufacturer helpline 
(personal communication, 2017) for further clarification, Agilent explained that they 
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had identified certain cell types (such as neurons) which fail to elicit respiration without 
pyruvate supplementation (data not provided by the manufacturer). Subsequently, in 
this study, an assay was undertaken to determine whether pyruvate and L-glutamine 
supplementation were necessary for the EFA medium when using the Seahorse 
technology for β-cell lines (figure 5.17).  
In INS-1E cells whose assay medium had not been supplemented with pyruvate and 
L-glutamine, basal respiration was significantly lower than those cells who had 
received pyruvate/L-glutamine. Moreover, with the addition of oligomycin, cells not 
treated with pyruvate/L-glutamine had only a slight decline in OCR. Conversely, INS-
1E cells treated with pyruvate/L-glutamine had a greater decline in OCR with the 
addition of oligomycin. Consequently, it is questionable whether changes in OCR in 
response to glucose and LC-FFA are actual responses to these compounds or an 
artefact of L-glutamine and sodium pyruvate metabolism.  
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Figure 5.17 The effect of pyruvate on INS-1E cellular respiration. INS-1E cells 
were seeded at 20x103 cells per well. INS-1E cells were starved of glucose for 2hrs 
and incubated for 1hr at 37°C under air prior to transferring to an XF96e Seahorse 
analyser. The extracellular medium of each well-contained media either not 
supplemented (without pyruvate) or supplemented with 1mM sodium pyruvate (with 
pyruvate). Basal respiration (oxygen consumption rate (OCR)) was measured for 
approximately 42mins. At 42mins 1μM oligomycin was introduced to inhibit ATP 
synthase. Respiration was measured very 6-7mins. Experimental points were the 
mean of 7 replicates. Error bars represent SEM.    
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Future work to record the OCR of β-cells after an acute exposure to glucose or fatty 
acids should subsequently be verified using techniques such as oxygen microsensors 
which record the OCR of individual cells (Jung et al. 1999). Using tools such as 
microsensors to measure the OCR of individual cells would overcome many of the 
limitations of this technology as discussed above.  
5.4.6 Summary 
This study aimed to investigate the mitochondrial bioenergetics of clonal β-cells 
including their insulin secretory and respiratory response after an acute injection of 
glucose and LC-FFA. INS-1E cells secrete insulin in response to both glucose and 
KCl. EndoC-βH1 cells secrete insulin in response to KCl or glucose in combination 
with C16:0 and IBMX. EndoC-βH1 cell insulin secretory response to insulin was not 
enhanced by the cells being in a pseudo islet configuration. INS-1E cells oxidise 
glucose in a dose-responsive manner although they do not oxidise LC-FFA via 
mitochondrial oxidative pathways. INS-1 823/13 cells, however, oxidise C18:1 but not 
C16:0. The ability of INS-1 823/13 cells to oxidise C18:1 but not C16:0 may offer a 
potential explanation as to why INS-1 823/13 cells do not die when exposed to C18:1 
but do die when treated with C16:0 (Kawai et al. 2001; Tuo et al. 2012). This is 
indicative that C16:0-induced cell death is not due to mitochondrial oxidation. EndoC-
βH1 cells probably do not oxidise either glucose or LC-FFA. However, due to the 
limitations of the Seahorse EFA technology these results require verification using an 
alternate low-throughput method.  
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Chapter 6. 
Discussion 
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The overall aim of this thesis was to elucidate the mechanisms of lipotoxicity in 
human-derived pancreatic β-cells. Upon beginning the study, the toxicity profile 
of LC-FFA was yet to be determined in the human-derived EndoC-βH1 cell line. 
In the period in which this PhD was being conducted, Tsonkova et al. (2018), 
Krizhanovskii et al. (2017) and Plotz et al. (2017) also studied the effect of LC-
FFA on EndoC-βH1 cell viability, although these studies did not investigate the 
toxicity profile of the odd and even-chained LC-FFA. Moreover, unlike the 
investigations detailed in this thesis, those studies (Tsonkova et al. 2018; 
Krizhanovskii, 2017; Plotz et al. 2017) which have investigated lipotoxicity in 
EndoC-βH1 cells have not studied the subcellular distribution of LC-FFA. 
Surprisingly, the EndoC-βH1 cell line proved to be the ideal model for studying β-
cell lipotoxicity, as EndoC-βH1 cells are seemingly resistant to the toxic effects of 
LC-SFA. As rodent-derived INS-1 β-cells undergo LC-SFA induced cell death, the 
difference in the way human and rodent-derived β-cell lines handle LC-FFA could 
be compared, thereby furthering our understanding of lipotoxic mechanisms. 
However, as EndoC-βH1 cells are a human-derived β-cell, it poses the question: 
is β-cell lipotoxicity a rodent phenomenon? 
Studies which have characterised the functionality of EndoC-βH1 cells have 
identified that they function in a manner similar to human islets (Andersson, 2015; 
Gurgul-Convey, 2015). Like EndoC-βH1 cells, Hall (2014) and Staff (2016) both 
found human islets to be resistant to the toxic effects of C16:0. Hall et al. (2014) 
found that treating human islets for 48h with 1mM C16:0 did not induce cell death. 
Moreover, Staff et al. (2016) found no increase in apoptotic markers in human 
islets treated with 500µM C16:0 for 2-4d. Conversely, however, Sargsyan and 
colleagues (2011) observed a significant increase in cell death in human islets 
treated for 24h with 500µM C16:0. Moreover, Maedler (2004) reported a ≥2.1 fold 
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increase in cell death relative to control in human islets exposed to C16:0 for 96h, 
at concentrations as low as 100µM. Subsequently, as EndoC-βH1 cells were 
found to be resistant to the toxic effects of LC-SFA, the results detailed in this 
study seemingly support those studies which report C16:0 not to be toxic to 
human islets (Hall et al. 2014; Staff et al. 2016).  
In my hands, however, EndoC-βH1 cells did not secrete insulin in response to 
glucose and neither did they oxidise glucose via mitochondrial pathways, even at 
a concentration as high as 30mM (section 5.4.1). This implies that EndoC-βH1 
cells do not act in a β-cell like manner as the key feature of a β-cell is its ability to 
secrete insulin in response to glucose. Further, Hastoy et al. (2018) found EndoC-
βH1 cells to be polyhormonal, expressing somatostatin as well as insulin, which 
is normally secreted by islet delta cells. This may be due to EndoC-βH1 cells 
being foetal in origin (Ravassard et al. 2011) and subsequently they may function 
differently to adult β-cells for example, by being polyhormonal and not secreting 
insulin (Riedel et al. 2011). Although, Hastoy et al. (2018) found the 
transcriptomic profile of EndoC-βH1 cells to be more similar to that of adult β-
cells compared to foetal. Consequently, the transcriptomic profile of EndoC-βH1 
cells is likely to be different from that of human β-cells in vitro. It cannot, therefore, 
be reported that LC-SFA induced β-cell death is a rodent phenomenon and does 
not occur in human β-cells, as the genes which regulate fatty acid metabolism 
may also be differentially expressed in EndoC-βH1 cells. The likelihood that 
resistance to LC-SFA induced cell death is a feature of the EndoC-βH1 cell line 
cannot be discounted. Differences in the transcriptomic profile of fatty acid 
associated genes in EndoC-βH1 cells compared to human β-cells can now, 
however, be verified. Using multi-omic maps of EndoC-βH1 cells and human-
derived β-cells generated by Lawlor et al. (2019) a bioinformatic investigation can 
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be conducted to assess differences and similarities in the transcriptomic profile 
of those genes associated with fatty acid metabolism in EndoC-βH1 cells relative 
to human β-cells.  
In summary, the resistance to the toxic effects of LC-SFA by EndoC-βH1 cells 
supports those studies which have reported human islets also to be resistant to 
the toxic effects of LC-SFA. However, human islets contain more cell types than 
just β-cells and their resistance to LC-SFA is not universally observed. Further, 
EndoC-βH1 cells have features which do not coincide with β-cells such as having 
a modest response to, or failing to, secrete insulin in response to glucose and 
being polyhormonal. It can therefore not be stated with certainty that lipotoxicity 
is a phenomenon only seen in rodent-derived β-cells.  
6.1.1 LC-FFA trafficking 
In rodent derived β-cells, C16:0 became concentrated in the Golgi apparatus and 
activated the ER stress response. Moreover, C16:0 failed to elicit changes in 
mitochondrial respiration upon acute injection. With the metabolism of C18:1 
however, C16:0 was found to accumulate in the cytoplasm, although, cytoplasmic 
accumulation of C16:0 in rodent-derived β-cells did not occur in the presence of 
other LC-SFA. When rodent-derived β-cells were treated with C16:0 in the 
presence of C18:1, the Golgi apparatus did not swell, and the ER stress response 
was seemingly not activated as the morphology of the ER remained unaltered. 
Moreover, unlike C16:0, C18:1 is oxidised by the mitochondria of rodent-derived 
β-cells, although to what extent remains unclear. As reported previously (Welters 
et al. 2004; Dhayal et al. 2008), C16:0-induced cell death was attenuated in the 
presence of C18:1 in rodent-derived β-cells. Strikingly, human-derived β-cells 
were found not to die when exposed to C16:0. Interestingly, human-derived β-
cells displayed a similar C16:0 distribution to rodent-derived β-cells when they 
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are co-treated with both C16:0 and C18:1. In human-derived β-cells, C16:0 did 
not accumulate at the Golgi and neither did it cause alterations to the morphology 
of the ER but instead distributed in a punctate manner throughout the cytosol. 
The accumulation of C16:0 in the cytoplasm may be a potential mechanism for 
the differential toxicity profiles of C16:0 and C18:1 in rodent and human β-cells. 
The accumulation of C16:0 in the cytoplasm is a potential mechanism whereby 
C16:0 does not accumulate at organelles such as the Golgi and ER which may 
trigger cell death.  
In Chapter 1 of this study, it was observed that inhibiting SCD1 activity was 
detrimental to human-derived β-cell viability. A study in murine renal proximal 
tubular epithelial cells (PTEC) found SCD-1 overexpression to prevent C16:0-
induced cell death (Iwai et al. 2016). Moreover, C16:0-induced ER stress was 
attenuated upon overexpression of SCD1, and there was a reported increase in 
lipid droplet formation. Interestingly, treating PTEC on its own with C16:0 did not 
stimulate lipid droplet formation (Iwai et al. 2016). Similarly, in the murine PTEC, 
the LC-MUFA, C18:1 also prevented C16:0-induced cell death, inhibited C16:0-
induced ER stress and increased lipid droplet formation when cells were treated 
with both C16:0 and C18:1 (Iwai et al. 2016). Consequently, the role of SCD1 in 
the resistance to LC-SFA induced cell death in human-derived β-cells requires 
further investigation.  
In summary, the routing of C16:0 is similar in human-derived β-cells relative to 
rodent-derived β-cells when C18:1 is also present (and metabolised). When 
treated with C16:0, EndoC-βH1 cells do not die and C16:0 accumulates in the 
cytoplasm. Similarly, when rodent-derived β-cells are treated with both C16:0 and 
C18:1, cells do not die and C16:0 accumulated in the cytoplasm. The cytoplasmic 
accumulation of C16:0 in both human and rodent-derived β-cells requires further 
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investigation as does the role of SCD1 in this process. Moreover, the results 
detailed within this study support a role for ER stress and the accumulation of 
C16:0 at the Golgi apparatus in the underlying mechanism of LC-SFA induced β-
cell death. 
 6.1.2 Limitations of this study 
The main limitation of this study was the rate at which EndoC-βH1 cells 
proliferate. Andersson et al. (2015) reported a doubling rate of approximately 
174h, which is much slower than that of INS-1 823/13 cells which replicated at a 
rate of approximately 44h. This made it challenging to obtain results as it often 
took a number of weeks to grow up enough cells to undertake three repeats of 
an experiment. Moreover, in the early stages of this PhD study, a working protocol 
to facilitate EndoC-βH1 proliferation was developed. The main points observed 
whilst developing this protocol included:  
1. Maintaining cells in a 25cm2 culturing vessel at a confluency of 60-70%, 
EndoC-βH1 cells seemingly grew best when in close proximity to one 
another. 
2. Using sterile BSA which has been opened and stored at 4°C for more than 
2 months seemingly kills EndoC-βH1 cells although the reason for this 
remains unclear. 
3. EndoC-βH1 cells do not proliferate when CO2 levels fluctuate at regular 
intervals: the cells must, therefore, reside at the back of a CO2 incubator.  
However, despite these challenges, the results recorded using EndoC-βH1 cells 
were consistent, and upon developing a culturing protocol which facilitated 
proliferation, the cells were relatively easy to handle, albeit slow in growth.  
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6.1.3 Overall summary 
The work of this thesis aimed to elucidate the mechanisms of lipotoxicity in 
pancreatic β-cells. The first objective of this study was to characterise the toxicity 
profile of LC-FFA (odd and even LC-SFA, and LC-MUFA) in the EndoC-βH1 cell 
line. The LC-SFA C15:0, C16:0, C17:0 and C18:0 were not toxic to EndoC-βH1 
cells, and neither was the LC-MUFA C16:1. Conversely, C19:0 caused EndoC-
βH1 cell death, as did the LC-MUFA, C18:1, bafilomycin and the SCD-1 inhibitor 
10,12-CLA.  
The second objective of this study was to compare the effects on the viability of 
LC-FFA in EndoC-βH1 cells with those in the rat-derived INS-1E β-cell line. Unlike 
EndoC-βH1 cells, C15:0, C16:0, C17:0, C18:0 and similarly, C19:0, were all 
highly toxic to INS-1E cells. The LC-MUFA, C18:1 was, however, not toxic to INS-
1E cells and attenuated the toxic effects of C16:0.  
The final objective of this thesis was to study the subcellular distribution of LC-
FFA in both human-derived EndoC-βH1 and rodent-derived INS-1 β-cell lines. In 
INS-1 cells C16:0 stimulated ER stress, caused apparent alterations to the ER 
morphology, and accumulated at the Golgi apparatus. C17:0 and C19:0 did not 
cause C16:0 to be routed to the cytoplasm in INS-1 cells. However, the 
metabolism of LC-MUFA, C18:1 caused C16:0 to accumulate in the cytoplasm in 
rodent-derived β-cells. Further, C16:0 was found not to be routed to the 
mitochondria for oxidation whereas C18:1 was. Moreover, in rodent-derived β-
cells treated with both C16:0 and C18:1, the ER morphology was maintained, and 
the Golgi apparatus did not become swollen.  
In EndoC-βH1 cells, C16:0 accumulated in the cytoplasm, with cytoplasmic 
distribution being unaltered in the presence of C17:0, C19:1 and C18:1. 
Moreover, C16:0 did not alter the morphology of the ER or Golgi apparatus of 
200 
 
EndoC-βH1 cells. Treatment with LC-FFA also did not alter the insulin content of 
EndoC-βH1 cells, although C16:0 was found to amplify GSIS in the presence of 
IBMX.  
In summary, differences observed in the viability profile of LC-FFA in human 
compared to rodent β-cells may be due to differential routing of lipids.  
6.1.4 Future work 
Key future work should focus on determining whether lipotoxicity occurs in the 
pathophysiology of T2D in humans, or whether β-cell lipotoxicity is a 
phenomenon specific to rodent-derived β-cells. As discussed in section 1.7 of this 
thesis, the majority of studies which have investigated the mechanisms 
underlying β-cell lipotoxicity are conducted in rodent-derived β-cells. It is possible 
therefore that LC-SFA may not be overtly toxic to human β-cells but cause them 
to dedifferentiate, losing insulin production. Jeffery et al. (2019) reported an 
increase in somatostatin expression in EndoC-βH1 cells exposed to 500µM 
C16:0 for 24h. Consequently, key future experiments should aim to characterise 
the expression of β-cell specific markers and markers of dedifferentiation in 
EndoC-βH1 cells exposed to LC-FFA.  
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Appendix 1 
 
Effect of C16:0 on the viability of EndoC-βH1 cells. EndoC-βH1 cells were 
treated with 0µM and 500µM C16:0 for 24h. Cell death was estimated using vital 
dye staining. Dots represent data points from four independent experiments. Data 
are expressed as the mean +/- SEM.  
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Appendix 2 
 
 
 
 
 
 
Effect of BSA vehicle control on Golgi morphology in INS-1 823/13 cells. 
INS-1 823/13 cells were treated for 6hrs with BSA vehicle only. INS-1 823/13 cells were 
then fixed in an osmium tetroxide fixative before being imaged with TEM.  
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Effect of C16:0 on Golgi morphology in INS-1 823/13 cells. INS-1 823/13 cells 
were treated for 6hrs with 250µM C16:0. INS-1 823/13 cells were then fixed in an 
osmium tetroxide fixative before being imaged with TEM.  
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Effect of C16:0 with C18:1 on Golgi apparatus morphology in INS-1 823/13 
cells. INS-1 823/13 cells were treated for 6hrs with 250µM C16:0 and 250µM 
C18:1. INS-1 823/13 cells were then fixed in an osmium tetroxide fixative before 
being imaged with TEM.  
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Effect of BSA vehicle control on Golgi morphology in EndoC-βH1 cells. 
EndoC-βH1 cells were treated for 6hrs with BSA vehicle only. EndoC-βH1 cells 
were then fixed in an osmium tetroxide fixative before being imaged with TEM.  
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Effect of C16:0 on Golgi morphology in EndoC-βH1. EndoC-βH1 cells were 
treated for 6hrs with 250µM C16:0. EndoC-βH1 cells were then fixed in an 
osmium tetroxide fixative before being imaged with TEM. 
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Appendix 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of BSA vehicle control on ER morphology in INS-1 823/13 cells. INS-
1 823/13 cells were treated for 6hrs with BSA vehicle only. INS-1 823/13 cells were then 
fixed in an osmium tetroxide fixative before being imaged with TEM.  
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Effect of C16:0 on ER morphology in INS-1 823/13 cells. INS-1 823/13 cells were 
treated for 6hrs with 250µM C16:0. INS-1 823/13 cells were then fixed in an osmium 
tetroxide fixative before being imaged with TEM.  
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Effect of C16:0 with C18:1 on ER morphology in INS-1 823/13 cells. INS-1 823/13 
cells were treated for 6hrs with 250µM C16:0 and 250µM C18:1. INS-1 823/13 cells were 
then fixed in an osmium tetroxide fixative before being imaged with TEM.  
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Effect of BSA vehicle control on ER morphology in EndoC-βH1 cells. EndoC-
βH1 cells were treated for 6hrs with BSA vehicle only. EndoC-βH1 cells were then fixed 
in an osmium tetroxide fixative before being imaged with TEM.  
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Effect of C16:0 on ER morphology in EndoC-βH1 cells. EndoC-βH1 cells were 
treated for 6hrs with 250µM C16:0. EndoC-βH1 cells were then fixed in an osmium 
tetroxide fixative before being imaged with TEM.  
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